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Abstract 
This study is designed to evaluate the effectiveness of using pressure ulcer (PU) risk 
assessment scales (RASs), namely the Braden scale, on patients' outcomes in terms of 
PU incidence. The study aimed to examine the effects of RASs (the Braden scale) 
compared to the effects of PU training and nurses' clinical judgement on patients' 
outcomes in terms of PU incidence. 
A non-equivalent pre-test post-test controlled groups designs were used and the data 
were gathered using an observational checklist, the Braden scale for PU risk 
assessment, and nurses' clinical judgement rating scale. 719 hospitalised patients at 
Riyadh Military Hospital in Saudi Arabia were selected from 9 Medical-Surgical 
wards and were divided into 3 groups (A, B and Q. In Group A, nurses received 
training on the Braden scale; in Group B, nurses received PU training, and Group C 
was control. The Braden score of :5 18 was used as a cut off score to determine at risk 
patients. The Agency for Health Care Policy and Research (AHCPR) (1992) 
classification system was used to consider PU incidence. Data were collected by one 
tissue viability specialist and two researchers. 
The findings showed that 22.9% of the patients developed PU (stage one to stage 
four). The PU incidence was relatively similar between the study groups (24.4% in 
Group A, 23.4% in Group B, and 21.1% in Group C) which demonstrates no 
significant effect for using RASs (the Braden scale) compared to PU training and 
nurses' clinical judgment on PU incidence. The findings also pointed out a significant 
difference in PU incidence among pretest (31%) patients and posttest (19%) patients 
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which suggest the clinical benefit of the PU prevention programme implemented by 
the RMH. Logistic regression analysis revealed that age, clinical judgement scores, 
Braden scores, standard hospital-bed mattress, neuro-surgical diagnosis, and skin 
barrier creams have predictive function in relation to PU development. The ROC 
analysis showed a relatively similar performance for Braden scale and nurses' clinical 
judgement in relation to PU development. 
The study concluded that there was no significant effect of using RASs (the Braden 
scale) on patients' outcomes in terms of PU incidence reduction. In respect of this, the 
study suggests that RASs (the Braden scale) and nurses' clinical judgement can be 
used together to improve patients' outcomes in terms of PU development. 
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Chapter One: Introduction 
This chapter discusses pressure ulcers (PUs), introduces the concept of risk, defines 
PU and offers a brief historical perspective of their roots and development. It provides 
background to the PU problem specifically in relation to hospitalised patients at 
Riyadh Military Hospital (RMH) and explores the potential usefulness and 
significance of this study to the RMH as a health care provider. It also explores the 
aims of the study and presents the study's time scale. 
Introduction 
Risk is present in every aspect of human life in different levels (such as environmental 
pollution, global warming and car accidents) and emerged particularly in clinical 
practice as health care systems are becoming complex with changing and 
contemporary growing areas of practice. Health technology and complexity of health 
resources may entail additional risks to the patients, the health care team and the 
health care institution. Although risk assessment and risk management have taken a 
central position in numerous health care institutions, different risks are unavoidable 
(Crowe and Carlyle 2003) such as patients' falls, nosocomial infections and medical 
errors (Braine 2006). The development of pressure ulcers represents one area of these 
risks. Nurses are key instruments in health care services, and encounter conflicting 
and challenging forces that may affect their roles in health care context as a result of 
complex, multidisciplinary, multi-professional and changing situations. Clinical 
judgments are foundations of decision making in health care practices. Nurses have 
12 
demonstrated several clinical decisions central to patient care and health care 
environment and have had a key role in assessing and managing clinical risks through 
identifying these risks and implementing subsequent measures to reduce their adverse 
effects on patients and health care institution. There is a substantial body of published 
work on `risk definition'. It reflects a range of distinct risk analysis perspectives and a 
high-level appreciation of risk knowledge creation. For instance, Thompson and 
Dowding (2002) define risk according to The Royal Society as ̀ the probability that a 
particular adverse event occurs during a stated period of time, or results from a 
particular challenge'. Macgill and Siu (2005) reviewed a substantial number of 
technical and social definitions of risk. For example, one technical definition of risk is 
`the possibility of loss, injury, disadvantage or destruction; to expose to hazard or 
danger; to incur risk of danger' and one social definition of risk is `uncertainty'. 
Although there is diversity in defining risk which may be related to complexity in 
nature and context of risk involving technical, economic, social, health, ecological 
and other dimensions; these definitions included probability and prediction. 
Nurse practitioners deal with numerous clinical risks every day and they are not able 
to produce exact probabilities about the outcomes of health problems they deal with. 
Therefore, crucial clinical decisions take place based on prediction of probabilities of 
the event either happening or not happening. For instance, the nurse may consider a 
newly admitted patient who is seventy years old with a fractured neck of femur as 
high risk for developing pressure ulcers based on his/her previous knowledge and 
expertise, and the patient may be placed on support surfaces whether he/she 
developed pressure ulcer or not. On the other hand, the nurse may not intervene when 
patients are assessed as not being at risk, and subsequently developing pressure ulcers. 
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Risk is integral to nursing practice and nurses are instrumental in maintaining 
patients' safety and risk reduction through the risk management process, which 
includes risk assessment, risk analysis and developing strategies to manage risk 
(Thompson and Dowding 2002; Braine 2006). The process of risk management has 
become increasingly important in controlling the rising cost of health care (East 1995) 
and the priority in the evolution of health care risk management has changed to 
improve patient safety (Kuhn and Youngberg 2002). 
RMH as a health care provider has been reactive to different clinical risks and the 
concepts of risk, risk assessment and risk management are not established. The 
complexity of clinical risks in RMH cannot be addressed through one discipline alone 
and requires the need for a culture of safety and risk reduction. The risk management 
process may present an avenue to evolve the concept of risk in the RMH as discussed 
further in Chapter Two. 
1.1 Pressure ulcers: definition and brief historical perspective 
Pressure ulcers (PUs) (also called bed sores, pressure sores or decubitus ulcers) 
remain a significant and complex health problem in hospital and community health 
care settings in terms of human suffering, pain, disfigurement, loss of productive time 
and financial burden. 
A PU is defined as a localised lesion caused by unrelieved pressure, shear or friction 
that results in damage to underlying tissues due to a prolonged period of ischemia. It 
usually occurs over bony prominences such as the sacrum (Agency for Health Care 
Policy and Research (AHCPR 1992; Hitch 1995; Cullum et al. 1995; Ek 1987; 
Nyhlen 1979). 
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The presence of PU in Egyptian mummies as mentioned by Thompson (cited in 
Theaker 2004) suggests that this problem has a long history. It was described for the 
first time by Fabricius Hildanus, who is often called the "father of German surgery", 
in 1593 as being caused by external natural and internal supernatural factors, which 
are known today as external and internal risk factors, as mentioned by Defloor (1999). 
Pare (a French surgeon) in the sixteenth century recognised the importance of 
pressure relief and nutrition in curing this disease, which matches modem thought on 
the subject (Levine 1992). 
Charcot (a French neurologist) in 1860 described PU as decubitus ulcers in patients 
suffering from acute or chronic brain and spinal cord diseases, noting that some 
patients developed PUs on their buttocks or sacrum before death (Levine 2005). It 
was associated with fatal septic infections and reported as a cause of thousands of 
deaths each year in the United States (Redelings et al. 2005). Higher mortality rates 
are expected findings for those patients who develop PUs, 65 per cent of whom 
developed them on the sacrum (Clough 1994). 
In the twenty-first century, available scientific knowledge about PU is still 
developing. One example is Halfens' (2001) historical overview of PU literature of 
the past 35 years. The aim of this review was to examine the attention given to PUs in 
clinical reports and scientific literature and the specific topics targeted by those 
authors. A Medline search revealed a total of 6,056 articles regarding PUs. A further 
analysis showed that the focus on PUs has grown from 1965 to1999. Moreover, most 
studies were based on descriptive designs. The reviewer concluded that the number of 
studies on PUs as compared to general studies means that greater attention is being 
is 
paid by clinicians and scientists to the problem. However, it is still far from adequate 
compared to the cost of PU prevention and treatment in health care. 
1.2 Background to the study 
1.2.1 Introduction 
The complexity of wound care management is continually evolving. Frequent changes 
can sometimes cause confusion, so the body of knowledge related to this specialty 
must be evidence-based, frequently updated and communicated. Much progress has 
been made in the last few years, but there is still more to discover. A wound care 
programme was developed at RMH in collaboration with the nursing administration, 
managers, educators, staff and other professionals. The goal of the programme was to 
provide a standardised level of care that meets the needs of patients and to educate 
nurses about standards, assessments and resources. The wound care programme began 
by researching the literature and using action research as a framework. Three aims 
were identified: to initiate a strategic change plan for wound management, to 
contribute to the development of the body of knowledge in wound management as an 
area of specialisation, and to promote the quality of nursing care provided on a daily 
basis. 
1.2.2 Base line evidence 
The first step in the nursing wound management action plan was to initiate a wound 
management database. An exploratory and descriptive methodology was utilised to 
build up an initial body of data. Ten wound care committee members were trained to 
collect data from a convenient sample of nine different medical-surgical wards. This 
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data was collected using observation and self-administered questionnaires with three 
sections (Appendix A). The first section consisted of observable patient data, the 
second of nurses' opinions of selected wound management practices, and the third 
measured nurses' knowledge of wound management. The results (Table 1.1) revealed 
that 36.4 per cent of patients developed PU following admission and 23.8 per cent 
were admitted with PUs. The results showed higher PU rates compared to other 
chronic wounds such as diabetic foot and venous leg ulcers. Among the nursing staff, 
44 per cent of them demonstrated a lack of knowledge in wound management (the 
response rate was 96 per cent) and PU risk assessment (Norton risk assessment scale); 
brief and incomplete wound management documentation was also reported. 
1.2.3 PU incidence and prevalence monitoring 
PU incidence and prevalence surveys were performed annually and considered as part 
of the action change plan at the RMH. It showed higher rates of PU incidence and 
prevalence from 2003 to 2006 compared to developed countries such as the UK and 
other European countries. Despite the reported reduction in prevalence and incidence 
rates, the results at the RMH showed that prevalence ranged from 19.9 per cent (in 
2006) to 23.8 per cent (in 2003) and the incidence ranged from 31.8 per cent (in 2006) 
to 36.4 per cent (in 2003) among hospitalised patients, as shown in Table I. I. It 
revealed that the incidence rate was very high in some wards: nearly 50 per cent 
among Isolation ward patients and approximately 40 per cent among male medical 
ward patients from 2003 to 2006, indicating a problem that required urgent attention. 
17 
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1.2.4 The role of the multidisciplinary teams on PU management in the RMH 
The nursing staff took the major role in caring for patients with PUs at the RMH, as 
opposed to the medical team's low level of participation in PU management. The RMH 
Operating Theatre's yearly report in 2006 revealed that only an average of six flapping or 
grafting operations per year were performed as surgical reconstructions by the plastic 
surgery team (Table 1.2). 
Table 1.2 Total reconstructive surgeries of PUs from 2003 to 2006 
Year Total surgeries 
at the RMH 
Total Plastic 
surgeries at the 
RMH 
Total Reconstructive 
surgeries of PU( Grafts or 
Flaps) 
2003 12667 428 5 
2004 12808 446 6 
2005 13173 423 6 
2006 13708 432 6 
Source: RMH-Operating Theatre Statistics 2003-2006. 
1.2.5 Educational activities 
The education policy at the RMH necessitates that the nursing staff must complete the 
mandatory wound care study yearly. According to RMH-Nursing Academic Affairs / 
Wound Care Study Day statistics (2004), 774 nurses had attended the wound care 
management study day. Wound care practice at the RMH was considered as an active, 
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challenging, conflicting and multidisciplinary area of practice which required nurses and 
other health care professionals to be knowledgeable about evidence-based wound care 
practice and updates. 
1.2.6 Wound management documentation 
The nursing documentation system at the RMH included various forms of PU assessment 
and management (Appendix B). The nurses have used the Nursing Data Base form since 
the 1980s, which included the Norton risk assessment scale (Appendix Q. These returns 
revealed a lack of documentation. Where this was used, it was most frequently in the form 
of nurses' notes. In addition, no crucial decisions regarding the prevention and management 
of PUs were based on the application of the Norton scale, but rather on nurses' clinical 
judgement. 
1.2.7 Wound care policy and procedures 
The Nursing Practice Committee at the RMH is accountable for reviewing all nursing 
policies and procedures. The wound care policy was revised in 2004 as a result of the PU 
survey findings and a decision was made to introduce wound management guidelines, 
including the Braden scale for PU risk assessment, as part of the wound care policy, wound 
care referral and pressure ulcer management. The PU management policy included PU risk 
assessment, skin inspection, pressure redistribution devices, turning and seating of the 
patients, training and education. 
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1.2.8 Wound care committee 
The Wound Care Committee was part of the RMH's Quality Assurance Committee. Its 
steering role was crucial in the development of the wound care management system 
through the implementation of a multi-professional, participatory and collaborative team 
approach. The Committee's mission and objectives and its members' functions were all 
established. 
1.3 Significance of the study 
The issue of PU prevention and management is of national and international concern. The 
true scale of the problem is unknown, but it is vastly underestimated. The literature 
suggests under-reporting of the problem, as many institutions believe that PU is a quality 
indicator of poor nursing standards, and lack awareness in relation to PU prevention and 
management, as mentioned by Day et al. (1997) and Anthony et al. (2006). 
A review (Kaltenthaler et al. 2001) of the numerous estimates of the incidence and 
prevalence of PUs from different countries including the UK, the USA, Canada and 
Europe, revealed variations in the study population, different data collection methods, a 
lack of national and international consensus on PU grading systems and risk assessment 
scales, and an inadequate documentation of prevalence and incidence, which lack 
comparability between data sets collected. 
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The figures from the RMH showed that PU was one of the most significant problems 
among hospitalised patients compared to other chronic wounds investigated. PU prevalence 
and the incidence rates were high compared to developed countries. In addition, the figures 
showed inadequate PU documentation, risk assessment and training. The current methods 
for identifying patients at risk were inadequate and subjective, which required the need to 
investigate the effectiveness of PU prevention strategies. 
The need to improve the figures of PU prevalence and incidence among hospitalised 
patients was well documented, with little evidence suggesting improvement, as mentioned 
by Pancorbo-Hidalgo et al. (2006), Flanagan (1995) and Panagiotopoulou et al. (2002). 
Theaker (2004) suggests that a problem of such magnitude and complexity cannot be 
effectively addressed by any one discipline alone. 
Risk assessment scales (RASs) emerged as an initial step in PU prevention and 
management programmes. While RASs have been implemented to improve patient 
outcomes, research evidence to clarify this issue was scant. Additionally, RASs showed 
variable and inadequate reliability and validity in clinical application. It was not clear 
whether RAS was effective by itself in reducing PU incidence, or whether the effect of 
training and/or nurses' clinical judgment contributed to the reduction. The research 
evidence on the clinical effectiveness of RASs was weak. Exploring this area might 
therefore help in building a scientific knowledge base about such phenomena, which is 
important in order to support personal experience and eliminate other forms of bias from 
clinical decisions. In other words, after nearly fifty years of using RASs and the existence 
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of more than 46 different RASs in clinical use, this study investigates whether or not their 
use actually improves patient outcomes. 
The implementation of the Braden scale in the RMH gave a unique opportunity to evaluate 
RASs and to explore the effects of using that scale, as well as training and clinical 
judgment regarding patient outcomes. This study introduces current evidence-based 
knowledge in PU prevention and management that enabled nurses to provide a better 
quality of nursing care. As a result, patient outcomes were improved, in terms of reducing 
PU incidence rates, through better identification of patients at risk and definition of those 
factors that contribute to PU development. As a result, patients' suffering was reduced 
along with pain, disfigurement and the time and cost of PU management. The reduction of 
the patients' length of stay and PU wound infection rates, as well as the improvement of PU 
wound healing times, may, however, be associated with PU incidence reduction. The 
findings of this study can also be implemented by nurses and health care teams to help 
provide optimum care and reduce suffering. 
1.4 Aims of the study 
This study aims to: 
1. explore the effects of using risk assessment scales (The Braden Scale) on patient 
outcomes in terms of pressure ulcer incidence rates. 
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2. examine the effects of pressure ulcer prevention and treatment training on 
patient outcomes in terms of pressure ulcer incidence rates. 
3. determine the effects of using clinical judgment as a way of deciding which 
patients are at risk of developing pressure ulcers on patient outcomes in terms of 
pressure ulcer incidence rates. 
1.5 The study and research time scale 
This study was conducted over five years and constituted two main stages: 
1. MPhil, which involved proposal development, review of relevant literature, preparation 
and review of the research instrument, formulation of the conceptual framework and 
preparation and conduct of the pilot study. 
2. PhD, which involved data collection, data analysis and writing up the thesis. 
The proposed study time scale was: 
1) Review of the literature, proposal development, preparation of the research instrument 
and conduct of the pilot study were developed over 36 months. 
2) Data collection, data entry and data analysis were managed in 14 months. 
3) Writing up the thesis over 10 months. 
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1.6 Summary 
This chapter has described the background of the study. It has explored the effects of RASs 
(the Braden scale), PU training and nurses' clinical judgement on patients' outcomes in 
terms of PU incidence. Risk and risk management concepts PU definitions and a brief 
historical perspective were provided. The background of the study included baseline 
evidence, PU incidence and prevalence monitoring, all of which demonstrated the extreme 
impact on nurses and patients at the RMH. The background described the development and 
implementation of educational activities, the wound management documentation, the 
wound care policy and the wound care committee at the RMH. The significance of the 
study has been explored and includes its value to the RMH as a health care system in Saudi 
Arabia and to other health care professionals. The aims of the study were explored and the 
study's time scale plan was presented. 
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Chapter Two: Literature Review 
Introduction 
The term "literature review" refers to the activities involved in identifying and searching 
for information on a given topic and developing an understanding of the state of knowledge 
regarding it (Polft and Hungler 1999). The literature review aims to be a source of research 
ideas, familiarising the researcher with what was known about the subject and providing a 
conceptual context for information on the research approach. 
Search strategy 
Relevant literature was reviewed from different nursing databases, namely British Nursing 
Index (BNI), British Nursing Index Archive (BNIB), Cumulative Index of Nursing and 
Allied Health Literature (CINAHL) and International Bibliography of the Social Sciences 
(IBSS). Other multidisciplinary databases such as MEDLINE (Pubmed), European Pressure 
Ulcer Advisory Panel (EPUAP), and National Pressure Ulcer Advisory Panel (NPUAP) 
were used to retrieve relevant data related to different aspects of the pressure ulcer problem. 
Additional databases such as the Cochrane library were also used. Searches were performed 
on all abstracts, research reports, systematic reviews, texts, published and unpublished 
theses and dissertations for the keywords "pressure ulcers" and "risk assessment scales". 
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Searching was limited for works in English; full texts judged as relevant were obtained 
where possible. 
The literature was searched for: 
1) studies that used quantitative methods to evaluate risk assessment scales 
2) studies conducted on hospitalised patients 
3) all studies considered to be systematic reviews of risk assessment scales 
4) studies considered to contain or constitute information about validity and 
reliability of risk assessment scale 
5) studies describing the PU problem in terms of definitions, consequences, 
incidence, prevalence, conceptual frames, risk factors, and classification systems 
6) studies including information about the role of nurses' clinical judgement in PU 
prevention, the effects of PU prevention programmes, and the effects of PU 
training programmes. 
Exclusion criteria included: 
1) studies reflecting personal experience or opinion 
2) case studies 
3) small sample sizes (less than 30 subjects in quantitative studies) 
4) studies that used qualitative methods 
5) studies that were medically oriented rather than nursing-focussed. 
The data were accessed through the Internet, CDs, videotapes, proceedings of international 
conferences, wound care committee meetings, wound care study days and clinical 
experiences. 
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The results of the search of nursing databases (BNI, BNIB and CINAHL) showed that no 
national studies were undertaken on PU prevention, management and risk assessment. PU 
literature mostly concerned the following: 
1) The epidemiologic aspect of PU in terms of incidence and prevalence 
2) The main complications of the PU problem in terms of cost burden, delayed 
healing time, increased infection rate and prolongation of patients' stay 
3) Various conceptual schemes and the process of PU development 
4) PU classification system 
5) PU prevention programmes 
6) PU training and education programmes 
The search showed a reasonable number (13 studies in 2003 to 33 studies in 2007) of 
publications about the PU risk assessment scales as shown in Table 2.1. The clinical 
effectiveness of using PU risk assessment scales on patient outcomes in terms of PU 
incidence or prevalence was shown in a limited number of studies (5 items up to 2007). 
The following subsections present a critical review of the literature relevant to the study 
undertaken and introduce a conceptual framework that facilitates the understanding of the 
study variables. 
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Table 2.1 Publications on pressure ulcer using nursing databases (BRNI, BNIB 
and CINAHL) from 2003 to 2007 
Year *Number of items 
published on PU 
*Number of items 
published on PU 
Risk Assessment 
Scales 
*Number of items 
published on Risk 
Assessment Scales 
2003 297 13 179 
2004 355 17 259 
2005 438 26 385 
2006 491 31 513 
2007 509 33 * NA 
* Search limited to research, full texts, and studies in English language 
* NA: Not Available. 
2.1 Incidence and prevalence of PU 
PU incidence was defined as new cases appearing during a specified period in a particular 
population, and PU prevalence as a cross-sectional count of the number of cases at a 
specified point in time (AHCPR 1992 and the European Pressure Ulcer Advisory Panel 
(EPUAP) in Defloor et al. 2005). 
Several studies report PU incidence and prevalence among hospitalised patients. 
Kaltenthaler et al. (2001) report a PU incidence rate of between 2.2% to 29% per annum 
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over a maximum of six weeks in the UK and 8.5 to 13.4 per cent over a one- to four weeks 
period for a maximum of two weeks in the USA and Canada. 
The prevalence reports from some European countries ranged from 7 per cent in 1995 to 28 
per cent in 2004 in Germany and 15 per cent in 1995 to 33 per cent in 2004 in Netherlands 
(Tannen et al. 2004 and O'Dea 1995), while the equivalent UK scope was from 5.1 to 32.1 
per cent, and the US and Canadian from 4.7 to 29.7 per cent (Kaltenthaler et al. 2001). In a 
recent study, Vanderwee et al. (2007) reported an 18.1 per cent PU (Stages One to Four) 
prevalence rate in 25 hospitals from five European countries. 
The figures from the RMH (the setting of this study) showed that the prevalence ranged 
from 19.9 to 23.8 per cent and the incidence ranged from 31 to 36.4 per cent among 
hospitalised patients. Compared to developed countries, these findings demonstrated higher 
rates of PU incidence and prevalence, despite a reduction in prevalence and incidence rates 
being reported (Saleh et al. 2006). 
PU prevalence and incidence were recommended by AHCPR (1992) and EPUAP (1998) as 
the main indicators for developing and evaluating PU programmes. Prevalence provides an 
insight into the magnitude of the PU problem at any given time, and aids in planning for 
health resources and facilities. PU incidence provides insight into the nature of patient 
groups who are at risk of PU development, and allows inferences to be made regarding the 
effectiveness of preventive measures, compliance with prevention and treatment protocols, 
and effectiveness of risk assessment tools (Defloor et. al. 2005 a and O'Dea 1995). The 
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introduction of a PU incidence monitoring survey is suggested as being helpful in 
highlighting the problem and in planning and implementing activities to improve PU 
management (Torrance and Maylor 1999, Halfens et al. 2001 and Klazinga 1994). 
In this study, figures of PU incidence and prevalence are particularly useful in providing a 
broad view of the magnitude of the problem facing RMH and to help establish baseline data 
for future improvement in such situations in the absence of national studies and 
documentation of PU prevalence and incidence (Saleh et al. 2006). 
Nevertheless, PU incidence and prevalence studies are methodologically limited as regards 
the interpretation of their outcomes, which makes it difficult to compare results between 
studies. There are four of these limitations, the first of which is a difficulty in comparing 
various populations in different health care settings (data collected from acute hospitals are 
not likely to reflect the community or home care population). Incidence and prevalence 
rates may be higher among several specific subpopulations such as orthopaedic and 
quadriplegic patients than in general hospital populations. The second limitation is that data 
collection methods range from direct observation of patients to retrieval of data from 
patient records. The third is the inclusion or exclusion of Stage One PUs from the study 
population, and the fourth is the under-reporting of PUs, different sample sizes, insufficient 
control of data acquisition, the use of different PU classification systems, the influence of 
discharge practices, and treatment and prevention protocols, all of which also make it 
difficult to compare (AHCPR 1992, Kaltenthaler et al. 2001, Bethell 2002, Bradley and 
Van der Wal 1995, Defloor et al. 2005, Klazinga 1994 and Whittington et al 2000). 
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2.2 PU Classification 
Classification (or grading/staging) of PUs is a significant aspect in PU prevention and 
management. The classification systems allow objective assessment of the degree of tissue 
damage. There are numerous PU classification systems used in clinical areas, the best 
known of which are AHCPR (1992) and EPUAP (1998). 
AHCPR (1992) classifies PUs in a way that is consistent with the recommendations of the 
NPUAP. Stage One PUs are characterised by the non-blanching erythema of intact skin; the 
heralding lesion of skin ulceration. Reactive Hyperemia should not be confused with Stage 
One PUs. The Reactive Hyperemia is normally expected to be present for one-half to three- 
quarters of the observed tissue as long as the pressure occludes blood flow to the area. 
Stage Two is marked by partial thickness skin loss involving the epidermis and/or dermis. 
The ulcer is superficial and presents clinically as an abrasion, blister or shallow crater. 
Stage Three involves full thickness skin loss involving damage to or necrosis of 
subcutaneous tissue that may extend down to, but not through, underlying facia. The ulcer 
presents as a deep crater with or without undermining of adjacent tissue. Stage Four 
involves full thickness skin loss with extensive destruction, tissue necrosis or damage to 
muscle, bone, or supporting structures such as tendons or joint capsules. Undermining and 
sinus tracts may also be associated with Stage Four PUs. 
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The EPUAP classification system agrees with AHCPR in classifying PUs into four stages 
and in specifying some signs of Stage One PUs in darker skin (e. g. discoloration of the 
skin, warmth, oedema and induration or hardness of the skin). 
These classification systems have several limitations such as: uncertainty about how to 
define Stage One PUs, as opposed to any other stage (Bethell 2003) and a related difficulty 
in assessing Stage One PU patients with darkly pigmented skin (AHCPR 1992). Defloor et 
at. (2007) have suggested classifying Stage One PUs (non-blanchable erythema) not as PUs 
but as alarm signals. Another limitation is that when an eschar is present, accurate 
determination of the stage of the PU is not possible until the eschar has sloughed or the 
wound has been debrided, as necrotic tissues may mask the true extent of the wound 
(AHCPR 1992). Yet another limitation is low inter-rater reliability (Harker 2000 and 
Defloor et al. 2007). 
In this study the AHCPR classification was adopted; there are currently no ideal 
classification systems, and none has been universally adopted (Reid and Morrison 1994 and 
Harker 2000). The AHCPR stages were present on patients from the RMH as shown in 
(Appendix L). 
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2.3 Consequences of PU 
1) Costs of PU prevention and treatment 
Several studies have estimated that the costs of PU prevention and treatment are very 
significant (Cullum et al. 1995, Richardson et al. 1998, Brooks and Semlyen 1997, 
Thomson and Brooks 1999, Day et al. 1997, Hermans and Bolton 1996, Clough 1994 
and Bennett et al. 2004). Xakellis and Frantz (1996) noted that eighty per cent of the 
total costs of PU treatment were generated by the four per cent of patients who required 
hospitalisation for their PUs, and Bennett et al. (2004) concluded that PUs have a 
significant impact in the UK, equivalent to four per cent of the total health care 
expenditure. In a recent report, skin breakdown including PUs, venous leg ulcers and 
diabetic foot ulcers was estimated as costing the UK up to £3.1 billion annually (Smith 
and Nephew Foundation report 2007). 
The majority of PU expenditure is on nursing time for dressing, positioning, and the 
provision of support surfaces (Clough 1994 and Bennett et al. 2004). Additionally, the 
treatment cost of PUs is significantly more expensive than their prevention (Clough 
1994). The studies reporting PU cost estimates were limited to reports of over- or 
underestimation. There has been underestimation of resources needed in treatment and 
prevention, such as surgical reconstruction and nosocomial infections of PUs. Studies 
also varied widely, but with the overall trend indicating rising costs. Furthermore, 
human costs in terms of patients' quality of life were difficult to estimate. 
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2) Increased infection rates have been reported in many studies (Anthony 1996, Lindholm 
2003 and Heym et al. 2004). 
3) Increased length of stay. Ash (2002) notes that patients who develop PUs have longer 
stays than those patients who do not, and Anthony et al. (2004) report that nosocomial 
PU is a significant predictor of increased length of stay once the patient's general 
condition and age are taken into account. 
4) Delayed wound healing as shown by Wallenstein and Brem (2004). Different rates of 
PU wound healing are reviewed by Bennett et al. (2004) who report that the mean time 
of healing was 28.4 days for Stage One, 93.8 days for Stage Two, 127.4 days for Stage 
Three, and 154.7 days for Stage Four. All of these stages had complications such as 
critical colonisation or infection, cellulitis and osteomyelitis. 
2.4 Guidelines on Pressure Ulcer Prevention 
PUs are accepted as a preventable but unavoidable disorder (Grewal et al. 1999, AHCPR 
1992 and Day et al. 1997). Thus, numerous clinical guidelines have been developed and 
implemented in health care systems during the past twenty years to assist nurses to take 
appropriate decisions to improve PU prevention and management (Clark 1999). 
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The first guideline was developed in Netherlands in 1985. Four years later, the NPUAP in 
the USA developed new guidelines (Clark 1999), followed by the AHCPR guidelines 
(1992), EPUAP (1998) and NICE (2003). Most of these guidelines aim to identify patients 
who are at risk of developing pressure ulcers and the specific factors which place them at 
risk. 
Do PU guidelines improve patient outcomes in terms of PU incidence or prevalence? 
Several studies and systematic reviews have been conducted to find evidence for using PU 
prevention strategies on reducing PU prevalence and/or incidence. Many reviews have 
demonstrated a reduction in incidence, and for any prevention programme there may 
additionally be other positive outcomes such as reduced costs. The use of PU clinical 
guidelines leads to reduction of PU occurrence after implementation (Regan et al. 1995 and 
Xakellis et al. 1998) in Clark (1999). 
PU prevention programmes consist of different components. Day et al. (1997) suggest that 
aggressive, ongoing PU prevention programmes, including thorough skin assessment and 
care, frequent repositioning, and careful selection of support surfaces (Cullum et al. 1995), 
have demonstrated significant reduction of PU incidence and time taken for treatment as 
well as dramatic cost savings; while Whitfield et al. (2000) conclude that an educational 
strategy has been seen as the most frequently employed intervention to reduce PU 
incidence or prevalence. The implementation of multidisciplinary working parties and 
multidimensional interventions including best practices and research-based protocols 
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(Hopkins et al. 2000), improved documentation (Gunningberg et al. 2001b) and systematic 
use of RASs are also suggested as effective strategies in improving PU prevention and 
reducing PU incidence and prevalence (Gould et al. 2000). 
These variations in PU prevention programmes make it difficult to compare between 
studies, and although many activities in PU prevention programmes are associated with a 
reduction in PU occurrence, other components such as RASs remain unproven. It is not 
clear which components of prevention studies are most effective in reducing PU prevalence 
and/or incidence (Whitfield et al. 2000). 
2.5 PU Risk Assessment Scales 
Risk assessment scales (RASs, also called risk assessment tools, calculators or scores) are 
key components in any prevention guidelines and constitute an initial step in PU prevention 
models that aim to identify those patients at risk. RASs are structured models including 
categories of factors that are associated, to varying degrees of reliability, with PU 
development (Scott 2000; Day et al. 1997). 
RASs are a key tool in facilitating PU prevention and assisting practitioners in allocating 
appropriate pressure relief devices or deciding on preventive intervention for an individual 
patient. In addition, dividing patients into risk groups is important for a comparison of PU 
prevalence and the differences between two study populations (Tannen et al. 2004). Maylor 
(1999) believes that RASs could be useful as a communication tool between nurses for 
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assessment and could help to standardise nurses' documentation. Thus clinicians are 
encouraged to utilise a risk assessment scale that ensures systematic evaluation of 
individual risk factors (AHCPR 1992). 
Pressure ulcer conceptual models and risk factors 
Numerous conceptual models have been developed in order to explore PU development and 
to serve as basis for the development of RASs (Lowthian 1970; Braden and Bergstrom 
1987; Defloor 1999). Defloor (1999) has introduced the most comprehensive conceptual 
scheme on PUs, based on a review of the literature related to the prediction and prevention 
of PUs. The author highlighted factors other than known risk factors (pressure and shear 
forces), which appear to contribute to the process of PU development. The scheme included 
four elements: pressure, shearing force, tissue tolerance for pressure and tissue tolerance for 
oxygen. This scheme may help in developing valid RASs and allow more adequate 
detection of those patients at risk of PU development (Oot Giromini 1995). 
Several studies have been conducted using different methods and among different 
populations in order to identify risk factors associated with PU occurrence. These studies 
suggest that the understanding of risk factors and their interaction may help in refining 
RASs and improving their predictive performance. As a result, numerous risk factors have 
been found among different risk groups. For example, anaemia, faecal incontinence, length 
of stay, and noradrenalin infusion have been associated with PU occurrence among 
critically ill patients (Theaker 2004). Age (Anthony et al. 2003, Halfens et al. 2000, 
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Gunningberg et al. 2001b and Tannen et al. 2004), diagnosis, and support surfaces were 
significant in relation to PU development among surgical patients (Schultz et al. 1999). 
Additionally, length of surgery (Schoonhoven et al. 2002 a) and gender (Tannen et al. 
2004) were also associated with PU development. The enormous number of risk factors 
associated with PU development makes it difficult to decide which risk factors should be 
included in a risk assessment scale. 
Examples of RASs 
There are numerous examples of RASs. Several new RASs have been developed and at 
least 40 such alternative scales have been described in literature, most of which exist in 
several variants (Defloor and Grypdonck 2004). Most of them are modifications of each 
other; the most commonly studied and reported scales in clinical use are the Norton, 
Waterlow and Braden scales. 
The Norton scale (Appendix G) is the first recognised RAS. It is based on Lowthian's 
(1970) conceptual model, which includes pressure and shearing force as the main causes of 
PUs. It considers five risk factors (or risk indicators): general physical condition, mental 
status, activity, mobility and incontinence. Each factor is rated 1 to 4, with total scores 
ranging from a minimum of 5 to a maximum of 20. A score of 514 is considered as a cut 
off indicating risk status (Flanagan 1995). 
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The Waterlow scale (Appendix G) considers additional risk factors (or risk indicators) of 
build/weight, continence, skin type, mobility, gender, age, appetite, tissue malnutrition, 
neurological deficit, surgery/trauma and specific medications. Waterlow divides the degree 
of risk into three categories: scores of 10 to 14 are considered to be at risk, scores of 15 to 
19 at high risk and scores of 20 and above at very high risk of developing PUs. The 
Waterlow scale includes guidelines of preventive measures and support systems needed 
according to each risk category (Waterlow, 2005). 
In the present study the Braden scale (Appendix J) is used. It is based on Braden and 
Bergstrom's (1987) conceptual model, which included two main causes of PUs: pressure 
and tissue tolerance. The Braden scale considers six risk factors (or risk indicators): sensory 
perception, moisture, activity, mobility, nutritional status and shear/friction. Each category 
is rated 1 to 4 except shear/friction, which is rated 1 to 3. The minimum risk score is 6 and 
the maximum is 23. In this study, patients are deemed to be at risk when their cut off score 
is : 518; there may be other Braden cut off scores for other research (Flanagan 1995 and 
Braden and Bergstrom 1987). 
These scales have been evaluated and several suggestions have been made to improve the 
performance of current scales and refine their structure (Papanikolaou et al. 2003,2007, 
Defloor and Grypdonck 2004). 
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Reviews of RASs 
The literature critically reviews RASs and discusses different issues in relation to their 
evaluation and refinement, clinical effectiveness and reliability. 
RASs evaluation 
RASs have been evaluated using reliability and validity in terms of sensitivity (the 
percentage of patients who were predicted to develop ulcers and went on to do so), 
specificity, (the percentage of patients who were predicted not to develop ulcers and did not 
do so (Flanagan 1995), and predictive value. These measures have varied greatly among 
RASs (AHCPR 1992), but are the most commonly used and recommended tools for 
evaluating the predictive validity of PU RASs (Defloor and Grypdonck 2004). The 
inconclusiveness of studies examining the reliability and validity of various RASs makes 
the choice of a definitive RAS impossible (Flanagan 1995). For example, among 
hospitalised patients, the sensitivity of the Waterlow scale was 89.5 per cent while its 
specificity was 22.4 per cent (Schoonhoven et al. 2002b). Although Pancorbo-Hidalgo et al 
(2006) have reported accumulated analysis of indicators of validity for the Braden, Norton 
and Waterlow scales as sensitivities of 57.1,46.8 and 82.4 per cent respectively and 
specificities of 67.5,61.8 and 27.4 respectively. Reed et al. (2001) have suggested that the 
Braden scale is the most sensitive and specific RAS currently available. This variability 
probably reflects the differences in study setting, populations and outcome measures that 
have been implemented (AHCPR 1992), study methods (Flanagan 1995), lack of an 
operational definition within risk categories (Edwards 1995), PU definition, demographic 
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data of assessed patients, sample sizes (Lindgren et al. 2002, Mitchell 2004 and Brown 
2004) and heterogeneity of length of observation (Defloor and Grypdonck 2004). 
Effects of clinical use of RASs on validity measures 
The validity measures of RASs' were highly variable in clinical practice. The main sources 
of such variability are: 
1) Different threshold scores (cut off points). The cut off point indicates the 
number of patients scored at risk of PU development using an RAS; as the 
number of at risk patients increases, the incidence rate decreases (assuming 
that PU incidence is the number of patients, from a total scored at risk 
according to an RAS, who developed new PUs), which in turn reduces the 
sensitivity of the RAS used. Several studies have used different cut off 
points among different risk groups. For example, although Bergstrom et al 
(1987) have suggested that by using a Braden score cut off point of 16, 
sensitivity was 100 per cent and specificity ranged from 64 per cent to 90 
per cent, Bergquist (2001) has evaluated the Braden scale scores in 
predicting Stage One to Four PUs and found that a Braden score of 19 was a 
better predictor in older people. Also, Brown (2004) has reported that a cut 
off of 18 or 19 were found to be the best predictors of risk of PU 
development using the Braden scale, while Defloor et al (2005) use a cut off 
score of less than 17 for the Braden scale to compare the predictive value 
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between the Braden and Norton scales. As a result, validity measures in 
terms of sensitivity and specificity were not relatively comparable, which 
make it difficult to conclude a pattern of using specific cut off points for 
particular RASs in settings and populations. 
2) The use of a wide range of preventive measures when evaluating RASs. 
The use of effective prevention will alter sensitivity and specificity (Defloor 
and Grypdonck 2004, Defloor et al. 2005). The use of protective measures 
(support surfaces, turning and nutritional support) may be effective in 
reducing PU incidence if applied to those patients greatly at risk of PU 
development; however, this would reduce the sensitivity of the RAS used 
(Anthony et al. 2006). On the other hand, administering effective PU 
prevention relies on nurse competence to correlate the severity and degree of 
risk to the effective prevention required. For example, Gunningberg et al. 
(1999) say that risk identification using RASs does not necessarily mean that 
a patient will receive more preventative care. Additionally, Gunningberg 
(2005a) found that PU prevention was not optimal, as many patients with 
PUs or at high risk of PU development were not given prevention strategies. 
3) Users' perceptions of the purposes of RASs. RASs were defined earlier 
(Scott 2000) as being devised to identify patients at risk of PU development. 
Edwards (1995) suggests that the Waterlow scale may be a predictor of PU 
development in elderly people, and Lindgren et al. (2002) also believe that 
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RASs predict PU development. Different perceptions of the purpose of using 
RASs may increase the outcome expectations in clinical use, and change 
their purpose to that of diagnostic screening. Defloor and Grypdonck (2004) 
have pointed out that RASs are not intended, unlike diagnostic tests, to 
identify the existence of a certain condition, but to ascertain the risk that a 
certain condition, such as PUs, may develop. RASs are also used to identify 
patients in need of preventive measures and are intended to contribute to the 
prevention of PU development. As a result, different perceptions of RAS 
may influence the reliability (Kelly 2005) and validity of RASs. 
Reliability of RASs 
RASs are shown in several studies to be reliable. Edwards (1995) reports that the Waterlow 
scale demonstrates 92.5 per cent reliability in terms of observer agreement, and it is 
possible that this scale is less reliable than Norton or Braden (Anthony et al. 2006 and 
Kelly 2005). Defloor et al. (2005) report the high reliability of both the Braden and the 
Norton scales, and Pancorbo-Hidalgo et al. (2006) have systematically reviewed the 
Waterlow, Norton, and Braden scales and found that the Braden scale is the most reliable in 
terms of inter-rater (inter-observer) compared to other risk assessment scales. The 
reliability of RASs might be influenced by the competence of individual nurses who assess 
risk in different ways (Gunningberg et al. 2001a and Reed et al. 2001). Additional factors 
such as training on the use of RASs (Defloor and Grypdonck 2005) and collecting accurate 
data will affect the reliability of RASs (Anthony et al. 2006). 
44 
Improving RASs validity and predictive performance 
Different approaches have been suggested through which to validate RASs and strengthen 
their performance. Several reviews conclude that RASs are inadequately reliable and that 
their predictive performance is insufficient (Papanikolaou et al. 2007, Defloor and 
Grypdonck 2004, Flanagan 1995, Lindgren et at. 2002, Mitchell 2004 and Defloor et at. 
2005). For example, Defloor and Grypdonck (2004) have suggested that utilising the 
outcomes of studies of different risk groups using two cut off points and combining two 
RASs will reveal significant data that may assist in the refinement of current RASs, while 
Papanikolaou et al. (2007 and 2003) have suggested the use of multivariate modelling of 
PU risk to determine and adequately weight the risk factors included in current RASs. For 
example, Anthony et al (2003) have used logistic regression and ROC analyses to consider 
significant predictive variables of PU development, and it was suggested that gender be 
removed from the Waterlow scoring system to simplify and improve its predictive 
performance. Vanderwee et al. (2007) have selected a new approach to examining whether 
the use of non-blanching erythema as indicator for the commencement of prevention care 
has better outcomes in terms of PU occurrence than conventional use of RASs. The 
findings were not significant enough to suggest refinements to RASs based on the 
characteristics of those patients with non-blanchable erythema who developed PUs despite 
the prevention care provided. 
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Clinical effectiveness of RASs 
A limited number of studies have reviewed the clinical effectiveness of using RASs. Few 
reviews have discussed the effects of using RASs on patients' outcomes in terms of PU 
prevalence and/or incidence. A critical review of these studies demonstrates a significant 
reduction in PU incidence (Bale et al. 1995 and Hodge et al. 1990) while Gunningberg 
(1999) finds no significant difference in the reported PU prevalence between an 
experimental group, on which risk assessment and PU classification were performed on a 
daily basis, and a control group, where intervention was not applied. The results of these 
studies were not conclusive enough to demonstrate robust evidence for the clinical 
effectiveness of using RASs on patients' outcomes, as many flaws were reported. These 
included: 
1) Specific patient groups at risk such as hospice patients (Bale et al. 1995) and 
patients with hip fractures (Gunningberg 1999) were studied. 
2) Outcome measures where PU incidence was used in Bale et al. (1995) and Hodge 
et al. (1990) and PU prevalence was used in Gunningberg (1999). 
3) Different interventions such as sophisticated prevention measures (Bale et al. 
1995) and greater awareness level of the nurses who applied PU prevention 
(Hodge et al. 1990). 
4) The effect of contributing factors (age, gender, and diagnosis) may be associated 
with PU development (Bale et al. 1995). 
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5) Although the Braden scale was the extensively studied RAS (Pancorbo-Hidalgo 
et al. 2006), the Norton (Hodge et al. 1990) and modified Norton (Gunningberg 
1999) scales were used in evaluating the clinical effectiveness of RASs on 
patient outcomes. 
However, the conclusions of these studies and systematic reviews by Cullum et al. (1995) 
and Pancorbo-Hidalgo et al. (2006) were that there is no evidence that RASs are effective 
tools for reducing PU occurrence. This does not mean that RASs are useless in practice; 
they may be effective within a formal risk-based programme (Halfens et al. 2000). 
Summary of reviews of RASs 
From 1990 on, a steadily increasing number of research projects on risk assessment tools 
were initiated (see Table 2.1). Most topics have been studied using a descriptive design 
(Halfens 2001). The literature reviewed indicates ambiguity in the way that certain risk 
factors have been chosen when devising RASs. Also, it was not clear how the risk factors 
were weighted to produce a total score and the role of the other factors in contributing to 
PU development. Numerous studies have evaluated RASs in the last 15 years; a limited 
number of them empirically investigated the risk factors that predict PU development 
(Pedley 2000, Anthony et al. 2006, Waterlow 1996, Lyne et al. 2000 and Scott 2000). 
A crucial problem affecting proper utilisation of RASs is related to the scale's reliability 
and validity in terms of sensitivity, specificity and predictive value, which vary according 
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to changes in patients' conditions and the nursing care they receive. The AHCPR (1992) 
stated that the reported specificity and sensitivity of RASs have varied greatly. This 
variability probably reflects differences in study settings, populations, outcome measures 
(such as inconsistent definition of Stage One PUs) and the degree to which preventive 
measures have been implemented. Furthermore, many RASs lack operational definitions of 
risk factors, leading to their poor predictive performance. However, RASs rely on the 
competence of individual nurses who all assess risk in different ways (Edwards 1995, 
Flanagan 1995, Reed et al. 2001 and Gunningberg et al. 2001a). 
The literature review showed that there are currently no RASs that are completely sensitive 
or specific. It is also not clear which one is the best, as there are no standards by which to 
compare RASs with each other. Furthermore, no RAS is perfect (Anthony et al. 2004). 
Defloor and Grypdonck (2004) suggest that making comparisons between the scales based 
on specificity and sensitivity is meaningless, and furthermore that the significance of 
differences is doubtful, as they do not usually take into account the prevention strategies 
that affect the outcomes, thereby their value is limited (Anthony et al. 2004 and Scott 
2000). This raises the question whether sensitivity, specificity and predictive values are 
indeed valid measures for the performance of RASs (Edwards 1995 and Defloor and 
Grypdonck 2005). However, such measures should continue to be used to test RASs until 
valid and refined ones have been created. 
Most RAS evaluation studies considered one scale and used different methods and different 
patient groups (Flanagan 1995, Pedley 2000 and Lindgren et al. 2004). For example, of the 
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many extant risk assessment scales, only the Norton and Braden scales have been tested 
extensively (Reed et al. 2001 and Pancorbo-Hidalgo et al. 2006). The Braden scale has 
been widely used as a risk assessment tool, evaluated in diverse sites that included medical- 
surgical units, intensive care units, paediatric wards and nursing homes. The Norton Scale 
has been tested with elderly patients in hospital settings (AHCPR, 1992). 
Arguably an ideal research environment in which to evaluate RASs in clinical practice is to 
administer a RAS for the patients, and then to offer no preventative intervention but for 
them to be closely monitored to identify those who develop PUs and those who do not. 
However, such research would not be ethically advisable (Defloor et a! 2004). The issue of 
threshold scores is another important one affecting the choice and the performance of a 
scale (Clark and Farrar 1991, Edwards 1995, Scott 2000 and Brown 2004). 
To sum up, the literature suggests that several studies evaluate and examine RASs in terms 
of predictive performance without producing any clear and consistent evidence that RASs 
are effective tools in improving patients' outcomes, and that a more valid way of evaluating 
the clinical effects of using RASs would be to measure these effects on patient outcomes in 
terms of PU incidence reduction. 
49 
2.6 Nurses' clinical judgment 
Clinical judgment (CJ) and clinical decision making have been used to describe the same 
entity (Kozier et al. 2004 and Atherton 2004). Additional terms are used to describe CJ in 
literature; these include clinical reasoning, clinical inference and diagnostic reasoning 
(Thompson and Dowding 2002). These terms are interlinked and it is difficult to make clear 
distinctions between them. In a nursing context, CJ is the most commonly used term to 
describe the way by which the nurses develop and select a set of alternative courses of 
action to decide patients at risk of PU development and the related prevention strategies. CJ 
becomes a complex process because of the distribution of resources, undetermined roles of 
health care members, the conflicting forces that may affect the decisions to be made, and 
the challenging and rapidly changing situation in which nurses are required to make many 
decisions every day. The prevention of pressure ulcers represents one area of decision 
making (Gunningberg et al. 2001 a). 
Theoretical background of CJ and decision making 
Thompson and Dowding (2002) and Shaban (2005) suggest that judgment and decision 
making theories can be divided into three categories: normative, descriptive and 
prescriptive. Normative theories assume that an individual is rational and logical. It 
concentrates on how decisions should be made in an ideal situation. Furthermore, 
normative theories are concerned with a decision's outcome and not with how decisions or 
50 
judgments are made. Descriptive theories describe how individuals reach judgments and 
decisions. Prescriptive theories try to improve these individual judgments and decisions by 
examining how individuals actually make them, and by trying to help them. 
Thompson and Dowding (2002) explain CJ as an information processing theory, which 
suggests that individuals go through a number of phases in their reasoning process. The 
common features of this process include the gathering of preliminary clinical information 
about the patient, the generation of initial tentative hypotheses to explain the data collected, 
the interpretation of information and its classification as confirming or refuting the initial 
hypotheses, and the subsequent evaluation and choice of a possible explanation based on 
the balance of the evidence. 
Another approach is suggested by Kozier et al. (2004) and Atherton (2004). CJ is proposed 
as a critical thinking process for choosing the best actions to meet desired goals. At the 
same time critical thinking is the process that includes creativity, problem solving and 
decision making. The critical thinking process, as related to the clinical setting, implicitly 
includes theoretical and applied knowledge. Theoretically, CJ includes an identification of 
purpose, a setting of criteria regarding desired outcomes, a weighing of the criteria and a 
seeking of alternatives, an examination of those alternatives by the application of creative 
thinking and scepticism, implementation of the decision into action and finally an 
evaluation of the outcomes. 
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Nurses seem to use past experiences when making clinical decisions regarding PU 
management. Thompson and Dowding (2002) have discussed how past experience may 
influence clinical judgment. Nurses may use similar patients with similar condition 
dialogue, past experience of a probable outcome of the patient's present state and a 
knowledge of the patient (Defloor and Grypdonck 2005) in order to form a judgment. 
CJs would be effectively enhanced through self-assessment (Kozier et al. 2004), seeking 
situations where good thinking is practiced and creating environments that support critical 
thinking (Atherton 2004), peer evaluation and reliance on memory (Thompson and 
Dowding 2002). 
Are RASs doing better than nurses' CJ? 
The literature suggests contradictory views about the role of CJ in clinical performance in 
relation to PU risk assessment and prevention. For example, Defloor et al. (2004) have 
argued the role of nurses CJ in PU prevention. The researchers point out that in most 
studies nurses decide autonomously whether or not a patient receives preventive care, and 
which preventive measures to use depending on experience, knowledge, beliefs, type of 
staff, workload, and equipment, thereby different patients will be identified as at risk and 
will receive preventive measures. Whilst Defloor et al. (2004) cast doubt on the 
generalisation of the results of these studies, Emparanza et al. (2000) develop a reliable PU 
severity scoring system based on assessments by experienced clinicians, which verifies the 
important role of CJ in clinical practice. 
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A limited number of studies have compared the PU RASs with nurses' CJ in terms of 
validity measures. Gould et al (2002) and Gould et al. (2004) have examined and compared 
the validity of RASs and nurses' CJ using patient simulation. Nurses were requested to rate 
the patients' risk using an RAS and visual analogue scale as a measure of their own clinical 
judgment, and these assessments were then compared with assessments of expert panel 
used as a gold standard. The results of Gould's studies have shown that nurses' clinical 
judgment agreed more closely with expert opinion than any of the RASs used, which would 
imply that using nurses' CJ is superior to the RASs in identifying risk of PU development 
(Anthony et al 2006). However, Pancorbo-Hidalgo et al's (2006) systematic review of 
RASs and nurses' CJs finds that although the Braden scale achieves the best predictive 
value of any RAS, and the Norton and the Waterlow scales do not perform better than 
nurses' CJ, RASs were better PU risk prediction tools than nurses' CJ. Additionally, 
Defloor and Grypdonck (2005) suggested that although the predictive value of the Braden 
and Norton scales was poor, their use is better than relying on nurses' CJ. 
The poor PU risk prediction performance of RASs (Flanagan 1995) and of RASs compared 
with CJ (Brown 2004, Defloor and Grypdonck 2005, Gould et al 2002 and Gould et al. 
2004) suggests that there is insufficient evidence on the relative accuracy of RASs and 
nurses' CJ, which makes it difficult to confirm whether RASs are better tools than nurses' 
CJ in identifying patients at risk of PU development; it also casts doubt on the evidence of 
their use in improving patients' outcomes (McGough 2000, Brown 2004 and Cullum et al. 
1995). It also suggests that the employment of validity measures such as sensitivity and 
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specificity are not appropriate methods by which to evaluate the predictive value of RASs 
compared to CJ (Defloor and Grypdonck 2005), and a check needs to be made against 
patients' outcomes (Anthony et al. 2006). 
As a result of these findings and the poor predictive value of RASs and CJ, it has been 
suggested that RASs aid and facilitate CJ (Scott 2000, Brown 2004 and Mitchell 2004) and 
encourage systematic evaluation of patients' risk of PU development (Flanagan 1995), as 
there is no robust research evidence to support the use of RASs as superior to nurses' CJ in 
identifying patients at risk of PU development. 
A key finding of these critical reviews is that there is a need to compare the effects of 
using RASs and nurses' CJ on patients' outcomes in terms of PU incidence - for instance, 
to provide clearer evidence about their role in improving patients' outcomes. 
2.7 PU education and training 
PU training and education is well documented in the literature, which suggests that it is 
fundamental in promoting awareness of PU prevention and best practice management 
(Butler 2004, Hopkins 1998, Banks 1998, Panagiotopoulou et al. 2002, Day et al. 1997, 
Scott 2000, Bostrom and Kenneth 1992, Pieper and Mott 1995 and King 2000). 
PU prevention programmes including continuing education programmes have demonstrated 
significant reductions of PU incidence and time taken for treatment (Buss et al. 1999, 
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Suntken et al. 1996 and Day et al. 1997). AHCPR (1992) has suggested that PU educational 
programmes should be structured, organised and comprehensive in order to reduce the 
incidence of PUs. PU training programmes should include information on aetiology, risk 
factors, risk assessment tools and their application, skin assessment, selection and/or use of 
support surfaces, development and implementation of individualised programmes of skin 
care, demonstration of positioning and instruction on accurate documentation of pertinent 
data. Several studies reviewed the effectiveness of education in improving PU risk 
assessment skills. For example, Gunningberg et al. (2001a) use a PU prevention 
educational programme including documentation of risk of PU development and they 
conclude that, even with limited utilisation of available knowledge and research findings in 
clinical practice, nursing staff knowledge and documentation of risk, prevention and 
treatment of pressure ulcers could be improved. 
Clarke et al. (2005) evaluated the implementation of PU programmes based on AHCPR 
(1992) guidelines in clinical practice and found that nurses' knowledge increased in relation 
to PU prevention and treatment. Increased nurses' knowledge about PU risk assessment and 
producing higher risk scores might not lead to better PU prevention (Anthony et al. 2006). 
Although nurses have a good knowledge of PU risk factors to identify those patients at risk 
of pressure development, they are not able to interpret such knowledge into practice in 
order to offer related PU prevention care (Panagiotopoulou and Kerr 2002). Therefore, in 
any PU prevention programme implementing RASs, training has been suggested as an 
essential component for the appropriate application of RASs (Defloor and Grypdonck 
2005) and to link the higher scores of a particular RAS to prevention intervention that 
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reduces the risk of PU development (Anthony et al. 2006). The literature reviews have 
shown the effects of PU prevention programmes, which consist of several components 
including the RASs and training on them. The training in this case may conceal the clinical 
effects of applying an RAS in terms of patient outcomes. Therefore, no clear research 
evidence will apply to an RAS itself in improving these outcomes. 
2.8 Theoretical background of risk and judgment 
As highlighted in Chapter One, risk is defined as the probability that a particular' adverse 
event occurs during a stated period of time, or results from a particular challenge 
(Thompson and Dowding 2002). Risk assessment is one of the most common judgments 
nurses make in clinical practice which can have a significant effect on the care that patients 
receive (Thompson and Dowding 2002). In health care, PU is considered a clinical risk: 
thus risk assessment becomes an essential component in any PU prevention and 
management programme. It provides a probabilistic function to identify those patients at 
risk of PU development. Though PU risk assessment is fundamental, inaccurate judgments 
of patients at risk of PU development may mislead therapeutic decisions such as providing 
inappropriate support surfaces. Therefore, it is imperative to explore and understand the 
foundations of risk which is central to risk assessment and risk management processes, with 
regard to judgments nurses make. 
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The literature on risk and risk management suggests that the nature of risk issues and 
contribution to effective risk management cannot be drawn from a single disciplinary 
perspective because the nature of risk issues is multi-dimensional and the qualities of 
complexity, conflict and uncertainty are taken to be fundamental in characterising the 
contemporary environmental risk issues (Macgill and Siu 2005). 
The literature review describes several theories which can useful in understanding risks and 
risk perceptions, which are central to risk assessment, risk management and decision- 
making. It includes an overview of Risk Management Models, Cultural Theory of Risk, 
The Risk Society Model, Psychometric Approach and Social Judgment Theory. 
Risk management models have been used in clinical practice to reduce the risk and to 
improve the quality of patient care (Scally and Donaldson 1998). They are used to 
strengthen management practices (Robillard 2001) and to help create a culture committed 
to managing risk through proactive and continuous development (Braine 2006). PU risk is 
one of these risks in the health care context. These models can be used to integrate PU risk 
management throughout continuous process of risk assessment, risk evaluation, and risk 
management activities. Although these models are committed to providing a 
comprehensive view of risk and risk management, they do not present an understanding of 
the relationship between risk, risk assessment and judgments. All these are essential to 
improve judgments and decisions related to PU risk prevention and management. Thus, 
these models cannot be used to contextualise the PU problem, but are restricted to framing 
PU risk management activities in health practice. 
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On the other hand, risk assessment is influenced by risk perception of individuals who 
apply it. Therefore, different influential streams of thought were used to describe and 
analyse risk and risk perception. An example of these theories is the Cultural Theory of 
Risk which argues that all risks are socially constructed and identifying risk requires 
configuration of ideas about what outcomes would be undesirable and what conditions put 
us in danger of experiencing those outcomes. The theorists assume that risks pose a threat 
not only to an individual's well being, but also to the prevailing social order (Casiday 2007, 
Cultural Theory of Risk 2007 and Thompson et al. 1990). Although this theory is helpful to 
view the social construct of risk, it lacks empirical support (Casiday 2007) and lacks a 
convincing rationale of how different beliefs and concerns might affect the relationship 
between risk and human judgments. The management of patients within a health care 
community can be framed within such a social construct although it may not provide an 
understanding on how nurses' judge patient's at risk of PU development nor would it help 
to improve nurses' decision making abilities in managing PU risk. 
Additional focus on sources of risk is presented by The Risk Society Model (Casiday 
2007). It assumes that a growing awareness of risk is a central part of reflexive interaction 
with the structures of modernity as its benefits have been accompanied by many dangers 
inherent to the process of industrialisation. The theory of risk society is predominantly 
concerned with `manufactured risks' where there is a potential to assess the level of risk 
that is being produced, or that is about to be produced (Ericson and Haggerty 1997). 
According to this model, the risk position is fundamentally dependent on knowledge and 
access to information, which may or may not be correlated to economic status, but often is. 
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This model is of limited generalizability across cultures and in fact may only apply to a 
very particular section of modem industrial society (Casiday 2007). Although this model is 
helpful to view new sources of risk and contribute to a deeper understanding of risk, it is 
restricted to examine the information that nurses use to produce different judgment as well 
as to clarify and improve the process of PU risk assessment. The psychometric approach 
has been acknowledged in exploring risk from a risk analysis perspective in order to 
understand how people vary in deciding on risk. Early work shows that people use a 
number of heuristics (are usually useful shortcuts of thinking) to evaluate information, and 
the experts are not necessarily any better at estimating probabilities than lay people (Slovic 
2000). Cognitive theorists suggest that people generally see most risks in society as being 
unacceptably high. They also found that both expert and lay people had a basically accurate 
view of which risks are fatal, but use different aspects of risk to perceive it. These aspects 
are a dread risk (i. e. uncontrollable, catastrophic, fatal and involuntary) and unknown risk 
(i. e. delayed, new and unknown to science) (Slovic 2000 and Casiday 2007). Affective 
theories influence risk perception assuming that affect causes evaluations of an object's 
riskiness. A key finding in support of this theory is the strong negative correlation between 
people's judgments of the risk and benefit of an activity. That is, activities judged to have a 
high risk are nearly always seen as having low benefits, and vice-versa (Slovic 2000). This 
approach is useful to understand how people perceive risk through risk analysis approach. It 
has been criticized in that it fails to take into account interactions among people, culture 
and politics which probably limit its usefulness (Casiday 2007). In the case of PU risk, 
where it is important to clarify how nurses perceive the risk of PU, the process of how they 
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identify people at risk, how they define that risk, and the relationship between risk and 
judgment, the information used to feed these processes are not fully explained. 
The previous approaches and theories of risk assessment and management described so far 
have strengths and weaknesses for examining the nurses' judgments in relation to those 
patients at risk of PU development. PU risk assessment is a key to these judgments in order 
to improve patient's care and reduce PU occurrence. 
The Social Judgment Theory (SJT) examines the relationship between risk, risk 
assessment and how available information can affect judgments and decision making. It 
provides a venue to enhance our understanding of cognitive processes between individuals. 
The SJT is built on the early work of the psychologist Egon Brunswik who found the 
principles of probabalistic functionalism and the core of SJT which is the Lens Model 
(Rand 1967, Ashton 1973, Louis 1983, Picart 1990 and Thompson and Dowding 2002). 
The SJT suggests that human judgment relies upon probabilistic information in making 
judgments about some relevant part of an uncertain environment (Ashton 1973). 
The SJT assumes that people make judgments from information that is probably relevant to 
the judgment objective, based on predictive validity, and can be organized and patterned in 
different ways (Picart 1990). Thompson and Dowding (2002) and Ashton (1973) have 
described Brunswik's lens model, which was originally taken from Hammond et al. (1964), 
as follows: It divides the world into two parts: the environment (ecological or real situation) 
(represented by the left side of the lens model) and the judgmental system (represented by 
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the right side of the lens model). A variety of different information cues are directly linked 
to the environmental side. Each of these cues has a different degree of validity attached to 
it. Individuals use these cues to make judgments based on their weighting system. As a 
result, the way the information cues have been used, the judgment may or may not reflect 
the ecological situation. The multiple regression analysis has become the most common 
methodology to model the association between information cues and individual judgment 
(Ashton 1973 and Thompson and Dowding 2002). The SJT can be employed as congruent, 
consistent and a valid way to examine the relationship between risk and judgments in PU 
problems. It conveys the core work in this study by clarifying the effects of using RASs as 
a method of PU risk assessment compared to nurses' knowledge and experience (CJ) on 
patient outcomes in terms of PU occurrence. It helps to conceptualize the main concepts 
under investigation and suggests ways to improve nurses' judgment and decision making in 
PU risk management. As the PU problem is multifactorial and can be viewed from different 
perspectives in clinical contexts, the SJT is flexible to model this problem addressing 
psychological, social, cultural and physical perspectives of it. The SJT has been 
acknowledged in the literature for the systematic examination of the accuracy of judgments 
and captures the accuracy of instruments designed to enhance professional judgments such 
as PU RASs (Thompson and Dowding 2002). 
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Figure 2.1 Brunswik's lens model in assessing risk of PUs development 
adopted from Thompson and Dowding (2002) which was originally taken 
from Hammond et al. (1964) 
Patient outcomes in terms 
of PU incidence rate (ra) 
X1 Nursing interventions in PU 








Information cues from 
RASs and! or nurses' 
knowledge and experience 
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9 Ye = The actual patient state in terms of signs and symptoms of PU such as 
inability to respond meaningfully to surroundings and skin maceration. 
9 XI Xn = Cues of information that are related to the patient state which may be 
used to judge the current state of the patient, or to predict the future state. The 
sources of this information are RASs and/ or nurses' knowledge and experience. It 
may vary in weight (For example, 2 points for obese patients and 3 points for 
those patients their weight below average by using Waterlow scale) or importance 
(For example, the degree of physical activity). It may represent the risk factors in 
RASs. 
" Ys = The nurse's judgment (clinical decision) about the level of risk of PUs 
developing, based on the way the information cues (Xn) have been used. This 
judgment is followed by nursing interventions in PU prevention and management. 
" ra = The achievement which shows the accuracy of the judgment made in 
association with ecological situation. It represents patient outcomes in terms of 
PU incidence rate. 
The application of the lens model in context of PUs risk assessment and risk management 
(Figure 2.1) may enhance understanding of the relationship between PU risk identification 
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and judgements or decisions that have been taken to combat risks of PU development. The 
model presents the actual risk of PUs development that the patient may experience (Ye). A 
set of cues (X1-Xn) are associated with PU development and actual patient state, with a 
particular degree of validity. The cues represent either the known categories of risk factors 
(risk indicators) in RASs such as mobility, activity, nutrition, shear and friction, sensory 
perception and moisture in the Braden scale, or the factors (risk indicators) that nurses 
perceive from their experience in PUs development. The risk factors are validated in RASs 
by using multiple and logistic regression analysis which indicates the degree to which the 
probabilistic cues can be used as a source of information about the state of risk of PUs 
development. The way nurses weigh information cues include their experience and the 
importance of information given, which may influence the judgement. It indicates the 
degree of relationship between a given risk indicators and nurse's judgment of patients at 
risk of PU development over a number of trials (utilisation). However, nurses' judgments 
(Ys) of those patients at risk of PU development may be influenced by the number of 
available information cues (risk indicators in RASs for instance) and the number of these 
cues that are associated with PUs according to their importance and/ or weight. This may 
illustrate variances in judgments of patients at risk of PU development when different risk 
assessment methods (such as RASs and clinical judgment) are used by different nurses. 
When judgments are made, they are translated into nursing interventions to prevent and 
manage the risk of PU development. Thereafter, the patients' outcomes (ra) in terms of PU 
incidence are measured to verify the accuracy of judgments in relation to actual patient 
status, which presents feedback about the overall relationship between PU risk assessment 
and nurses' judgments. Thus, the adoption and application of this approach may facilitate 
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and improve the management of clinical risks including PUs through better understanding 
of the relationship between risk assessment and CJs and employment of tools that improve 
nurses' judgments in clinical practice such as continuous training in PU prevention and 
management. 
2.9 Conceptual framework 
A conceptual model deals with abstractions (concepts) assembled by virtue of their 
relevance to a common theme (Polft and Hungler 1999). It broadly presents an 
understanding of the research problem and reflects the assumptions and philosophical 
views of the model's designer. It guides the researchers' quest for extension of knowledge 
by providing both direction and impetus. 
In this study, a general model (Figure 2.2) was devised to explain the relationship between 
concepts within the study. It broadly presents an understanding of the effects of using RASs 
on patients' outcomes as an area of interest and reflects the philosophical views of the 
researcher. This model is based on the literature review's finding that there is no clear 
evidence in relation to the effects of using RASs, compared with nurses' clinical judgment 
and PU prevention and management training programmes, in improving patients' outcomes 
in terms of PU incidence reduction. 
This model presents assumptions that interlink different concepts. It included the following 
concepts: The Braden scale for PU risk assessment (Appendix J), PU prevention and 
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management training programmes (Appendix E), nurses' clinical judgement (see chapter 2, 
section 2.6), nursing interventions such as frequent turning, protective mattresses (see 
chapter 3, section 3.5.3), skin barrier creams and nutritional supplements and vitamins in 
PU prevention and management, and patient outcomes (the consequences of PU 
development, see chapter 2, section 2.3) in terms of the PU incidence rate. 
In this model, the effects of RASs (the Braden scale) have been compared to the effects of 
PU training programmes and nurses' CJ, all of which are in a complex relationship with 
each other; this may mask the effect of an RAS itself, as each variable has independent 
effects on nursing interventions toward PU prevention, which in turn influence patients' 
outcomes in terms of PU incidence. On the other hand, the implementation of a RAS is 
clinically associated with nurses using their CJ to identify those patients at risk of PU 
development and then deciding on PU prevention interventions. This may be pointless 
without training, which also makes it difficult to provide clear evidence about the effects of 
RASs themselves. This model therefore suggests a new approach to examining the effects 
of RASs on patient outcomes. The patients were divided into three groups, and the nurses 
who provided them with care received different interventions. Group One nurses (the 
Braden scale group) underwent a mandatory wound care management study day, PU 
prevention training programme and specific training on the application of the Braden scale. 
These nurses were required to implement the Braden scale on their patients in the post- 
intervention stage. Group Two nurses (the training group) also underwent the wound care 
management study day and PU prevention training including an overview of RASs. These 
nurses, however, were not required to apply any of RASs and were given the choice of 
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applying a RAS or using their own CJ in relation to PU prevention. Group Three nurses 
(the clinical judgment group) undertook the same mandatory wound care management 
study day as the others, but these nurses continued to use CJ in relation to PU prevention. 
Thereafter, the patients' outcomes in terms of PU incidence were measured according to 
Fletcher's (2001) formula (see chapter 3, section 3.11) 
According to the conceptual model, this approach was presumed to provide clear evidence 
regarding the clinical effectiveness of using RASs on patient outcomes in terms of PU 
incidence rates. It also resolves the interaction between the effects of RASs, nurses' CJ and 
PU training on improving patient outcomes. 
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2.10 Summary of Literature Review 
A critical review of the research literature revealed that there is a lack of national and 
international consensus on PU definition, aetiology, classification systems, risk factors, risk 
assessment scales and cut off threshold scores. It showed a lack of consistent and 
standardised research methods in terms of different populations, data collection methods 
and patient observation methods, as well as periods of observation. Moreover, most of the 
studies are of descriptive design. 
The literature review showed inadequate training and knowledge, under-reporting of PUs 
and variations in preventive measures that made it difficult to compare the data collected. 
This would urge the need for a consistent and standardised research methodology to 
explore the clinical effectiveness of a PU prevention policy and to clarify which 
components of prevention are effective in promoting patient outcomes. 
Risk assessment scales were reviewed and showed that validity measures in terms of 
sensitivity and specificity were extensively used to evaluate the predictive performance of 
RASs in relation to the risk of PU development. It showed also that these measures are 
highly variable in clinical use due to different threshold scores used, the wide range of 
preventive measures implemented and users' perceptions of the intended purpose of a given 
RAS. 
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The clinical effectiveness of using RASs was discussed in a limited number of studies, all 
of which examined the Norton scale and/or its modification. The conclusion of these 
studies was that there is no evidence that RASs are effective tools in improving patient 
outcomes in terms of reducing PU occurrence. 
Despite their limitations, and that fact that no information is currently available to suggest 
that adaptation of RASs or the assessment of any single risk factor or a combination of risk 
factors predict risk as well as the overall scores obtained by the RASs, Lindgren et al. 
(2002) believe that they may be useful for prediction of PU development in clinical 
practice. Their use ensures systematic evaluation of individual risk factors (AHCPR 1992, 
Lyne et al., 2000). However, RASs should be used in conjunction with CJ as part of a 
comprehensive PU prevention programme. Additionally, further refinement and 
investigation of RASs and their role in PU prevention are suggested. 
This literature review reminds us that variability in findings is expected when we attempt to 
predict and prevent PU occurrence. It is necessary to remember patients' individual 
characteristics and consider the patient care environment as confounding variables in any 
RAS prediction model used. Therefore, a suggested valid means of evaluating the clinical 
effects of using RASs is to measure these effects on patients' outcomes in terms of PU 
incidence reduction. 
The literature review revealed contradictory views about the role of nurses' CJ; it suggested 
that there was insufficient evidence on the relative accuracy of RASs and nurses' CJ, since 
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both had poor predictive validity. A need to compare the effects of RASs and nurses' 
clinical judgment on patient outcomes in terms of PU incidence was suggested. 
Based on literature reviewed, it is noted that there is diversity in the level of nurses' 
knowledge about PU care. Furthermore, in spite of the fact that nurses are knowledgeable 
about risk factors and risk assessment, they do not always appear to turn their knowledge 
into practice. However, nurses' knowledge would be improved through continuous training 
and utilisation of comprehensive PU prevention and management programme. PU training 
and education may mask the effects of using RASs themselves in improving patient 
outcomes. 
Foundations of risk and risk assessment were reviewed. Different theoretical backgrounds 
have been described including their strengths and weaknesses. The Social Judgment Theory 
has been introduced to explain the relationship between PU risk assessments and nurses' 
clinical judgments. It enhances understanding of the usefulness of using RASs compared to 
CJ in PU risk management in health. 
A general conceptual model was devised to facilitate a greater understanding of the 
relationships between different concepts used in the study. The conceptual model 
introduced a valid means of evaluating the effects of using RASs on patient outcomes in 
terms of PU incidence, a means which resolves the complex interaction between the effects 
of RASs and nurses' CJ and PU training. 
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Chapter Three: Methodology 
Introduction 
This chapter introduces the study methodology and includes the usefulness of using a 
quantitative design, the setting of the study, the study sample design, the instruments 
employed in the study, the validity and reliability of the Braden scale, the process of data 
collection, ethical considerations, the plan of data analysis process and the pilot study 
report. 
Research is the process of collecting information about a particular subject, and includes 
careful or diligent searching, studious inquiry or examination and investigation or 
experimentation. Research aims for the discovery and interpretation of facts, revision of 
accepted theories or laws in the light of new facts and practical application of such new or 
revised theories or laws (Merriam-Webster 2001). 
This study exemplifies a scientific nursing research process, which is based on a definition 
of scientific research. Nursing research is a systematic investigative approach to knowledge 
about issues of importance to the nursing profession. It aims to improve practice and 
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3.1 A quantitative approach 
There is no single way to understand our complex world through using one research 
method. Hence the main approaches utilised in nursing research are quantitative and 
qualitative, it is clear that there are several research problems which cannot be fully 
understood by any method in isolation. Both qualitative and quantitative methods have 
strengths and weaknesses. Therefore, both are essential to the development of nursing 
knowledge in such a way that the strengths of one approach complement the limitations of 
the other. This study adopted the quantitative research approach for the following reasons: 
1) The nature of the research problem under investigation required the need to express 
the effects of using PU risk assessment on patients' outcomes by using a quantitative 
measurement such as PU incidence rate. The quantitative approach emphasises the 
objectivity of the data collected, which deal with numbers rather than an individual 
response. 
2) The quantitative approach is efficient in testing hypotheses. 
3) The quantitative approach is consistent with the world view of the research problem 
under investigation. 
4) Most studies in nursing research continue to be quantitative. 
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5) Although several studies have been carried out on this topic, the current level of 
knowledge regarding the effectiveness of RASs on patient outcomes is scant. The 
quantitative approach can be useful and relevant to examine the effectiveness of using 
RASs as a nursing intervention and whether or not it works. 
6) The need for evidence-based nursing practice is well recognised. The quantitative 
research provides a large amount of information and thus a powerful body of 
knowledge about such a specific research problem. 
3.2 Study design 
This study aims to clarify and explore the effects of utilising RASs, education and clinical 
judgment on patient outcomes in terms of PU incidence rate among hospitalised patients at 
the RMH in Saudi Arabia. 
3.2.1 Hypotheses 
The following simple non-directional tentative hypotheses were formulated in the null form 
to achieve the aim of the study, guide scientific inquiry and provide direction to the 
research design: 
o Risk assessment scales (The Braden scale) have no effect on patient outcomes in terms 
of pressure ulcer incidence rate among hospitalised patients. 
o There is no effect for pressure ulcer prevention and treatment training on patient 
outcomes in terms of pressure ulcer incidence rate among hospitalised patients. 
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o There is no effect concerning the use of clinical judgment as a way of deciding patients 
at risk of developing pressure ulcer on patient outcomes in terms of pressure ulcer 
incidence rate among hospitalised patients. 
A hypothesis is a tentative prediction or explanation of the relationship between two or 
more variables (Polft and Hungler 1999). It offers direction and facilitates understanding 
and interpretation of the results. The previously stated hypotheses were consistent with 
previous research findings and may support the evidence for understanding the phenomena 
under study. The hypotheses were stated in simple, non-directional and null form for the 
following purposes: 1) to express the relationship between one independent and one 
dependent variable in each hypothesis; 2) to raise expectation regarding the relationship 
between variables, but do not expect the nature and direction of that relationship; 3) to 
provide a capability for testing procedures. 
3.2.2 Study design 
A research design is a researchers' overall plan for obtaining answers to the research 
questions or for testing the research hypotheses (Polft and Hungler 1999). It spells out the 
basic strategies that the researcher adopts to develop information that is accurate and 
interpretable and incorporates some of the most important methodological decisions such as 
the data collection plan, the sampling plan and the analysis plan. 
A prospective, non-equivalent control group, pre-test post-test, quasi-experimental, 
quantitative designs have been used to test the hypotheses and achieve the aims of the 
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study. A quantitative approach allows the researcher to examine the relationships between 
variables and test the effects of variables proposed in the conceptual model. A quantitative 
approach was required in this study because it was congruent and efficient in testing the 
hypotheses, it emphasised the objectivity of data collected (which deals with measurements 
and numbers), it was consistent with the phenomenon under investigation (most of the 
studies in nursing research concerning pressure ulcers were quantitative), and it can be 
useful and relevant in examining the effectiveness of using RASs as nursing interventions 
whether it works or not, which in turn contributes to an enhancement of evidence-based 
nursing in this area of practice. The quasi-experimental design was used to test the 
hypothesis in this study. It involved manipulation of the independent variable, but lacks at 
least one of the other two properties, either control or randomisation. It is acknowledged in 
the literature as a useful way of testing causality in settings when it is impossible or 
unethical to randomly assign subjects to treatment and control groups or to withhold 
treatment from some subjects (Talbot 1995). In the present study there was manipulation 
and control but randomisation was lacking. This design was convenient to this study 
because it is unethical to randomly assign patients under investigation in the same ward 
(this may prevent a group of patients from receiving adequate PU prevention and treatment 
facilities such as protective mattresses), and also because it was not suitable to randomly 
assign the nurses caring for the same patients, as a team, in the same ward. The great 
strength of quasi-experimental designs lies in their practicality, feasibility, and to a certain 
extent, generalizability. The basic difficulties in utilising this design are their relative 
weakness compared to experimental design: they do not allow the researcher to make 
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casual inferences and increased threats to internal validity (Talbot 1995) and (Polft and 
Hungler 1999). 
Non-equivalent control group pre-test post-test design was used for the following reasons: 
1) It involved manipulation and control of two or more groups of subjects. 
2) It assumed that the experimental and control (also referred to as the comparison 
group) groups are not equal, because of the inability to randomise the subjects (Polft 
and Hungler 1999). 
3) It was often used when it was impossible or unethical to withhold treatment from 
one or more groups - for example, withholding pressure ulcer prevention measures, 
then observing whether the patients developed PU or not. 
4) This design was suitable to this study. The patients were selected on the basis of 
specific units within the hospital. They were from three groups called A, B and C. 
The groups were not equal, as no randomisation among patients was used. 
Manipulation (treatment or intervention) was applied to groups A and B while group 
C was left untreated and was referred to as control or comparison group. 
The pre-test post-test non-equivalent control group design was used, which indicated data 
collection from all groups including the control group before and after introducing the 
manipulation (be it treatment or intervention). This enabled the researcher to improve the 
level of analysis of results. It showed whether the groups were initially similar in relation to 
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study variables or not. Furthermore, it allowed the researcher to analyse the differences not 
only between group scores on the pre-test (before intervention) and post-test (after 
intervention) but also the differences within group scores on these measures. As a result, 
the effects of different manipulations such as the Braden scale and training would be 
separated out. The literature acknowledged the use of this design, which may strengthen the 
results in a way that controls some threats to internal validity such as compensatory rivalry 
and demoralisation of control/comparison group subjects (Polft and Hungler 1999) and 
(Talbot 1995). 
A prospective design was utilised in the study. Prospective design starts with presumed 
causes and then proceeds chronologically to the presumed effect (Polit and Hungler 1999; 
Talbot 1995 and Seers and Critelton 2001). A prospective design was used in this study 
because the nature of the phenomena (pressure ulcer development) under investigation 
required it. 
In this study, the patients from groups A, B and C were observed weekly for signs and 
symptoms of PU development (stage one to stage four). The patients were observed 
longitudinally, for eight weeks in the pre-test and post-test phases to identify the PU 
incidence rate. PU incidence is the dependent variable constituting the study's main patient 
outcome measure. The prospective design allowed the researcher to investigate the 
presumed effects of introducing the Braden scale (the intervention introduced in group A) 
and the PU prevention and treatment training in group B (the intervention introduced in 
group B) on the patients' outcomes in terms of PU incidence rate among the three groups 
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A, B and C. The literature acknowledged the usefulness of using prospective design in 
providing evidence about the nature of relationships between variables. Although 
prospective designs are stronger than retrospective ones, they also entail a loss of follow up 
of subjects over time (also known as attrition or drop-out), a certain expenditure of time for 
collecting data, and high costs (Polit and Hungler 1999; Talbot 1995 and Seers and 
Critelton 2001). 
3.2.3 The characteristics of the quasi-experimental design 
1) Manipulation, which is an intervention or treatment introduced by the researcher in an 
experimental or quasi-experimental study. The researcher manipulates the independent 
variable to assess the impact on the dependent variable (Polft and Hungler 1999). 
A) Interventions applied to group A 
The nurses who provided care to patients in this group received the following 
interventions: 
1. Mandatory wound care management study day. The purpose of this study day 
was to introduce the nurses to contemporary wound management guidelines, which 
were essential to care for patients with wounds in their clinical settings. This 
educational activity was intended to provide the nurses with knowledge and skills 
about evidence-based wound management practice. This study day included 
sessions on the normal wound healing process, factors delaying the healing process, 
strategies of wound assessment and wound management, modem dressings, wound 
bed preparation and wound cleansing and irrigation. It also included case 
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presentations. PU management guidelines were an integral part to this study day as 
well (Appendix D). 
2. A PU prevention and management training programme, which was intended to 
provide the nurses with knowledge and skills about PU prevention and management 
guidelines. It included PU definition, PU physiology and epidemiology, the chronic 
wound healing process and factors that delayed that process. The programme 
enabled the nurses to develop PU prevention and management plans through the 
utilisation of international PU prevention and management guidelines. The 
programme included detailed discussions about various RASs such as the Norton, 
Waterlow and Braden scales (Appendix E). 
3. The Braden scale training. Nurses in this group had special training on the 
application of the Braden scale. The training included presentations, demonstrations 
and a 23-minutes video about the Braden scale. Thereafter, the nurses were required 
to use and implement the Braden scale on their patients in the post-test phase. The 
application of the Braden scale assumed to facilitate the nurses' decision making in 
relation to PU prevention and management. During this stage, the nurses received 
motivation, support and guidance from the research team and head nurses. 
B) Interventions applied to group B 
The nurses who provided care to patients in this group received the following 
interventions: 
1) A mandatory wound care management study day. 
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2) A PU prevention and management training programme. The nurses in this group 
did not receive special training about the application of the Braden scale, and they 
were not required to apply RASs (the Braden scale) to their patients. They had the 
choice of applying RASs or clinical judgement in relation to PU prevention and 
management. 
C) In group C, the nurses had to attend a wound care management study day. They did 
not undergo a PU prevention and management training programme or any specific 
training related to RASs. In this group, the nurses continued with the current practice, 
which included clinical judgement in relation to PU prevention and management. 
2) Control, i. e. screening out all extraneous influences on the dependent variable to avoid 
altering the true relationships between study variables (Polft and Hungler 1999) and (Talbot 
1995). In this study, the typical application of the control situation was not feasible because 
it was impossible to isolate a control group and do nothing to their subjects. In the present 
case, to evaluate the effectiveness of using RASs (the Braden scale) in group A compared 
to the effects of the PU prevention and treatment training programme in group B on the 
patients' outcomes in terms of the PU incidence rate, it would be unethical to offer no 
prevention care for the control group (the clinical judgement group). Therefore, the study 
required the need to evaluate the new interventions (the Braden and training programme), 
not against the total absence of care but rather against a control group receiving different 
methods of care. 
Although the patients from groups A, B and C were not identical, they may have shared 
some characteristics. The nine wards were randomised by using simple random drawing to 
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be included in the study groups (A, B or C) that may have strengthened the control of 
extraneous variables. The application of a non-equivalent control group pre-test post-test 
design may also support the control on extraneous variables as well. 
3.3 Setting 
This study was conducted at Riyadh Military Hospital (RMH), formerly Riyadh Kharj 
Hospital (RKH), which is located in Riyadh, the capital of the Kingdom of Saudi Arabia 
(KSA). The RMH is a flagship of the Medical Services Department (MSD) of the Ministry 
of Defence and Aviation (MODA). The RMH was officially opened in December 1978. It 
provides a major portion of the primary, secondary and tertiary medical services for 
military personnel and their families in the KSA. The RMH includes 1,192 beds distributed 
in the following wards: Emergency, Gynaecology, Theatres, Neonatal Intensive Care Unit, 
General Intensive Care Unit, Royal Intensive Care Unit and Medical-Surgical Wards 
(Appendix F) and 158 beds in Cardiac Centre. There are 7,179 staff in the RMH, one third 
of whom are nurses from more than 30 different nationalities (RMH 2005). The occupancy 
rate is nearly 100 per cent and average daily admissions for medical-surgical wards account 
for 12 to 15 patients. The nursing department at the RMH applies a hospital-wide policy 
and nursing standards integrated with well-established staff development programmes 
including mandatory study days that control promotion, hiring and career development. A 
wound care study day is mandatory for medical-surgical staff, as patients admitted to 
medical-surgical wards at the RMH show higher rates of PU than other wards. The subject 
of PUs was not studied either at local RMH or at national level. Nine medical-surgical 
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wards were selected purposively by the administrators and the researcher for research 
programme: Female Medical, Neurosurgery, the Isolation Ward, Male Medical, Ortho- 
Spinal Surgery, Medical-Surgical VIP, Oncology, General Rehabilitation and the Renal 
ward. These wards were divided randomly into three groups (A, B and C) by simple 
random drawing. These wards were selected from the RMH because they had shown a high 
PU rate (Table 1.1) the patients shared some aspects of their nature and backgrounds 
despite the wards representing different medical specialities, and because, as regarding 
administrators, these wards were the main areas requiring the reduction of PU incidence 
rates. More detailed descriptions of the selected wards can be found in (RMH-Nursing 
Administration/Nursing Unit Profile 2005). 
3.4 Sample 
This term refers to a subset of the units that compose the population (Polit and Hungler 
1999). Sampling designs can be grouped into the categories of probability and 
nonprobability sampling. Probability sampling involves random selection in choosing 
elements of the population, while in nonprobability sampling the elements are selected by 
non-random methods. Probability sampling is the more respected of the two approaches 
because greater confidence can be placed in the sample's representative nature (Polit and 
Hungler 1999) and (Talbot 1995). Since the aim of the study was to investigate the effects 
of RASs on the patients' outcomes in terms of PU incidence among hospitalised patients at 
the RMH, a non-probability purposive sampling design was used. It was based on the 
understanding that the researcher had the background knowledge and experience about the 
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population and the issue under study to select the subjects in the sample. Purposive 
sampling has been used in certain situations such as the evaluation of newly developed 
instruments and cases when the researcher wants a sample of experts' opinion (Polit and 
Hungler 1999) and (Talbot 1995). This sampling design was used because of the nature of 
the phenomena under study. The investigation concerns the effectiveness of new 
interventions (the Braden scale) on the patients' outcomes in terms of PU incidence rate. 
Therefore, a certain population based on nurses' experience with PU to produce better 
responses was needed. Although probability sampling provides better representativeness 
due to randomisation, it was not chosen for this study, as many irrelevant subjects might 
have been included, resulting in flaws and inappropriate outcomes. For example, 
randomisation of the hospitalised patients at the RMH may have given paediatric and 
maternity patients who may not have had the same level of PU risk, and whose nursing 
staff do not have the experience in PU prevention and management, the chance to 
participate. The use of nonprobability purposive sampling involved the selection of nine 
Medical-Surgical wards with 237 beds and 264 nursing staff for investigation. These wards 
were believed to include patients whose health conditions were stable compared to those 
from critical care units, in order to facilitate the follow up of patients over the eight week 
observation period. Additionally, it decreased the drop-out (attrition) rate among patients 
due to death, transfer or discharge. The purposes of selection of these nine medical-surgical 
wards was considered and discussed earlier in section 3.3 
Since the study design was a non-equivalent controlled group design, the nine medical- 
surgical wards were divided into the three groups A, B, and C. Each group included three 
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wards assigned by the probability simple random drawing method. Groups A and B were 
interventional and group C was the control, thus strengthening the monitoring of external 
factors which may have affected the subjects within groups. Group A included the Isolation 
Ward, Male Medical and Ortho-Spinal Surgery; Group B included General Rehabilitation, 
the Renal Ward and Neurosurgery; Group C included the Female Medical Ward, Medical- 
Surgical VIP and the Oncology Ward. 
Eligibility (inclusion) criteria were developed to define the study's population. In order to 
be included, the patient should have been hospitalised or newly admitted for hospitalisation 
and conform to a cut off score of <_ 18 according to the Braden risk assessment scale, and/or 
have been admitted for hospitalisation with a PU of stage one to stage four according to the 
AHCPR classification system (1992). The development of such criteria may enhance a 
homogenous sample as a means of controlling external factors. The nurses who provided 
care for these patients were asked to complete a clinical judgement rating scale, which 
describes the nurse's decision on the patient's risk of PU development. The participant 
nurses were introduced to the study's purpose and were informed that participation was 
optional and information would be kept anonymous and confidential as per research 
protocol and best practice guidelines (Polit and Hungler 1999). 
Sample size estimation by the use of the power analysis procedure 
Estimation of the sample size is one of the major concerns for researchers, especially the 
estimation of a sufficient sample size needed for the study to demonstrate significant 
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results. The power analysis procedure is a method for developing sample size estimates 
(Polit and Hungler 1999). There are three requirements for estimating sample size by using 
the power analysis procedure: the significance criterion (a); the population effect size; and 
power (1- ß). In this study, a (the risk of Type I error) was specified to 0.05 as a standard 
for a criterion; power (1- ß) was established for 0.80; and the population effect size as 
medium (0.3) according to Polit and Hungler (1999). When these parameters were entered 
in the G POWER test (Faul and Erdfelder 1992), the results of the power analysis showed 
that the required sample size is 108 patients. This figure was arrived at by using an x2 test, 
df =2, critical x2 = 5.99, and actual power = 0.80 (Appendix H). Although 108 patients 
were needed for the study, more patients were included to produce more significant power 
and reliable findings. 719 patients took part in this study, 225 patients from group A, 228 
patients from group B and 266 patients from group C. Of the sample, 521 patients 
completed eight weeks' observation and 198 patients did not. Of those who did, 265 
patients were in the pre-test phase and 256 patients in the post-test. 
3.5 Instrument 
A systematic data collection instrument was developed. The instrument (Appendix I) 
consisted of the following data collection tools: the Braden scale for pressure ulcer risk 
assessment, the rating scale of the nurses' clinical judgement, and the pressure ulcer wound 
assessment and wound management checklist. This instrument was integrated with two 
written sets of questions to cover one session of focus group discussions. The instrument 
was constructed in this manner to facilitate the collection of appropriate and relevant data 
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consistent with the nature of the phenomena under study, and to capture all variables of 
interest. The areas assessed were PU incidence, PU risk assessment, nurses' clinical 
judgement for those patients at risk of PU development, PU wound assessment and PU 
wound management. It also covered the views of nurses who applied the Braden risk 
assessment scale to their patients in clinical areas. 
3.5.1 RASs (The Braden scale) 
RASs are structured models consisting of categories of factors that are associated, to 
varying degrees of reliability, with PU development (Scott 2000) and (Day et al. 1997). 
RASs were believed to be a useful and practical method to encourage evaluation and 
facilitate clinical decision making in order to provide pressure relief devices (Flanagan 
1995; Maylor 1999 and Tannen et al. 2004). Numerous RASs have been developed. 
However, none are perfect, as their predictive validity is doubtful, and comparison 
standards between the scales are absent (Anthony et al. 2004). The inconclusiveness of 
studies examined the predictive validity of RASs made the choice of a definitive RAS 
impossible (Flanagan 1995). 
Following the RASs review, a well known risk assessment scale (the Braden Scale) was 
used to assess the patient's risk of PU development (Appendix J). The Braden scale was 
devised in the USA by Braden and Bergstrom in 1986. It consisted of six categories of risk 
factors (risk indicators): sensory perception, moisture, activity, mobility, nutritional status 
and shear/ friction. In the categories of nutrition and sensory perception, there were two 
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layers of potential responses. Most identified risk factors were rated between 1 (the least 
favourable) to 4 (the most favourable) except for friction/shear, which was given a 
maximum rating of 3 The possible scores ranged from a maximum of 23, representing the 
lowest risk of PU development, and six, representing the highest risk (Flanagan 1995). 
Subsequent studies suggested various threshold scores; a cut off score of <l8 was used in 
this study to consider patients at risk of PU development. The cut off score 5l8 was found 
the most predictive score in black patients who were 75 years and older as mentioned by 
Brown (2004), and as shown in Pancorbo-Hidalgo et al. (2006), who reviewed the use of 
the Braden scale in long-stay patients in elderly care centres. The Braden scale was chosen 
for this study because it was based on a theoretical model and because it had been tested 
extensively in different clinical settings and among different patients' groups. Nevertheless, 
numerous studies revealed a poor predictive validity for this scale. It was, however, 
suggested by others as having reasonable sensitivity and specificity compared to currently 
available scales (Bergstrom et al. 1987; Reed et al. 2001; Brown 2004 and Pancorbo- 
Hidalgo et al. 2005). It was also chosen because the risk factors indicated by the scale were 
described and operationally defined. A written permission to use the Braden scale was 
secured from the authors (Appendix K). 
3.5.2 Clinical Judgement rating scale 
A clinical judgment rating scale was devised (Appendix I). The nurses were asked to 
complete the CJ scale and to decide whether the patient was at minimal, moderate, high or 
severe risk or not at risk according to their experience with patients at risk of PU 
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development. The rating was completed immediately following research teams' 
assessment, and placed in the patient's record. The rating was done at the nurse's 
convenience in the clinical areas. Members of the research team were available for 
assistance and support. 
3.5.3 PU wound assessment and wound management checklist 
A checklist for PU wound assessment and management was developed and was based on 
the current literature (Lindholm 2003; Banks 1998; Thomas 1994; Cutting and Harding 
1994; Amanda 2000; Dealy 1994; Manning 1997; and Ramstadium 1999). Wound 
management experience and available forms of wound assessment and wound management 
at the RMH were also considered in developing the checklist. This checklist served to 
ensure the continuity of care to those patients who were admitted with PU and/ or 
developed PU (referred to as NCPU); to record factors associated with those defined by the 
study, which may explain variations in PU incidence among different groups such as 
gender, age and medical diagnosis; and to provide objectivity of the data collected and to 
eliminate subjectivity as much as possible (Appendix I). The checklist consisted of the 
following sections: 
A. Patients' general characteristics, including hospital file number, ward, room 
number, date of admission, gender, age, and diagnosis. 
B. PU wound assessment, which included the following: 
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1. The AHCPR (1992) classification system, used to assess patients' skin. This 
classification system was consistent with the recommendations of the NPUAP 
Consensus Development Conference (1989). It was derived from the previous 
staging system proposed by Shea (1975), the Wound Ostomy and Continence 
Nurses Society (WOCN) and the International Association of Enterostomal 
Therapy (1988). It classifies PU in four stages (Appendix L), which were 
described in chapter 2 (section 2.2). The research team recognised, in relation to 
the PU classification system, that inpatients with darker skin, discoloration of the 
skin, warmth, oedema, induration, or hardness of the skin were considered as 
indicators of stage one PU, and that special consideration was given to patients 
with casts, orthopaedic devices and support stockings. 
2. PU location 
The following anatomical areas were identified: occiput, sacrum, trochanter, 
ischium, shoulder, heels, elbows, toes, ears, spine, knees, ankle, buttocks, lower 
legs and metatarsum. The research team specified other observations related to 
location, including the lack of an evident open wound, for example, stage one 
with non-blanching erythema of intact skin and /or non specific PU wound area. 
3. PU wound size 
The research team was requested to specify the wound measurements if there was 
an open wound (Stage two, three or four). The wound size was specified by length 
and width in centimetres (referred to as cm. ). The same nurse performed wound 
measurements to maximise objectivity. 
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4. Wound tunnelling, undermining and/or sinus formation was assessed. The research 
team indicated whether undermining was present or not and stated the depth of the 
undermining wound. 
5. Wound necrosis was assessed according to the presence or absence of invisible 
necrosis or dead tissues, non adherent yellow slough, loosely adherent slough, 
adherent soft black eschar and/or firmly adherent black eschar. 
6. Wound exudate was assessed as to whether it was small, moderate or heavy. 
7. Wound assessment also included slight, moderate, or offensive odour. 
8. Wound assessment included assessment of whether wound granulation was dusky 
and pale, bled readily and/or was over granulated. 
9. Wound epithelialisation was assessed for pale and dullness, tissue maceration, and/ 
or fragile and dry wound lining. 
10. PU wounds were assessed for scab and/ or hypertrophic scar formation. 
11. The patient was assessed for wound pain. He or she was asked to indicate whether 
the pain occured only at the dressing change, was continuous, or was related to any 
other source. 
12. Wound infection assessment included swab culture (e. g. bacterial, viral, or fungal 
infection) and local signs and symptoms of wound infection such as hotness, 
redness, pain, and/or induration. 
C. PU Wound management 
1. The dressing modality used in the management of PU wound was monitored, 
including primary dressings such as alginates, hydrocolloids, hydrogels, 
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hydrofiber, foam and silver-based dressings as well as VAC therapy and 
medicated wound creams and ointments. 
2. Surgical intervention was recorded for wound debridement, PU flaps and/or 
surgical PU grafts. 
3. The patient was monitored for protective measures. This included the following 
categories: 
a) Protective mattresses such as Standard hospital bed mattress (Stryker®, Inc. 
Canada), Alternating pressure relief system, (Therakair®, Kinetic Concepts, 
Inc. USA), (Gen Air 8000®, Genadyne, Inc. USA) (Atmosair®, Kinetic 
Concepts, Inc. USA) and Gel overlay or Air Fluidised Bed (Clinitron®, Hill- 
Rom, Inc. USA). 
b) Skin barriers cream. 
c) Vitamin supplements and special nutritional formulas. 
d) Patients' turning (positioning) schedules every 2,3 to 4, or 6 hours. 
3.6 Choosing and training the research team 
The data were collected by the researcher, who was the Tissue Viability Nurse Specialist 
(TVNS) at the RMH, and two staff nurses. It was not feasible for the researcher to collect 
all the data. Hence, two staff nurses have been recruited to the project. Both nurses had 
medical-surgical nursing experience of six to eight years, as well as being available as part 
of the RMH nursing team. The two staff nurses received training before they started the 
actual data collection. They attended the wound care study day, research training 
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(Appendix M), PU training and the Braden scale training. They were subsequently 
instructed to the data collection protocol which included patient observation according to 
the instrument, data recording, data filing and the patient follow up procedure. 
Special consideration has been given to the PU classification system, skin assessment and 
PU location in order to validate the primary outcome measure (PU incidence Stage one to 
Four) as follows: 
- The researcher emphasised the central objective of the 
investigation to the two nurses who were involved in identifying 
and classifying PU (Stage One to Four) Therefore, the training 
courses (mandatory wound care management, PU prevention and 
treatment and PU risk assessment scales), which included 
theoretical and practical sessions, have addressed PU staging to 
satisfy this objective. 
- The methods used in the research teams' training included case 
studies, PowerPoint presentations, video tapes, CDs, internet 
access to NPUAP and EPUAP and demonstration in clinical wards. 
About fifty pictures representing different PU stages from patients 
in RMH were used to develop competency in PU classification by 
using AHCPR (1992). Demonstrations on patients were conducted, 
and they were given the opportunity to implement a trial on a 
group of patients, by undertaking skin observation, inspection and 
palpation. 
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- The research team nurses attended TVNS clinical rounds and 
demonstrated knowledge and practice of PU classification on a 
daily basis over three months prior to the start of data collection. 
- The research team nurses had the ability to distinguish Stage One 
PU by using a transparent pressure disk, identify the blister 
formation as Stage Two PU, define involvement of subcutaneous 
tissues as Stage Three PU and inspect wound tunnelling and sinus 
formation in Stage Four PU. They also were able to define Stage 
One PU in dark-skin patients as well as to differentiate between PU 
and continence ulcers by using EPUAP (1998) guidelines. 
- At the end of three months training period, the research team 
nurses demonstrated independently a satisfactory level of 
agreement with TVNS's PU classification as they asked to perform 
PU classification on a group of medical-surgical patients under 
direct supervision of the TVNS. 
- The research team nurses worked closely with the TVNS to 
collect the data. The patients were initially inspected by the TVNS 
for skin changes and PU incidence (Stage One to Four) and 
discussed verbally with the research team nurses, then they 
performed patient assessments including PU staging. In cases of 
difficulty and/ or discrepancy in staging, the patient re-assessed 
and discussed by the team nurses together with the TVNS and then 
a consensus approach was adopted between the three data 
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collectors. AHCPR (1992) and (Appendix L) which represents PU 
classification in RMH have been used as a reference. The TVNS 
was available closely to the research team nurses to offer them 
hand-to-hand assistance and support. 
3.7 Ethical considerations 
Ethical approval was obtained from the Research and Ethics Committee at the RMH 
(Appendix N), project number 292/2004, and from the Ethics Committee of the Faculty of 
Health and Life Sciences at De Montfort University in 2004 (Appendix 0). Furthermore, 
written permission from Braden and Bergstrom was obtained to utilise the Braden scale 
(Appendix K). For purposes of continuity of care, ethical access was considered for those 
patients involved in the study. The patients were provided with a standardised care 
irrespectively of whether they developed PU or were admitted with PU by medical and 
nursing teams. The researcher safeguarded the confidentiality of the participants, whether 
patients or nurses, by assigning them with identification file number rather than using their 
names to access actual research information, which was restricted to the research, medical 
and caring teams. Patients signed a hospital consent form on admission. Written consent 
was obtained from the patients before they were included in the study. The consent form 
was signed, in many cases, by a family member who attended the patient, as many 
participated patients were elderly and/or unconscious. It should be noted that, due to 
cultural conditions in Saudi Arabia, family members (head of family) are allowed and 
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authorised to give consent on behalf of their relatives, and the husband is authorised to give 
consent on behalf of his wife and/or any members of his family. Verbal consent was then 
obtained from the participant patient or family member every time the patient was accessed 
for observation. 
The aims of the study and the expected benefits were discussed with nursing administration 
staff. Written consent was then obtained from the head nurses of the participating wards. 
The nurses who participated by providing their clinical judgement gave their consent 
verbally. They were given an overview about the study's objectives and benefits, and they 
were made aware that the research team would check the patients and records 
unexpectedly. Participation in the study was voluntary. The participants were free to leave 
the study at any time, and patient participants could refuse inspection by the research team. 
The nurses who participated in the study were supported and motivated by the research 
team, head nurses, and nursing administration. The participant nurses were given a day off 
duty and certificates of participation as incentives. 
The wards under study were not anonymous, as the clinical areas in the RMH are divided 
into single medical specialities, which made it difficult not to identify the wards under 
study. 
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3.8 Pilot study 
Polft and Hungler (1999) define a pilot study as a small-scale version, or trial run, done in 
preparation for a major study. It allows the investigator to determine the reliability of the 
measuring instrument (Talbot 1995). 
One Medical-Surgical ward was chosen by the researcher to conduct the pilot study. This 
ward was a non participating ward in the study. It had 28 beds and provided care for male 
and female patients of various medical and surgical diagnoses. A written consent was 
secured from the head nurse of the ward (Appendix P). 
Ten staff nurses from this ward were selected by the nurse in charge and the researcher 
according to their availability on the weekly rota. The selected nurses were asked to 
perform the Braden assessment once on a single selected patient. The ward staff were 
involved in group A training, and they received the mandatory wound care management 
study day, PU prevention and treatment training, and special training on the application of 
the Braden scale. The nurses were motivated by the researcher's and nursing 
administration's team to be provided certificates of participation and one day off. 
The nurse in charge was asked to choose the patient. Since this patient was unconscious, a 
written consent was obtained from the patients' family member (the head of family). The 
chosen patient was examined for eligibility by the researcher (TVNS) and the following 
information was obtained: the patient was female, 63 years old, bed-ridden, unable to move 
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in the bed, received feeding via NGT (Naso-Gastric Tube), was incontinent, unable to 
respond meaningfully to surroundings, and required maximum assistance to move in bed. 
The patient was free from PUs (Stage one to Stage four according to AHCPR (1992). 
Moreover, when the Braden scale was applied by the TVNS, it showed that the patient was 
at severe risk of PU development. 
3.8.1 Piloting procedure 
The procedure was explained both to the family member who attended the patient and to 
the selected nurses. As the nurses were on 12 hours' duty, piloting was carried out twice; 
the first group, including five morning shift nurses, were asked to perform the Braden 
assessment on the assigned patient independently and under the indirect supervision of the 
researcher. The nurse who finished the assessment was instructed by the nurse in charge to 
have a break for 20 minutes outside the ward. The second group, which also included five 
evening shift nurses, were asked to do the same. The nurses were cooperative. The Braden 
assessments were returned independently to the researcher. The subsequent inspection of 
the patient did not bring to light any deficiency in the patients' care. 
3.8.2 Pilot study analysis 
Inter-rater reliability of the Braden assessments revealed 100 per cent agreement among the 
participating nurses that the elected patient was at severe risk of PU development. The 
analysis of participants' responses among the Braden risk factors showed that most of the 
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assessments were in agreement with the assessment produced by the researcher. It 
described the patient as having very limited sensory perception, constantly moist skin, 
being bedfast and completely immobile, receiving adequate nutritional supply, and 
suffering from shear/friction. The verbal feedback given by the participants after the 
piloting procedure was transcribed by the researcher thus: The Braden scale could be used 
to assess patients' risk of PU development. It was not suggested that any categories or risk 
factors be added to the scale. It was comprehensible and easy to use and training was 
essential for proper application. Additionally, the Braden scale was helpful in determining 
patients at risk and in prioritising prevention facilities. 
3.9 Reliability of the Braden scale 
The reliability of an instrument refers to the degree of consistency with which it measures 
the attribute under study (Polft and Hungler 1999). The reliability can be assessed in the 
following ways: 
1) Stability refers to the extent to which the same results can be obtained from 
repeated applications. This can be evaluated by the test-retest procedure. 
2) Internal consistency means the extent to which different parts of the instrument 
are equivalent in terms of measuring the critical attribute. It can be evaluated by 
using the split-half technique or coefficient alpha (Cronbach's alpha and the Kuder- 
Richardson formula 20). 
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3) Equivalence requires determining the consistency of the instrument in yielding 
measurements of the same traits in the same people. This approach is used when 
different observers are using the same instrument to measure the same phenomena 
at the same time. Equivalence can be estimated by inter-rater (or inter-observer) 
reliability. 
In this study, the equivalence approach was used to estimate reliability of the Braden scale 
because two data collectors collected the Braden scores from the whole sample 
independently and simultaneously, and also because this approach is typical to 
observational studies, where there is a greater burden on the observer to produce 
observation bias or error. The Braden scale has never been used before in the RMH, which 
raises the need to minimise the possibility of error between data collectors when assessing 
the risk of PU development by using the Braden scale. Hence, the reliability of this scale 
should be estimated. 
The inter-rater reliability of the Braden scale was supported in the pilot stage, where ten 
nurses assessed one selected patient in the medical-surgical ward. 
Since the reliability of Braden scores depends on the nurses who apply it, the participant 
nurses at the pilot stage received training about the Braden scale; this enhanced the 
accuracy of their ratings. 
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The inter-rater reliability was computed as a function of agreement between nurses' 
observations. The results indicated 100 per cent agreement that the observed patient was at 
severe risk of PU development using the Braden scale, which in turn agreed with the 
researchers' (TVNS) assessment. It should be noted that, although the nurses agreed that 
the assessed patient was at severe risk as shown by total Braden scores, there were tiny 
differences such as mobility and sensory perception among the Braden sub-scores. As a 
result, the reliability of the Braden scale in the RMH showed acceptable levels of variation, 
which is in agreement with those estimates reviewed in the literature. For example, 
Pancorbo-Hidalgo et al. (2006) reported high (Pearson's r: 0.83-0.99) inter-rater reliability 
from 22 studies reviewed the Braden scale. 
3.10 Validity of the Braden scale 
Polft and Hungler (1999) defined validity as the degree to which an instrument measures 
what it is supposed to be measuring. There are different aspects of assessing the validity of 
an instrument: 
1) Face validity, which refers to whether the instrument appears to be measuring 
what it is supposed to. 
2) Content validity, which evaluates the adequacy of items included in an 
instrument for the construct that is being measured. It is based on the judgement 
made by a panel of experts. 
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3) Criterion-related validity, which establishes the relationship between the 
instrument and certain criteria. It shows whether the instrument is a useful predictor 
of subsequent behaviours or conditions. 
4) Construct validity is concerned with the attributes of the instrument rather than 
the scores it produces. The two main approaches to assessing construct validity are 
known-group technique and the examination of the relationships between the 
instrument's attributes based on theoretical predictions. 
In this study, experts supported the face and content validity of the Braden scale. It was 
judged by the research supervisors, members of the wound care committee and the nursing 
administration team in the RMH. All of them acknowledged the usefulness of using the 
Braden scale in PU risk assessment. 
The literature provided a greater supporting degree of evidence on the Braden scale 
application. Numerous studies reviewed the validity of the Braden scale and the literature 
acknowledged it as having optimal validation. Among RASs, the Braden scale was the 
most extensively studied tool. Pancorbo-Hidalgo et al. (2006) systematic review of 33 
studies showed 22 with validation data on the Braden scale. They added that this scale was 
tested in different clinical settings and was found to embody reasonable sensitivity and 
specificity measures. The Braden scale was also supported to a greater degree of validity 
evidence by Bergstrom et al. (1987); Reed et al. (2001), Brown (2004) and Halfens et al. 
(2000). 
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Based on findings in the literature, no attempt has been made to revalidate the Braden scale, 
which was employed in this study as a valid PU risk assessment tool. Consequently, other 
means of validity measures such as criterion-related validity and construct validity were not 
supported. 
3.11 Data collection 
In coordination with nursing administration and head nurses of the participating wards, a 
three-phase plan was developed to collect the data from 1s` February 2006 to the end of 
February 2007; each phase was extended for at least four months to give time to obtain a 
larger sample size. The data collection process included implementation of the study 
instrument which was described earlier in this chapter in section 3.5. 
The following points should be considered in order to obtain a better understanding of the 
data collection process: 
1) The data were collected from inpatients and newly admitted patients. 
2) The patients who met the inclusion criteria of Braden scores <_18 and/or had 
PU (stages one to four according to AHCPR (1992) were included in the 
study. 
3) Every patient included in the study was observed every week for eight 
weeks. Longer observation periods were avoided due to the probable 
degradation of data quality with the passage of time. 
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4) Every patient included and completed eight weeks observation in the period 
from February 2006 until September 2006 has been considered as a pre-test 
patient. 
5) Every patient included and completed eight weeks observation in the period 
from October 2006 until March 2007 has been considered as post-test 
patient. 
6) All patients included at the beginning of the study who did not completed 
eight weeks observation because of death, transfer to a non-participating 
ward or discharge from hospital were dropped from the survey and put in a 
separate category as excluded patients. The patients who were admitted with 
PU and then attained Braden scores of more than 18 during the eight weeks 
observation were also excluded. 
The phases of the data collection process were as follows: 
1) Phase One included pre-test data collection. During this phase, the patients were 
included in the study from the first of February 2006 until the end of June 2006. The 
patients who were included by the end of June 2006 completed the eight-week 
observation period. The data was collected from 265 patients in this phase. 
2) Phase Two included implementation of the interventions (manipulations) to 
different study groups (A, B, and C) as described earlier in this chapter in section 
3.2.3. This phase extended from July 2006 to September 2006. It also included data 
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collection from those patients who were included at the end of phase one and had 
not completed eight weeks observation. 
3) Phase Three was extended from the first of October 2006 to the end of February 
2007. During this phase, the data was collected after the nurses applied the Braden 
scale to their patients from group A, and included post-test data collection. The 
Braden scores independently produced by ward nurses in this phase were separated 
and kept in patients' hospital files. The data was collected from 265 patients in this 
phase. 
During the first round of data collection, verbal consent was obtained from the head nurse 
and nurse in charge of participating wards. Verbal consent was obtained individually from 
inspected patients or a family member every time the patient was inspected. 
The decision as to which patients were included was made after Braden scores were 
obtained from, and skin assessment of pressure points was performed on, all patients in the 
wards under investigation at the beginning of the first and third phases of the study. Data 
from the included patients and from newly admitted patients was then collected throughout 
the study. Detailed PU wound assessment of those patients who were included and had 
stage one to four PU was carried out by using the PU wound assessment checklist. 
All patients' assessments were produced by the research team in the presence of the ward 
nurse. Each patient had an individual study record, which included Braden scores, a 
protective measures record and a checklist of wound assessment and wound management if 
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they had PUs. All patients' records were kept in the research teams' office, including those 
for patients dropped from the study. 
Patients included in the study were observed weekly for eight weeks for Braden scores, 
skin assessments, protective measures, and wound healing in patients with PUs. During the 
visits, the routine nursing care was followed and PU prevention plans were not replaced by 
the research team, unless they were consulted to do so. Among those patients with PUs, 
regular wound care protocols were followed. 
When patients developed new PUs (NCPU) (stage one to stage four PU according to 
AHCPR (1992)) at any time in the observation period, the ward nurse was informed and 
these changes were added to the observational checklist. The patients who developed new 
PUs continued a weekly assessment until they completed eight weeks observation. 
The incidence rate was calculated according to Fletcher (2001) who defined it as the 
percentage of patients who develop a condition within an at-risk population. The 
operational definition of PU was the presence of Stage One PU at least once during the 
observation period, as mentioned by Halfens et al. (2000); if the patient developed more 
than one PU lesion, only the first one was taken into account. 
The research team discussed patients' conditions when there were conflicts regarding PU 
staging and wound assessment. 
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Data collection methods 
The data collection methods included structured observation to gather clinical data from 
patients, the self-report method to obtain nurses' clinical judgements regarding patients, 
and focus group discussion with selected nurses from group A to consider their views of the 
Braden scale. 
1) Structured observation 
This is a systematic method of selection, observation and recording of behaviours, events 
and settings relevant to a problem under investigation (Polft and Hungler 1999) and (Seers 
and Critelton 2001). The patients' observations included clinical data using the structured 
observational checklist. The observed data included Braden scoring, skin inspection, 
protective measure recording, and when there was PU wounds, wound assessment and 
wound management. 
Observation procedure was performed according to a programmed plan by the research 
team; the participating wards were scheduled for unannounced visits. 
2) Nurses' Clinical Judgment 
The self-report method was used to gather nurses' clinical judgement of PU risk 
assessment. Verbal consent was obtained from head nurses of the participating wards and 
the participants on every occasion. A clinical judgment rating scale was introduced. Ward 
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nurses were asked to decide the patients' risk of developing PU without knowing patients' 
Braden scores. The Clinical Judgement rating scale was administered by ward nurses and 
supported by the research team. This scale included a cover letter which introduced and 
clarified the aims of the study, as well as instructions on how to fill out the rating scale 
appropriately. The rating scale consisted of the two extremes of no risk and severe risk of 
PU development, and the nurses were asked to indicate each patient's risk on this scale. 
The completed questionnaires were thereafter returned to the research team who were 
available to offer assistance and support. 
3) Focus group discussion 
A self-report method was used to obtain nurses' views on the application of the Braden 
scale after the data collection was completed. The focus group discussion method was 
acknowledged in the literature as a technique that is becoming increasingly popular in the 
study of health problems (Polft and Hungler 1999). A structured self-report method was 
used to encourage respondents to define and elaborate different aspects of the study. Ten 
nurses were chosen from Group A wards to participate in the discussion. They were 
recruited by the head nurses of the participating wards who asked for interested staff to 
participate, and the first ten nurses were selected. The interviewer (TVNS) was the 
moderator of the discussion and he guided it according to a written set of questions which 
had to be covered. The discussion was about 90 minutes long. Among the points for 
discussion were the following: 
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1) Evaluate the concept of risk assessment in PU prevention and the PU 
management programme. 
2) Did the application of the Braden scale made any difference to PU prevention 
and management? 
The interviewer transcribed the notes from the participants' responses and from 
supplemented transcripts of participants' own notes. The interviewer thereafter included a 
summary of the important responses, which gave participants the opportunity to clarify, 
refine and correct some of their responses. The main advantages of this method were that it 
was flexible, that many views were explored in a short period of time, and that it gave the 
opportunity for participants to share their clinical experience which could not have been 
gathered via the questionnaire. 
3.12 Data analysis plan 
The data analysis is designed to test the hypotheses and aid data interpretation. It answers 
three questions addressed through this study about the following: 1) The effects of RASs 
(the Braden scale) on PU development. 2) The effects of PU prevention programme. 3) The 
effects of RASs (the Braden scale) compared to effects of nurses' CJ on PU development. 
Data were analysed by using descriptive and inferential statistical procedures (tests). The 
descriptive analysis aimed to describe the frequencies, measures of central tendency and 
measures of dispersion for personal and demographic characteristics of the patients. The 
inferential statistics may be parametric or nonparametric. Parametric tests assume data are 
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normally distributed and there may be other limitations. Nonparametric tests have fewer 
requirements or assumptions about population characteristics and most importantly do not 
assume a normal distribution (Pagano 1986). The main reasons for preferring parametric to 
nonparametric tests were that the parametric tests were more powerful and more flexible 
than nonparametric tests, and where appropriate parametric tests were employed. While 
parametric tests are robust to violations of underlying assumptions, nonparametric tests 
were used when there was extreme violation of an assumption of the parametric test or 
where nominal data were being analysed. 
Chi-square test was used to test independence of nominal variables. Student t test for 
independent groups and one way ANOVA were not used to test differences between 
respectively two or more than two groups because the data were not normally distributed. 
Mann-Whitney U (MW) test and Kruskal-Wallis (KW) test were used to test differences 
between respectively two or more than two groups with data that were at least ordinal, but 
not sufficiently normally distributed to warrant parametric testing 
Logistic regression analysis was used to produce a predictive model from those recorded 
variables which are related to PU development. It identified those variables that best 
explained the occurrence of PU. Logistic regression analysis shows the significance of 
individual predictor variable and provides a coefficient estimation (B) associated with each 
predictor, which shows the nature of the relationship. Moreover, it provides estimates about 
the odd ratios (OR) of predictors, which indicates an estimate of relative risk (the risk of the 
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event occurring in a given condition, versus the risk of it occurring in a given different 
condition). 
While sensitivity and specificity, important measures of a risk tool, are highly dependent on 
the particular threshold employed, the Receiver Operating Characteristics (ROC) curve 
analysis enables the researcher to decide whether the RASs (the Braden scale) performance 
is superior or equal to CJ performance in terms of PU development. The ROC curve 
analysis draws a graphical plot of sensitivity and specificity of the scores at each possible 
threshold compared to a reference line, which evaluates the predictive performance of both 
scales by a given area under the ROC curve. As a result, the findings of the ROC are crucial 
to select the possibly optimal tool in performing PU risk assessment. ROC curve analysis 
was used to show the effects of the Braden scale compared to nurses' clinical judgement in 
relation to PU development, which answers the third question in this study whether there is 
a difference between using the RASs (the Braden scale) and CJ on patients' outcomes in 
terms of PU reduction. 
All statistical procedures used Statistical Package for the Social Sciences (SPSS). 
3.13 Summary 
This chapter introduced the study's methodology. A quantitative quasi-experimental design 
was used. It included a non-equivalent pre-test post-test controlled groups design to 
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examine the hypotheses and to achieve the aims of the study. The characteristics of quasi- 
experimental design were discussed; these included manipulation and control of extraneous 
variables that might distort the relationship between the use of RASs and PU incidence. 
The study was conducted in the RMH-Saudi Arabia and included 719 hospitalised patients 
from nine medical-surgical wards; patients were chosen according to eligibility criteria. The 
instrument included the Braden scale for PU risk assessment, a rating scale to assess 
nurses' clinical judgement and a checklist to assess PU wounds and to monitor PU wound 
management. The data was collected by the researcher (TVNS) and two trained staff nurses 
who were employed in the wound care management team. Ethical access was considered by 
research and ethics committee in the faculty of Health and Life Sciences at De Montfort 
University, and by the research committee in the RMH. Consent was also obtained from the 
authors of the Braden scale. A pilot study was conducted on ten nurses from a non- 
participating medical-surgical ward to support the Braden scale's reliability and to review 
the adequacy of the data collection plan. Integrated methods of data collection were used, 
including patients' observation and nurses' self report. A data analysis plan considered 
hypotheses testing and interpretation of the findings. 
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Chapter Four: Findings 
Introduction 
This chapter describes the findings of the effects of using the Braden scale for PU risk 
assessment compared to the effects of clinical judgment and training on patient outcomes in 
terms of PU incidence. It thereby supports and enables nurses to provide better PU 
management practices. 
This chapter includes both descriptive and inferential statistical procedures. The descriptive 
statistics (Appendix S) include frequencies and percentages to describe the data, and is 
divided into four main sections: general characteristics of the sample, which includes type, 
group, age, gender, and diagnosis; PU incidence, prevalence, PU stages and PU location; 
protective measures, including protective mattresses, patient turning, creams and skin 
barriers, and vitamins; and the Braden scores and nurses' CJs. 
The inferential statistical procedures include the Chi-Square (x2), Kruskal-Wallis (KW) and 
Mann-Whitney (MW) tests to examine the effects of the Braden scale, training and nurses' 
clinical judgements and other recorded variables on PU incidence among different patient 
groups and within the pre-test and post-test data. Logistic regression analysis is also used to 
predict the factors that contribute to PU development. Receiver operating characteristic 
Curve (ROC) analysis is used to represent the predictive performance of the Braden scale 
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and nurses' CJs on PU development. Analysis outcomes are presented in tables, figures, 
box plots, histograms and bar charts. 
The results show that of the total number of patients observed throughout the study (719 
patients), 72.4 per cent (n=521) of the patients completed the eight week observation period 
and 27.6 per cent (n=198) did not complete this period because of discharge, transfer or 
death. Of the patients who did complete the period, 265 were observed in the pre-test and 
256 in the post-test phases. 31.3 per cent (n=225) of the patients were from Group A, 31.7 
per cent (n=228) from Group B and 37 per cent (n=266) from Group C. 
4.1 Pressure ulcers incidence 
The PU incidence rate (referred to as Nosocomial PU (NCPU)) is defined in chapter three 
(section 3.11). Of the sample, 22.9 per cent (n=165) of the patients developed Stage One to 
Four PUs. The findings showed that 31 per cent (83 of 265) of the NCPU developed in pre- 
test while only 19 per cent (49 of 256) developed in post-test (Table 4.1). 




Pre-test 0* 182 68.7 
1* 83 31.3 
Total 265 100.0 
Post-test 0 207 80.9 
1 49 19.1 
Total 256 100.0 
'Notes: 0= Patients who did not develop PUs (Stage One to Four) over eight weeks observation 
1= Patients who developed PUs (Stage One to Four) over eight weeks observation 
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In GA, 24.4 per cent (55 of 225 patients) were reported with NCPU, in GB 23.7 per cent 
(54 of 228 patients) were reported with NCPU and in GC 21.1 per cent (56 of 266 patients) 
(Table 4.2). 
Table 4.2 Pressure ulcer incidence in the study groups 
Study Groups Frequency Percent 
. 
Group A 0* 170 75.6 
1* 55 24.4 
Total 225 100.0 
Group B 0 174 76.3 
1 54 23.7 
Total 228 100.0 
Group C 0 210 78.9 
1 56 21.1 
Total 266 100.0 
`Notes: 0= Patients who did not develop PUs (Stage One to Four) over eight weeks observation 
1= Patients who developed PUs (Stage One to Four) over eight weeks observation 
Although similar PUs incidence rate has been reported between groups in the overall 
sample (Table 4.2), it was different when the data were divided into pre-test and post-test 
phases (Table 4.3). Similar PU incidence rates were reported in Group A and B in the post- 
test phase (21.6 percent and 22.4 percent respectively), and in Group C only 15.1 percent of 
the patients developed PUs in post-test phase. 
The results also showed reduction of PU incidence rate in the study groups in the post-test 
phase compared with pre-test phase. 32.4 percent of GA patients developed PUs in the pre- 
test phase compared to 21.6 percent in the post-test, 29.7 percent of GB patients developed 
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PUs in the pre-test compared to 22.4 percent in the post-test, and 31.6 percent of GC 
patients developed PUs in the pre-test phase compared to only 15.1 percent in the post-test 
phase which demonstrated significant decrease of PU incidence rate in GC compared to 
changes in other groups in the post-test phase. 
Table 4.3 Pressure ulcer incidence in the study groups and in the study 
phases 
Study Groups Study Phases 
Frequency 
Percent 
Group A Pre-test 0* 53 67.1 
1* 26 32.9 
Total 79 100.0 
Post-test 0 58 78.4 
1 16 21.6 
Total 74 100.0 
Group B Pre-test 0 64 70.3 
1 27 29.7 
Total 91 100.0 
Post-test 0 59 77.6 
1 17 22.4 
Total 76 100.0 
Group C Pre-test 0 65 68.4 
1 30 31.6 
Total 95 100.0 
Post-test 0 90 84.9 
1 16 15.1 
Total 106 100.0 
'Notes: 0= Patients who did not develop PUs (Stage One to Four) over eight weeks observation 
1= Patients who developed PUs (Stage One to Four) over eight weeks observation 
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4.2 Inferential analysis 
4.2.1 Hypotheses testing 
The following hypotheses were statistically tested: 
o Using a risk assessment scale (The Braden scale) has no effect on patient outcomes in 
terms of PU incidence rate among hospitalised patients. 
o PU prevention and treatment training has no effect on patient outcomes in terms of PU 
incidence rate among hospitalised patients. 
o The use of CJ as a way of deciding patients at risk of developing PUs has no effect on 
patient outcomes in terms of PU incidence rate among hospitalised patients. 
The a level used was a=0.05,2-tailed for all tests. 
The Chi-Square (x2) test was used to make inferences about the existence of significant 
relationships between the group variable and PU incidence. The group variable in this case 
represented the effects of using a RAS (the Braden scale) in group A, PU training in group 
B and CJ in group C. 
In this study, the group variable was at the nominal level of 1 for group A, 2 for group B 
and 3 for group C, and PU incidence was at the nominal level of 1 for the presence of a PU 
and 0 for its absence; this implies that the Chi-square test can be used to answer the core 
questions of this study concerning whether there is a significant effect for the group 
variable on PU incidence. The Chi-square test examines the differences between expected 
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and observed values among groups A, B, and C in relation to PU incidence. Furthermore, it 
presents the values of variables under study in a contingency table, which facilitates 
comparisons between groups A, B, and C in relation to PU incidence. 
As a result, the findings will separate the effects of using RASs (the Braden scale) on PU 
development from those of PU training and the use of CJ. 
The findings show no statistically significant (Pearson x2= 0.895; degrees of freedom (df. ) 
= 2; P=0.639) effect between the groups and PU incidence as shown in Table 4.4. 
Based on previous statistical tests, the null hypotheses were accepted: no statistically 
significant effect for the groups on patients' outcomes in terms of PU incidence was 
evident. 
The following sections explore the effects of recorded variables 
1) The null hypothesis was accepted: there is no statistically significant effect detectable 
between the groups regarding PU incidence. Thus, it is essential to explore other 
recorded factors which may mask this effect. Besides, it may have an additional effect 
on PU development. 
2) The results show that PU incidence is significantly (Pearson x2= 17.023; d. f. = 2; P< 
0.001) different between pre-test and post-test phases of the study (N= 719). Thus, it 
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is necessary to explore other recorded factors that may partially explain the significant 
reduction of PU incidence in the post-test phase. 
4.2.2 The effects of recorded variables on group and incidence 
This section explores the effects of recorded variables on group and incidence and includes 
the tests used, the procedure of examination and the findings. 
The effect of recorded variables was tested according to their level of measurement which 
included the following tests: 
1) The Chi-Square (x2) test for nominal variables was used to examine whether groups 
were different in relation to the recorded variables of PU incidence, gender, 
diagnosis, protective mattresses, skin barrier creams and vitamins. Furthermore, it 
examined whether PU incidence was different among other nominal variables. 
2) Mann-Whitney U (MW) test was used to examine whether PU incidence was 
different among the recorded variables of age, turning schedules, Braden and CJ 
scores. Kruskal-Wallis (KW) test was used to examine whether groups were 
different in relation to the recorded variables of age, turning schedules, Braden 
scores and CJ scores. 
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The examination procedure included the following: 
1) Of those variables examined by the Chi-Square (x2) test of independence for 
nominal variables, the association between variables was tested by descriptive 
cross-tabulation. The group or incidence variables were entered in rows and the 
recorded variables were entered in columns, and expected and observed counts were 
indicated. Pearson x2 value, d f., and P value were calculated to decide the level of 
statistical significance of the association between variables. 
2) Of those variables examined by KW and MW tests, the groups and incidence were 
used as grouping variable and the recorded variables were used as testing variables. 
The x' value in KW test and U value in MW test, d. f. and P value were calculated to 
elucidate the association between variables. 
Results for the groups were different in relation to gender, diagnosis, vitamins, age, 
protective mattresses, Braden scores and CJ scores, with variable levels of statistical 
significance, while PU incidence, skin barrier creams, and turning schedules were not 
statistically significant among group variable as shown in Table 4.4. 
They also show that PU incidence was different among patients' diagnoses, age, creams, 
protective mattresses, Braden scores and CJ scores with variable levels of statistical 
significance, while gender, vitamins and turning schedules were not statistically significant 
among PU incidence, as shown in Table 4.4. 
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Table 4.4 The effects of recorded variables on the group and PU incidence 
N= 719 
The effects within the group The effects within PU 
incidence 
Variables x2 d. f P value x2 d. f P value 
Incidence rate 0.895 2 0.639 a ------- ------ ------- 
Gender 192.93 2 *<0.001 a 0.702 1 0.402 a 
Diagnoses 286.59 14 *<0.001 a 22.319 7 *0.002 a 
Age 52.134 2 *<0.001 b ------ ---- *0.001 c 
Vitamins 10.809 2 * 0.004 a 1.582 1 0.209 a 
Skin Barrier 
Creams 
0.542 2 0.763 a 9.000 1 *0.003 a 
Protective 
Mattresses 
70.394 4 *<0.001 a 16.316 5 *0.006 a 
Turning Schedule 1.714 2 0.424 b ------ ----- 0.969 c 
CJ 37.096 2 *<0.001 b ------ ----- *<0.001 c 
BS 26.704 2 *<0.001 b ------ ----- *<0.001 c 
Notes * Significant at a=0.05 (2-tailed) 
a X2 test 
b KW test 
c MW test 
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4.2.3 Logistic regression analysis 
This section examines the effects of group variable together with other variables on PU 
incidence. It also explores the relationship between the recorded variables and PU 
incidence. It includes logistic regression procedures and the findings. 
Logistic regression analysis was used to determine the effect of group variable on PU 
incidence and whether or not the recorded variables were explanatory factors in PU 
development. It is a procedure that uses maximum likelihood estimation for analysing the 
relationship between multiple independent variables and a dependent variable that is 
categorically measured on a nominal scale as mentioned by Polfit (1996). 
The logistic regression procedure included entering predictors in the analysis process. The 
binary logistic regression was chosen as it is suited models where the dependent variable is 
dichotomous. Nominal predictor variables (recorded variables) were coded (dummy 
coding) as dichotomous variables. The following variables were transformed and re-coded 
as different variables in dichotomous level (0, present and 1, not present) before entering in 
the logistic regression analysis: 
1) Diagnoses which transformed into medical, surgical, oncology, renal, neuro-surgery 
and rehabilitation variables. 
2) Protective mattresses which transformed into Standard, Therakair, Alternating, 
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Genadyne, Atmosair, Clinitron, Gel, and Water variables. 
3) The Braden scale was recoded into reversed categories where the high scores coded 
as high risk and the lower scores represented low risk, while group, age, gender, CJ, 
turning schedule, skin barrier creams and vitamins variables were left in the same 
coding. PU incidence was the dependent variable. It was encoded into (0, not developed 
PU and 1, developed PU). 
Although some variables such as gender and turning schedules were not significant within 
the group and PU incidence variables (see Table 4.4), all of them were entered in logistic 
regression analysis because: 
1) Although these variables have no effect on group or PU incidence, they may have 
an effect when entered with a group of variables, as logistic regression analysis 
shows those variables that best explain the occurrence of PUs. 
2) Although some studies showed no association between these variables and PU 
development, others showed such relationships. For example, gender was not 
found significant in relation to PU occurrence in (Schultz et al. 1999) and 
(Whittington et al. 2000), but Tannen et al. (2004) found that gender was 
different among those patients who developed PU. 
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The logistic regression used the forward conditional method. The probability for stepwise 
entry was at 0.05 and removal at 0.10 for maximum iterations of 20. Clinitron and water 
variables were removed from the analysis because they were constant for all selected cases. 
The logistic regression analysis was produced twice: the first on the sample (N=719) and 
the second time on post-test cases (n=256). The analysis report included Wald x2, B 
coefficient estimation associated with each predictor, P value, and Odds Ratio (OR) to 
provide estimated relative risk. Logistic regression analysis was performed at a=0.05 
level of significance. 
4.2.3.1 Predictors of PU development in the sample 
Logistic regression analysis was used to estimate the probability of recorded variables to 
predict PU development among the study sample. 22 variables were entered in logistic 
regression analysis and two were removed. Logistic regression, which consisted of seven 
steps, was performed for the research sample (N=719) with no missing cases. As shown in 
Table 4.5, the outcome of logistic regression analysis showed a predictive model of six 
predictors which were significantly related to PU development: age, CJ scores, reversed 
Braden scores, standard hospital-bed mattress, neuro-surgical diagnosis and skin barrier 
creams. The group variable has neither protective nor predictive effects on PUs 
development. The creams have a statistically significant protective function in PU 
development. These factors have a comparable power in the prediction of PU. The risk of 
PU development was more than two times as great among those patients who had neuro- 
surgical diagnosis compared to those who have different diagnosis (OR = 2.669). 
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Table 4.5 Logistic regression analysis: Predictors of PU development in the sample 
N= 719 
Predictor Variable B Wald x2 *P Value OR 
Age 0.124 8.920 0.003 1.132 
CJ scores 0.166 3.986 0.046 1.181 
Reversed Braden scores 0.147 11.557 0.001 1.159 
Standard mattress 0.595 7.818 0.005 1.814 
Skin barrier creams - 0.597 9.036 0.003 0.550 
Neuro-surgical diagnosis 0.982 5.759 0.016 2.669 
Notes * Significant at a=0.05 (2-tailed) 
4.2.3.2 Logistic regression: Predictors of PU development in post-test cases 
Logistic regression analysis was repeated in order to estimate the probability of recorded 
variables to predict PU development among post-test cases. This was necessary to test 
whether the interventions had any effect. The cases were selected from the sample if the 
type was only post-test (n = 256) and the same previous logistic regression procedure, 
including three steps with no missing cases, was produced. The outcome of the analysis 
showed a predictive model of only two predictors, reversed Braden scores and neuro- 
surgical diagnosis, which were significantly related to PU development. These factors also 
had comparable power in the prediction of the risk of PUs. The risk of PU development 
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was nine times as great among those patients who had neuro-surgical diagnosis compared 
with those patients who had different diagnosis (OR = 9.376) as shown in Table 4.6. 
Table 4.6 Logistic regression: Predictors of PU development in the post-test 
cases 
n=256 
Predictor Variable B Wald x2 *P Value OR 
Reversed Braden scores 0.263 9.209 0.002 1.301 
Neuro-surgical diagnosis 2.238 8.732 0.003 9.376 
Notes T Nigniiicant at a=U. US (Z-tailed) 
4.2.4 ROC Analysis of the Braden and CJ performance in predicting risk of PU 
development 
This section compares the performance of the Braden scale and CJ in predicting risk of PU 
development. It includes the ROC analysis procedure and the findings. 
Receiver Operating Characteristics Curve analysis (ROC) is a graphical plot of the 
sensitivity and one minus the specificity for binary classifier system of a diagnostic test. It 
is used when sensitivity and specificity of a risk tool (or in this case a risk assessment scale 
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(The Braden scale) and CJ scale) are highly dependent on a particular threshold score 
employed (Altman and Bland 1994) and (Anthony 1999). The evaluation of the Braden 
scale and CJ performance was given by the area under the ROC curve, which enables the 
researcher to decide whether RASs (the Braden scale) performance is superior or equal to 
CJ performance in terms of PU development. 
The ROC procedure included data entry of the incidence variable as a state variable with 
value =1 as a positive value and the Braden and CJ entered as test variables. The Braden 
variable was recoded in reversed categories where the high scores coded as high risk and 
the lower scores represented low risk to provide more logic and direction of the ROC curve 
when compared with CJ. A diagonal reference line, standard error under the nonparametric 
assumption and confidence interval of 95 per cent, and coordinate points of the ROC Curve 
were used. The procedure was repeated twice, the first time for the sample (N = 719) and 
the second among selected post-test cases (n = 256). 
4.2.4.1 Comparison of Braden scale and CJ predictive performance in the study 
sample 
The ROC curve showed a very similar performance for the Braden scale and CJ among the 
study sample (N=719). The Braden scale and CJ curves were above the reference line 
which indicated a predictive usefulness as shown in Figure 4.1. The values of area under 
the ROC curve (AUC) for the Braden scale and CJ revealed very mild differences. It was 
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0.635 for the Braden scale and 0.592 for CJ, which indicated that both predict the risk of 
PU occurrence equally for the study sample as shown in Table 4.7. 
Figure 4.1 Comparison of CJ with the Braden scale in the sample 
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Table 4.7 Area under the ROC curve analysis of CJ and the Braden scale in the 
sample 
N= 719 
Variables AUC *P Value AUC 
lower bound value 
AUC 
upper bound value 
Reversed Braden scale 0.635 < 0.001 0.588 0.682 
CJ 0.592 < 0.001 0.543 0.640 
* Significance level at (a = 0.05) 
4.2.4.2 Comparison of Braden scale and CJ predictive performance in the post- 
test cases 
When the ROC was analysed, the performance of the Braden scale and CJ for the patients 
post-intervention (n = 256) revealed different outcomes compared to the study sample 
analysis. It showed that the AUC value for the Braden scale was 0.659 compared to 0.519 
for CJ. Moreover, the analysis showed that P value was (0.001) for the Braden scale and 
0.684 for CJ at (a = 0.05). These findings indicate that using the Braden scale is better than 
random, but CJ is no better than random in this (smaller) dataset. 
When the data were split by type and group, the ROC analysis showed that the Braden 
scale and CJ performance could predict the risk of PU development among each group at 
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the pre-test and post-test stages of the study. The analysis of pre-test patients revealed a 
relatively similar performance of the Braden scale and CJ while analysis of the post-test 
patients (n = 256) revealed some differences among GA and GB. 
The ROC analysis of the Braden scale performance compared with CJ in post-intervention 
showed that the ROC curve was very similar in GA (Figure 4.2) and different in GB 
(Figure 4.3) and in GC (Figure 4.4). The Braden scale and CJ curves were above the 
reference line in GA and GB, while in GC the Braden scale curve was adjacent to the 
reference line and the CJ curve was below it, which indicates poor predictive performance 
for both the Braden scale and CJ in predicting risk of PU development in this group. 
The analysis showed that the AUC value of the Braden scale 0.643 and 0.545 for CJ in GA, 
which indicates similar PU prediction performance. It was 0.806 for the Braden scale and 
0.646 for CJ in GB, which demonstrates the best predictive usefulness of both the Braden 
scale and CJ compared to other groups. That is to say that an improvement was evident in 
performance in both the Braden scale and CJ. Among GC, the AUC values showed 0.536 
for the Braden scale and 0.399 for CJ which indicates the worst predictive performance of 
the Braden scale and CJ compared to GA and GB. 
The analysis also showed that the Braden scale revealed the only significant P value (< 
0.001) at a=0.05 for GB when compared with CJ and the Braden scale P values in other 
groups as shown in Table 4.8. 
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Figure 4.2 Comparison of CJ with the Braden scale in the post-test cases 
(GA) 
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Figure 4.3 Comparison of CJ with the Braden scale in the post-test cases 
(GB) 
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Figure 4.4 Comparison of CJ with the Braden scale in the post-test cases 
(GC) 





















Table 4.8 Area under the ROC curve analysis of CJ and the Braden scale in the 
post-test cases in different groups 
n=256 
Group Variables AUC *P Value AUC AUC 
lower bound upper bound 
value value 
GA Reversed Braden 0.643 0.082 0.483 0.802 
scale 
CJ 0.545 0.586 0.390 0.700 
GB Reversed Braden 0.806 < 0.001 0.697 0.914 
scale 
CJ 0.646 0.069 0.502 0.789 
GC Reversed Braden 0.536 0.649 0.380 0.692 
scale 
CJ 0.399 0.199 0.248 0.549 
* Significance level at (a = 0.05) 
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4.3 Summary 
This chapter described and explored the effects of RASs (the Braden scale), training, CJ 
and other recorded variables on PU development among hospitalised patients. A total of 
719 patients were included in the study from nine medical and surgical wards at the RMH. 
The population distribution among groups and study phases was described (Appendix S). 
Recorded variables of age, gender, diagnosis distribution among the study groups and 
patient types were also described (Appendix S). The results revealed a 22.9 per cent 
incidence rate of PU for the whole sample. It was relatively similar between the three study 
groups. 31 per cent of pre-test patients developed NCPU while only 19 per cent developed 
among post-test patients. Half of NCPU were Stage One and the majority of them 
developed in the sacral area. It was noted that 60 per cent of those patients who developed 
NCPU were over 60 years old. 
The findings revealed poor utilisation of protective mattresses, as 56 per cent of the patients 
were placed on standard hospital-bed mattresses. It also showed that there were no effect 
for vitamins and changing of the patients' position on PU development. 
The findings showed that most of the patients were scored at mild and high risk using the 
Braden scale while most of them were scored at moderate and minimal risk using CJ. There 
was correlation between the two scoring methods (Appendix S, Table 1). 
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The inferential statistical procedures revealed no statistically significant effect for study 
groups on PU development. Of the recorded variables, age, gender, diagnosis, vitamins, 
protective mattresses, Braden and CJ were statistically significant within the study groups, 
whereas diagnosis, age, skin barrier creams, protective mattresses, Braden and CJ were 
found statistically significant in relation to PU incidence. 
Although the logistic regression analysis reveals no effects for study groups on PU 
incidence, it shows that age, CJ, reversed Braden, standard hospital-bed mattress, skin 
barrier creams and neuro-surgical diagnosis have a statistically significant effect in 
predicting risk of PU development throughout the study sample. 
When logistic regression analysis was repeated selectively on post-test cases, the predictive 
model was different. Only reversed Braden and neuro-surgical diagnosis were found 
statistically significant in predicting risk of PU development. 
The ROC analysis reveals a relatively similar performance for Braden and CJ among the 
study sample, while it shows different outcomes in the post-test selected cases. It shows 
that Braden has better performance than random, but not CJ. However, the ROC analysis 
indicates that Braden performance gives the best predictive usefulness in group B compared 
with other groups. There was evident improvement in the predictive performance of both 
the Braden and CJ performance in the post-test cases. 
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Chapter Five: Discussion 
Introduction 
This chapter discusses the impact of PU risk assessment and risk management on health 
care. It discusses the study findings of the clinical effects of using RASs compared to 
nurses' CJ and the effectiveness of using PU prevention programme in the RMH in 
reducing PU incidence. Additionally, it also interprets and explores PU incidence rate and 
the effects of recorded variables on PU development among patients at the RMH. This 
chapter encompasses the attainment of the aims of the study, which examines the effects of 
using RASs as proactive tools in PU prevention and whether their use improves patients' 
outcomes or not. 
5.1 The impact of PU risk and risk management on health care 
This section presents implications of using theoretical backgrounds in risk and risk 
management to clarify the impact of PU risk and risk assessment on risk management in 
health care and incorporates this understanding to explain key finding of the study. 
Risk is defined according to The Royal Society as ̀ the probability that a particular adverse 
event occurs during a stated period of time, or results from a particular challenge' 
(Thompson and Dowding 2002). Risk is central to nursing practice as nurses demonstrate 
key roles in health care practices. Nurses experience different clinical risks on a daily basis 
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from different perspectives and the risk of PU development is one of these risks. Based on 
this definition of risk, nurses have a responsibility to reduce the adverse effects of PU risks 
in patients. PU risk assessment is one of the key components in risk management 
programmes in which the nurses can be proactive to reduce the risk of PU occurrence 
through early identification of patients at risk of PU development. Therefore, preliminary 
PU risk assessment is important, as substantial clinical decisions are based upon these 
initial assessments in order to implement subsequent measures to reduce the risk of PU 
development such as providing special protective mattresses. Thus, PU risk assessment is 
one of the most important judgments nurses make in the health care context. Nurses use 
two methods in PU risk assessment: RASs, which are based on categories of PU risk 
factors and CJs, which are based on knowledge and experiences in PU risk and risk 
management. The two methods use different ways to perceive given sets of information to 
make judgments of PU risk, and then implement appropriate risk management modalities. 
The accuracy of their decisions in relation to PU risk and risk management is based on their 
abilities and competencies to perceive sources of risk and to effectively utilise different sets 
of information available in RASs and/ or nurses' knowledge and experience (CJs) in 
association with patient health state. Nurses' decisions should then reflect the actual and 
potential patient's risk of developing PU. As a result, variations of decisions related to PU 
risk and risk management are associated with the usefulness of information that is provided 
in forms of RASs and/ or nurses' knowledge and experiences (CJs). Hence, nurses' should 
be aware whether RASs are effective tools compared to nurses' judgments in PU risk 
management. 
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Several studies evaluate and examine accuracy of RASs in terms of predictive performance 
(See Chapter Two, section 2.5) with no clear or consistent evidence that RASs are effective 
tools in improving patients' outcomes (Gunningberg 1999), and this raises the question 
whether sensitivity and specificity are indeed valid measures for the performance of RASs 
(Edwards 1995 and Defloor and Grypdonck 2005). This also indicates ambiguity of the role 
of RASs compared to nurses' CJ in PU risk assessment. 
In this study, a new approach is introduced to examine clinical effectiveness of RASs 
compared to nurses' CJ by measuring their effects on patient outcomes in terms of PU 
incidence instead of using conventional assessment tool's sensitivity and specificity 
measures. This approach is suggested to be consistent and a valid way to provide evidence 
on clinical effectiveness of using RASs compared to nurses' CJs in PU prevention. 
A key finding of the current study confirms that RASs are not better or more effective than 
nurses' CJ in improving patient outcomes in terms of PU incidence rate. RASs and CJs are 
dependent in producing similar predictive performance and demonstrate equal clinical 
effects on patient outcomes (Figure 4.1). This agrees with limited number of researches 
such as McGough (2000) and Gould et al. (2004), but disagree with many others such as 
Pancorbo-Hidalgo et al. (2006), Halfens et al. (2000) and Defloor and Grypdonck (2005). 
However, it provides new evidence in relation to clinical effectiveness of using RASs in PU 
prevention programmes, which is essential to suggest PU policy refinement. 
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In the light of this finding, SJT theoretical approach contributes to interpret, explore and 
clarify the relationship between PU risk assessment and risk management. In applying the 
SJT model to the study, using the RAS (The Braden scale) (Figure 5.1) in Group A and CJs 
(knowledge and experiences in PU risk management) (Figure 5.2) in Group C have 
produced similar outcomes in terms of PU incidence. 
The SJT model is used to explain how nurses use knowledge (information cues) about the 
risk of PU to develop judgments essential in PU prevention. As highlighted in Chapter Two 
(Section 2.6), although RASs present structured models, nurses use past experiences when 
making clinical judgments in PU prevention (Thompson and Dowding 2002 and Defloor 
and Grypdonck 2005). The nurses use an unknown number of information cues (X1-Xn) 
(Figure 5.2) when their decisions are based on knowledge and experiences (CJs), and these 
cues may include those factors used in RASs (Figure 5.1). 
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Figure 5.1 Application of SJT model using PU RASs (the Braden scale) 
Adopted from Thompson and Dowding (2002) which was originally taken from Hammond 
et al. (1964) 
Patient outcomes in terms of PU 
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Figure 5.2 Application of SJT model using nurse's CJs (Knowledge & 
Experiences) Adopted from Thompson and Dowding (2002) which was originally taken 
from Hammond et al. (1964) 
Patient outcomes in terms of PU 
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and experiences) 
The SJT model is based on assumptions that different nurses reach different judgments 
(decisions) by using the same information cues. The findings show that nurses were 
consistent in producing similar patient outcomes (NCPU) based on either using RASs or 
their own knowledge and experiences (CJs). This demonstrates a consistent way by which 
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the nurses perceive and consider information cues to perform PU risk assessment. Thus, 
exploration of these information cues (X1-Xn) (Figure 5.2) that are used in decisions made 
in Group C (CJs Group) is an area for future investigation. 
The SJT model is normative and an objective. It helps to explore how judgments 
(decisions) are made and suggests ways to improve it. In applying this model to PU risk 
assessment, the role of the nurses' past experiences in PU assessment and management is 
clear. Therefore, novice nurses are not fully competent to make relevant decisions 
associated to PU prevention compared with experienced ones because they lack necessary 
information cues (X1- Xn) to produce them. This suggests that these information cues 
would be improved through two approaches: continuous ongoing PU training and effective 
use of RASs. Although the findings show that RASs are not effective or better tools than 
nurses' CJs in PU risk prevention, they present a systematic and objective tools that may 
aid and facilitate PU risk assessment and nurses' CJs associated to PU management. RASs 
provide a structured set of risk factors (such as Braden scale in Figure 5.1) necessary to 
remind and improve nurses' perception of PU risk. Therefore, RASs and nurses' CJs are 
suggested to work together in order to improve patient outcomes in terms of PU occurrence 
and to help novice nurses to develop their knowledge and expertise in PU management. 
Based on this discussion, although the SJT model encourages nurses to think more deeply 
in the process of risk assessment and associated judgments, it is limited in assuming that 
information attached to judgments can always be identified and in that information is 
consistent in association with judgments made. This is applicable in this study, as 
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information cues (X1-Xn) used in CJs method (Figure 5.2) are unknown. On the other 
hand, although the information cues used in RASs method (Figure 5.1) are objective, they 
are changing and continually refined. Thus, the SJT theoretical approach is used as a way 
to improve awareness to areas of concern in the process of PU risk assessment and 
associated clinical judgments. 
To sum up this section, risk management including PU prevention in clinical practice is an 
area needs improvement. Accurate risk assessment is one way in which risks would be 
managed effectively using proactive tools. Application of SJT in PU prevention may 
demonstrate better use of risk assessment tools which facilitates and improves nurses' 
decisions vitally important to reduce PU incidence. In this study, using RASs and CJs, 
which are the two available methods in PU risk assessment, demonstrate similar effects on 
patient outcomes. Based on this evidence, using current RASs together with nurse's 
knowledge and experience (CJ) are suggested to improve PU prevention as part of a 
comprehensive PU prevention programme including an effective risk-based system. Hence, 
this contributes additional evidence to the knowledge base of PU prevention and 
management. Furthermore, it may be used to review and refine the policy of using RASs as 
a key component in PU prevention and management programmes. 
5.2 Methodological considerations 
This section discusses strengths and weaknesses of the study methodology which clarifies 
the significance and contribution of the study to the body of knowledge. 
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The present study contributes to an understanding of PU assessment, because it comes at a 
time when there is no evidence comparing the use of RASs and CJ in clinical practice. It is 
not clear whether RASs may reduce PU occurrence, or whether they are superior to nurses' 
clinical judgment in deciding the patients at risk of PU development (Cullum et al. 1995). 
Although the present study is quasi-experimental, it is prospective and uses controlled 
groups in pretest posttest design to enable the researcher to examine and explore the clinical 
effectiveness of the study variables. The studies on clinical effectiveness of RASs on PU 
prevention are limited (Whitfield et al. 2000) and restricted to examining the Norton scale 
or its modifications, while there are no research studies on the clinical effectiveness of 
other RASs such as the Braden or Waterlow scales (Pancorbo-Hidalgo et al. 2006). 
Drawbacks to these studies include the use of prevalence as an outcome measure 
(Gunningberg et al. 1999), the provision of pressure-reducing support surfaces to patients, 
and prevention intervention (Bale et al. 1995 and Hodge et al. 1990). Another drawback is 
related to the use of a specific patient subgroup, namely patients with hip fractures 
(Gunningberg et al. 1999). In relation to this study, the findings concur with those of Gould 
et al. (2004). Although Gould's study supports nurses' CJ, their findings were limited, as 
simulation was employed rather than considering actual patients. There are concerns about 
assessing patients using this method, concerns which include the inability to communicate 
with patients or to touch them in order to judge the condition of their skin, as well as the 
need to know the patients before it is possible to assess them. 
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This study is one of few to confirm the clinical effectiveness of RASs and is the first study 
to examine the clinical effectiveness of the Braden scale as RAS on PU reduction, used 
recently in the RMH. 
Several studies have reported difficulties in collecting accurate and reliable data about PUs 
(Anthony et al. 2006 and Gunningberg et al. 1999) due to their multifactorial nature, the 
uniqueness of individual patients' attributes and the lack of nurses' knowledge. 
During the present study, the research team who collected the data was extensively trained 
so that they could provide highly reliable findings. Training on the Braden scale was 
restricted to Group A nurses. The research team was responsible for collecting Braden 
scores for patients, while Group A nurses produced their own Braden scores without 
knowing the research team's scoring. The research team also did not know which wards 
were experimental. The patients were observed for eight weeks, and those who did not 
complete the observation period were excluded from the list of pretest and posttest patients. 
The researcher recorded all the known variables such as patients' age, gender, diagnosis, 
PU protective measures (protective mattresses, skin barrier creams, vitamins and nutritional 
supplements and patients turning schedules) that may have distorted the findings. 
The age, gender, diagnosis, vitamins, protective mattresses, CJ and Braden scores differed 
significantly between the study groups. When extensive inferential analysis was performed, 
the age, diagnosis, skin barrier creams, CJ, Braden scores and protective mattresses were 
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significantly different relative to PU incidence. Logistic regression analysis examined these 
factors to show those variables which were more likely to predict PU incidence. The results 
showed that the patients' age, application of skin barrier creams, neuro-surgical diagnosis, 
standard hospital-bed mattress, CJ and Braden scores were predictive of PU development. 
The present study shows that, when the effects of RASs (the Braden scale) have been taken 
into account, neuro-surgical diagnosis in particular is seen to be particularly relevant: the 
findings showed that the risk of PU development was nine times as great among those 
patients who had neuro-surgical diagnosis as among those who had different diagnosis, a 
result which necessitates the need for further exploration of PU occurrence in this subgroup 
of patients. The protective mattresses were the confounding variable most strongly in 
evidence, which may have distorted the effect of RASs on PU incidence (Defloor et al. 
2005, Defloor et al. 2004). The findings of this study indicated that the effect of protective 
mattresses was of limited value in all study groups (the incidence rate was similar among 
the three groups) because the mattresses did not match the patients' risk severity, especially 
those at high and severe risk of PU development. Despite its availability in different 
medical and surgical wards, the protective mattresses were not properly and frequently 
used. 
A controlled group pretest posttest design was used to control external variables. The 
researcher was aware of the input of other uncontrolled variables, control of which was 
outside the scope of this study, on the relationship between RASs (the Braden scale) and 
PU development. For example, the presence of the researcher as the TVNS in RMH may 
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have encouraged nurses in control groups to provide more PU prevention due to the 
Hawthorne effect. Moreover, in some circumstances nurses from different study groups 
may have met with each other to discuss the study interventions. 
The sensitivity of the Braden scale is high (94 per cent) at a cut off <18 as a threshold, i. e. it 
was predictive of PU development. The inclusion of those patients with PUs thus increases 
the level of risk for developing new PU which may encourage the nurses to provide more 
prevention, and then reduce NCPU (Lindgren et al. 2002 and Defloor et al. 2004), and the 
use of a cutoff point (<18) indicated more patients at risk, all of which alters the sensitivity 
of the Braden scale. The current Braden scale has been supported to a greater degree of 
validity by Bergstrom et al. (1987), Reed et al. (2001), Brown (2004), Halfens et al. (2000) 
and Pancorbo-Hidalgo et al. (2006). 
However, this implies that this study provides an alternative valid solution by which the 
effectiveness of RASs in clinical practice can be evaluated by measuring the inference in 
PU incidence reduction; to a certain extent, findings can be generalized to patients of acute 
hospitals when similar clinical characteristics have been considered. 
5.3 Interpretation and discussion of the main findings of the study 
This section discusses the key findings of the current study, which includes the following 
themes: The clinical effectiveness of using RASs on patient outcomes in terms of PU 
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incidence rate compared to nurses' CJs and the effects of using PU prevention programmes 
in RMH. 
The clinical effectiveness of the RASs (The Braden scale) 
As shown in the methodological discussion, this study offers a valid way to evaluate the 
effectiveness of the RASs on patients' outcomes in terms of PU incidence rate. The Braden 
scale was introduced to Group A nurses as a RAS, who were specially trained to use it, and 
were requested to employ it in their assessment of patients. During the application the 
research team provided support and motivation to the nurses, and collected the Braden 
scores from all patients in the different groups. The effectiveness of introducing the Braden 
scale to Group A nurses should be noted in relation to the reduction of the PU incidence 
rate, which was collected prior to and after introduction of the Braden scale. The findings 
show that there was no statistically significant (x1= 0.895; df. = 2; P= 0.639) effect for the 
study groups on PU incidence. These findings demonstrate that there was no clinical impact 
for the RASs (the Braden scale in this study) on patients' outcomes in terms of PU 
incidence reduction. It also substantiates similar findings of Gunningberg et al. (1999), who 
find that the systematic, clinical use of RASs (Modified Norton Scale) (MNS) has no 
effects in reducing PU prevalence; it is in agreement with the systematic review of 
Pancorbo-Hidalgo et al. (2006) who conclude that there is no evidence that the RASs are in 
themselves effective tools in reducing PU incidence. Nevertheless the nurses in Group A 
were more aware of PU prevention, and the use of the Braden scale was expected to 
increase their PU prevention performance; the patients did not receive more preventive 
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care. However, the use of RASs and the production of high risk figures might not lead to 
improvement in prevention strategies (Anthony et al. 2006, Gunningberg et al. 1999, 
Gunningberg 2005a and Halfens et al. 2000). For example, the findings showed that 44 per 
cent (110 of 248 patients) of those patients who were rated high risk according to the 
Braden scale and 42.4 per cent (70 of 165 patients) of those patients who were rated high 
risk by nurses' CJ were placed on standard hospital-bed mattresses. The nurses provided 
appropriate protective mattresses to those patients scored at mild and moderate risk 
according to either the Braden scale or CJ. These findings are also congruent with those of 
Gunningberg (2005a) and Schoonhoven et al. (2002b), who found that PU prevention 
strategies were insufficient in all medical care groups, especially in acute care where more 
patients are at risk. 
Based on the findings, nearly half (47.2 per cent) of NCPUs were Stage One. The nurses 
may not have recognised that Stage One PUs are pressure ulcer injuries and would be a 
cause of tissue damage. It was suggested that the Stage One PU be used as an indicator of 
when to start the prevention programme (Vanderwee et al. 2007, Defloor et al. 2004 and 
Defloor et al. 2007); the nurses may have waited until Stage two to four ulcers have 
developed before they provided the appropriate protective measures. The patients were 
followed for eight weeks. Hence, the nurses undertook initial assessments and planned 
interventions with no further re- assessment of the patients' conditions over the remaining 
period. 
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PU prevention training was given to nurses, but may not have been applied in practice. 
Panagiotopoulou et al. (2002) argue that good nurses' knowledge of PU risk factors and 
areas at risk was evident. Nevertheless, nurses were not able to translate such knowledge 
into practice in order to offer related preventive interventions. Clarke et al. (2005) 
evaluated the implementation of evidence-based nursing practice programmes in pressure 
ulcers and found that practitioners had increased knowledge of pressure ulcer prevention 
and treatment strategies, but did not have enough time to implement this knowledge. 
Gunningberg et al. (2001a) conclude that, even with limited utilisation of available 
knowledge and research findings in clinical practice, nursing staff knowledge and 
documentation of risk, prevention and treatment of pressure ulcers for patients with hip 
fractures could be improved. Based on the study setting, the protective mattresses were 
made available in medical and surgical wards. Nurses did not use appropriate protective 
mattresses available in their areas and also made no effort to borrow them from other 
wards. Nurses were given knowledge about PU prevention, but they were not trained to use 
that knowledge in patient care. Different educational strategies may be needed to enhance 
and improve nurses' practical implementation of PU knowledge. 
From another point of view, the attendance of the researcher as the TVNS at the RMH may 
encourage the nurses' from Group C (the control group) to apply more preventive 
measures, which may reduce number of patients who developed PU in this group compared 
to other groups. As a result, the effect of RASs (The Braden scale) on PU incidence 
between different study groups could not be made clear. 
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One more point should be noted in respect of the lack of effect of RASs on the PU 
incidence: the study was conducted on different patient groups. The patients may exhibit 
different characteristics which may not influence all predictors (risk factors) of PU 
development. These factors were not recorded by the RASs (The Braden scale) itself and 
were not included in the study instrument. For example, Anthony et al. (2000) found that 
serum albumin was predictive for PU development, whereas it is not recorded in the present 
study. Moreover, the factor nutrition in the Braden scale is formulated as the intake of 
nutrition and not as the nutritional condition of the patient (Halfens et al., 2000). 
The effectiveness of the PU prevention programme at the RMH 
Although the RASs (the Braden scale) had no effect on PU incidence reduction, and the 
incidence rate was relatively similar between the study groups, there is a statistically 
significant (x2= 17.023; d f. = 2; P<0.001) difference in PU incidence rate between the 
pre-test and post-test stages. The PU incidence declined from 31 per cent (83 of 265) in the 
pre-test stage to 19 per cent (49 of 256) in the post-test stage. Although PU prevention was 
not optimal, as many patients developed NCPUs and did not receive appropriate prevention 
treatment, the findings reveal that the PU prevention programme based on the AHCPR 
(1992) guidelines which was applied at the RMH was effective. These findings are in 
agreement with those of Regan et al. (1995) and Xakellis et al. (1998) Clark (1999), which 
show that clinical guidelines lead to reduction of PU occurrence after implementation. It is 
also in accord with Day et al. (1997) who suggest that aggressive prevention and ongoing 
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continuing programmes have demonstrated significant reduction of incidence and time 
taken for treatment, as well as dramatic cost savings. 
The PU prevention programme at the RMH was developed as a multi-professional, 
participatory and collaborative team approach. The TVNS position was created in addition 
to the Wound Care Committee. The PU incidence and prevalence monitoring system was 
considered, and PU training activities were developed to encourage nurses to change their 
performance towards PU prevention and management. The programme also utilised the PU 
wound documentation system and the Braden scale for PU risk assessment. Furthermore, 
the PU programme at the RMH started a project for supplying and maintaining PU 
preventive aids such as pressure-reduction mattresses. 
The findings are in accord with Gunningberg et al. (2001b) who investigated the incidence 
of PUs in 1997 and 1999 among patients with hip fractures. They found a significant 
reduction of the overall incidence of PU from 55 per cent in 1997 to 29 per cent in 1999. 
Their programme revealed changes in nursing and treatment routines among patients at 
risk, as well as improved nursing documentation, and indicated general changes in staff 
performance in relation to PU prevention. 
In addition to set a PU management plan by the TVNS at the RMH, which improved PU 
documentation, the nurses received mandatory wound care training, and the PU incidence 
results were used as a tool to clarify and highlight the problem (Torrance and Maylor 1999, 
Klazinga 1994), all of which encouraged the nurses to provide PU prevention and increase 
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their attention to the problem, which in turn improved their practice towards those patients 
at risk of PU development. 
Gould et al. (2000) review demonstrated that the implementation of a multidisciplinary 
working party, clinical guidelines, PU prevention equipment, improved documentation and 
staff education were effective in preventing PUs. Additionally, more systematic use of 
RASs was recorded as part of PU interventional studies. All of which have been 
implemented in the RMH. 
The RASs are a key component in any PU prevention guideline, being an essential initial 
step in PU prevention models (Scott 2000, Day et al. 1997 and AHCPR 1992). The Braden 
scale has been introduced to the RMH as an essential component in PU prevention 
guidelines in addition to PU education and prevention material; this accords with Halfens et 
al. (2000), who suggest that using a risk assessment scale is only helpful if it is used as part 
of a complete risk-based programme. They explain that using a risk assessment scale 
without knowledge, skills, time and materials to prevent patients from developing PUs will 
have no effect. 
Although the findings reveal that bringing the Braden scale to bear on PU incidence 
reduction at the RMH was ineffective, the use of RASs is essential to support nurses' 
clinical judgement in making appropriate decisions about PU prevention (Scott 2000, 
Edwards 1994 and Brown 2004). In acute hospital settings like the RMH, which involves 
patients whose health is constantly changing, it will be difficult to assess PU risk correctly 
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by relying only on clinical judgement because the patients are not well known to the nurses 
(Defloor and Grypdonck 2005). Moreover, CJ is influenced by level of experience nurses 
have (Thompson and Dowding 2002), which can be subjective compared to RASs as 
objective tools However, using RASs would be helpful to improve nurses' documentation 
(Maylor 1999) and present objective assessments, especially when demonstrated by novice 
nurses. 
Although the findings showed no effects on PU incidence for Group B, where RASs were 
not enforced while PU training was implemented, the effect of education on PU prevention 
is well documented (Buss et al. 1999, Suntken et al. 1996, Day et al. 1997, Gould et al. 
2000, Whitfield et al. 2000 and Gunningberg et al. 1999) as a strategy in clinical guidelines 
such as AHCPR (1992) and NICE (2003). The nurses at the RMH receive mandatory 
wound management education, and the effects of education programmes in general is 
evident when it is used as an adjunct to other components of a PU prevention programme. 
The nurses were able to clinically judge most of the patients at risk as the findings showed 
that of those patients identified as at risk by the Braden scale, with a cut off point 518,0.6 
per cent (4 of 719) of the patients were identified as not at risk. This implies that the nurses 
have the knowledge and skills to decide and define those patients at risk of PU 
development compared to the experienced research team using the Braden scale for 
scoring. The area under the ROC gives the best predictive usefulness of both the Braden 
scale and CJ among Group B patients when compared to other groups, and this highlights 
the effective role of education and training in improving the performance of PU predictors; 
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this is in agreement with Defloor and Grypdonck (2005) who suggest that introducing new 
RASs always needs to be accompanied by training. 
The nurses at the RMH had good knowledge regarding PU prevention, but utilisation of 
such knowledge was limited. The nurses' practices could be improved to reproduce optimal 
prevention (Panagiotopoulou et al. 2002, Clarke et al. 2005 and Gunningberg et al. 2001 a). 
Nurses at the RMH need more empowerment, support and motivation to implement their 
knowledge of PU prevention. Different educational strategies are also needed to improve 
utilisation of this knowledge. 
Exploration of the way the nurses make their decisions to prevent PU and the factors that 
hamper proper interpretation of their decisions in prevention practice are suggested areas 
for future investigation. It is, however, suggested that PU training be maintained at the 
RMH until optimum changes in knowledge and skills are achieved, which in turn may lead 
to better PU prevention. 
In respect of the presence of several activities (PU risk assessment, clinical guidelines, PU 
prevention equipment, PU documentation, and wound care team and staff education) in the 
prevention programme implemented at the RMH, it seems difficult to decide exactly the 
activities which most influence PU prevention. However, it is suggested that all 
components of the programme be considered, paying special attention to significant PU 
predictors (age, Braden scale, CJ, neuro-surgical diagnosis, protective mattresses and skin 
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barrier creams) which the present study finds help in the improvement of prevention 
activities. 
The RASs (the Braden scale) and CJ predictive performance 
The findings show no significant difference between use of a RAS (the Braden scale) and 
nurses' clinical judgement on the patient outcomes in terms of PU incidence rate. The 
incidence rate was 32 per cent in Group A, where the Braden scale was introduced at the 
pre-test stage, but only 21.6 per cent at the post-test stage. Unexpectedly, this difference 
does not show that using RASs (the Braden scale) is clinically effective or superior to using 
CJ or PU training because the incidence rate was 32.6 per cent in pre-test in Group C, 
where no RAS was applied, but only 15.2 per cent at the post-test stage. These findings 
suggest that a RAS (the Braden scale) and nurses' CJs were relatively comparable and 
produced equal effects on patients' outcomes, which is consistent with McGough (2000), 
who suggested that RASs were not better or more effective than nurses CJs, and with 
Gould et al. (2004), who found that nurses' clinical judgements were in more close 
agreement with expert panels than assessment produced by any of the three RASs (Norton, 
Waterlow and Braden) examined. The findings were, however, at variance with Pancorbo- 
Hidalgo et al. (2006), Halfens et al. (2000) and Defloor and Grypdonck (2005), who 
suggest that the use of RASs is better than a reliance on nurses' CJs. It should be noted that 
the agreement with Gould et al's. (2004) study is less important than disagreement with 
other studies, as Gould and colleagues examined few patients, relying instead on patient 
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simulation. There were more comments on the simulation method as rendering impossible 
communication with patients and the ability to touch their skin to decide its condition. 
Although Braden Scores (BS) have been produced by the research team and the Clinical 
Judgement (CJ) scores produced by ward nurses, relatively similar scores among those 
patients at high and minimal risk were produced by using both scoring systems. The 
findings also showed that Braden scores (BSs) and CJs were significant within the study 
groups and PU incidence. Logistic regression analysis using demographic variables, 
protective measures, BS and CJ reveal that BS and CJ have a statistically significant 
prediction function in PU development. The ROC analysis of BS and CJ performance in 
PU prediction revealed very mild differences in the area under the ROC between BS and CJ 
(0.635 for BS and 0.592 for CJ) which suggests relatively equal predictive performance of 
both risk assessment scoring systems among the study sample. 
The findings show that 44 per cent of those patients who developed NCPUs were scored at 
high risk by using BS compared to only 30 per cent scored as high risk by using the nurses' 
CJ; ROC analysis reveals a small area under the curve for both BS and CJ (0.635 for BS 
and 0.592 for CJ) in relation to the reference line. These findings demonstrate inadequate 
performance of both risk assessment systems, a finding which concurs with that of Gould et 
al. (2004) who suggest that neither RASs nor nurses' CJs should be regarded as very 
accurate. 
158 
However, training has been suggested in order to improve RASs performance (Defloor and 
Grypdonck 2005). The findings indicate that although the area under the ROC showed 
relatively similar performance for BSs and CJs among Group A patients, BSs and CJs give 
the best predictive usefulness among Group B patients, where training was dominant. 
When logistic regression analysis was repeated among post-test cases, the results show that 
only BS and neuro-surgical diagnosis were predictive of PU development, while CJ and 
other variables were moved out from the prediction model. These findings confirm BS 
predictive performance compared to CJ which is in agreement with numerous studies 
validating the BS predictive usefulness (Pancorbo-Hidalgo et al. 2006, Halfens et al. 2000, 
Schultz et al. 1999 and Defloor and Grypdonck 2005). Furthermore, the ROC analysis (See 
Figures 4.2 and 4.3) show that the area under the curve of the BS is wider and the ROC 
curve of the BS is superior to the one produced by the CJ, which portray, admittedly with 
low power, the usefulness of using BS compared to CJ. 
The findings are not sufficient to prove that the use of RASs is superior to CJs. Both risk 
assessment systems are poor. Although with the conclusions of Gould et al. (2004), it 
should not be taken as definitive proof to support nurses' CJs on account of RASs because 
they suggest that both risk assessment methods are not very accurate and the use of the 
expert model as a standard is not reasonable. The findings could be explained in different 
ways: the nurses may have become more knowledgeable as they received rigorous wound 
care training, the whole prevention programme implemented at the RMH may have had an 
impact on the reduced effects of the RASs, and the attendance of the TVNS may have 
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encouraged and motivated the nurses to provide more PU prevention. Other factors beyond 
the scope of this study and which were not recorded may also explain this. 
Although the performance of the BS was poor and inadequate and there was no difference 
between using BSs and CJs in PU risk assessment, the use the RASs (the Braden scale) to 
aid and facilitate nurses' CJ should continue (Scott 2000, Edwards 1994, Brown 2004, 
Flanagan 1995 and Mitchell 2004). Nurses' CJs alone cannot be relied upon, because in 
acute settings they do not have the chance to get to know the patients over a long period of 
time (Defloor and Grypdonck 2005). The RASs would be used by experienced and novice 
nurses accompanied with proper training (Pancorbo-Hidalgo et al. 2006 and Defloor and 
Grypdonck 2005). Furthermore, the RASs are systematic tools and can save nurses time 
and direct their attention towards providing preventive PU care (Halfens et al. 2000). 
The use of available validated scales presenting alternatives for assessing PU risk should 
continue until new validated risk assessment scales are created. The performance of RASs 
may be improved when utilising the research findings (Defloor and Grypdonck 2005 and 
Schoonhoven et al. 2002), taking into account the multifactorial nature of the PU problem. 
For example the use of non-blanchable erythema as an early sign of PUs (Vanderwee et al. 
2007) indicates the importance of PU risk assessment which goes beyond a paper exercise 
performance in assessing patients at risk. Continuous skin inspection and/or assessment 
may also improve RASs performance. 
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The present study describes the role of nurses' CJs in identifying those patients at risk of 
PU development, but does not scrutinise their performance. The challenge is to explore 
how they identify patients at risk, the factors that impact on their success and the role that 
RASs play in this process (Gould et al. 2004). Consequently, many questions in relation to 
risk assessment of PU and nurses' opinion in assessing patients at risk of PU development 
remain unanswered until further studies resolve both. 
Focus group discussion 
The research team also undertook a focus group discussion in order to elicit the views of 
nurses regarding the research project and its impact on their practice. The nurse participants 
indicated that they had given careful thought to the problem under study. 
Participants were asked about the concept of PU risk assessment and the application of the 
Braden scale in PU prevention. 
The focus group discussion revealed that there had been changes in nurses' knowledge and 
practice regarding PU prevention. Nurses paid more attention to PU prevention as they 
received rigorous PU training and as they were requested to apply the Braden scale on their 
patients. These findings support the effects of the PU programme at the RMH. The nurses 
stated the importance and usefulness of using risk assessment in PU prevention for the 
patient and nurses as well; they mentioned that it improved their documentation and 
communication. According to participant nurses, it would be difficult when risk 
assessments are not used regularly or initially on patients' admission. Furthermore, they 
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added that risk assessment may help in making more accurate PU prevention plans. Some 
nurses commented that risk assessment may help in paying more attention to PU 
complications where PU wounds exist. Moreover, the nurses suggested that the risk 
assessment was part of patients' daily physical assessment, which facilitates in identifying 
those patients at risk of PU development. 
The focus group discussion also revealed that the application of the Braden scale had been 
supported by the participant nurses. It was recognised as an effective tool in identifying 
patients at risk of PU development and it was understandable and easy to use. The nurses 
highlighted training as essential strategy to improve their performance of risk assessment. 
The discussion revealed that the use of the Braden scale facilitated and aided nurses' 
decision making. Nurses recognised the benefits of using of the Braden scale as it indicated 
which risk factors to focus on and the degree of risk; the prevention strategy would then be 
easy to decide according to clinical guidelines. They added that it also saved their time and 
effort. 
In summary, the focus group discussion found that: 
1) nurses realised the value of utilising risk assessment tools in clinical practice. 
They recognised it as a helpful and essential strategy in a comprehensive PU 
prevention programme. Risk assessment was acknowledged by nurses as a source of 
motivation for continuously inspecting patients. 
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2) the Braden scale was supported by the participant nurses as clinically 
understandable, easy to use and valid in order to identify those patients at risk. 
However, they emphasised that more training was required to improve risk 
assessment performance. 
3) the use of RASs (the Braden scale) facilitated the nurses' decision making 
abilities and focused their attention on specific risk factors. 
The focus group discussion findings support the notion that the use of RASs facilitate and 
aid nurses' CJ, but are at variance with the finding that there was no clinical effect for the 
RASs on patients' outcomes. The discussion revealed that there is an effect when using 
RASs on patients' outcomes through the application of a holistic and comprehensive PU 
prevention programme. 
Although the focus group discussion was flexible, it raised many important points and gave 
the opportunity for participants to share their clinical experience. It reflects the views of 
participants which may be biased and may have given idealised responses expected of 
them. 
5.4 Interpretation of additional findings of the study 
This section presents interpretation of recorded variables in the study in relation to PU 
incidence which includes: PU incidence and prevalence, the impact of patients' 
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demographic characteristics on PU incidence (gender, age and diagnosis) and the impact of 
protective measures on PU incidence (protective mattresses, skin barrier creams, turning 
schedules and vitamins and nutritional supplements). 
PU incidence and Prevalence 
Numerous studies have been conducted to estimate PU prevalence and incidence. An 
overview of these shows a lack of consistency and of standardisation in research methods in 
terms of different populations, data collection methods, patient observation methods and 
periods of observation due to a lack of consensus on PU definition, aetiology, classification 
systems, risk factors, risk assessment scales and cut off threshold scores. As a result, the 
prevalence and incidence estimates cannot be compared with each other. 
The EPUAP method of estimating incidence and prevalence has been acknowledged in the 
literature. It facilitates the development of prevalence estimates and is sufficiently robust to 
measure and compare prevalence among different countries according to Gunningberg 
(2005b) and Vanderwee et al. (2007). 
The pressure ulcer incidence rate in this study was 22.9 per cent, and reflects nosocomial 
ulceration among hospitalised patients at the RMH. This figure is particularly useful in 
providing a broad view of PU at the RMH and in establishing baseline data for future 
improvements where national studies and documentation of PU are lacking (Halfens et al., 
2001, Klazinga, 1994, Saleh et al. 2006). It may also be used as one measure for the 
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development of PU prevention strategies within the RMH as a health care facility. The PU 
incidence rate was the main outcome indicator in this study for the evaluation of the 
effectiveness of RASs on patients' outcomes (Cullum et al. 1995). 
Although the incidence rate improved since the implementation of the wound care 
programme at the RMH in 2003 (the incidence rate in that year was 36.4 per cent) as shown 
in chapter one (Table 1.1), it is still high when compared with developed countries (Saleh et 
al. 2006) such as the UK, the USA and Canada. It was 2.2 per cent per annum to 29 per 
cent over a maximum of six weeks in the UK and 8.5 per cent over a one- to four-week 
period to 13.4 per cent for a maximum of two weeks in the USA and Canada (Kaltenthaler 
et al. 2001). This demonstrates the need for further exploration of different PU incidence 
figures to show the effectiveness of the prevention programme implemented, a need which 
is partly addressed through this study. The effect of using RASs, which is the initial step in 
any prevention programme, was examined in respect of patient outcomes as a key aim of 
this study. 
The PU incidence figures at the RMH seems better than PU prevalence, since 33.7 per cent 
(242 of 719) of the patients were admitted with Stage One to stage four PU. PU prevalence 
is high, being comparable with international reports in developed countries such as the UK 
and Europe. It ranged from 5.1 per cent to 32.1 per cent in the UK (Kaltenthaler et al. 2001) 
while it was ranged from 7 per cent in Germany to 15 per cent in the Netherlands in 1995 
and 28 per cent in Germany to 33 per cent in Netherlands in 2004 (Tannen et al. 2004 and 
O'Dea 1995). 
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The PU prevalence figures at the RMH could be explained in regard to the EPUAP 
statement on prevalence and incidence monitoring of PU occurrence (Defloor et al. 2005). 
More admissions are to be expected, as the RMH is the central military referral hospital in 
Saudi Arabia and the prevalence is affected by the presence and effectiveness of PU 
prevention and treatment programmes. There are no PU prevention programmes 
implemented among those patients who receive care by home health and community 
services in Saudi Arabia. As a result, there was no significant variation in prevalence rate 
between the pre-test and post-test stages. 
Prevalence was not included in evaluating the effects of RASs on patient outcomes (Cullum 
et al. 1995); it gives an insight into the magnitude of the problem of PU which may aid in 
planning for health resources and facilities rather than making inferences about the 
effectiveness of PU prevention programmes, in part or as a whole (AHCPR 1992, Defloor 
et al. 2005, O'Dea 1995). 
Although the overall incidence rate in this study (22.9 per cent) is higher than the rate 
reported in developed countries such as the UK and Europe, the severity of NCPU is 
consistent with the findings of international studies such as Whittington et al. (2000) and 
Schultz et al. (1999). The study revealed that nearly half (47.2 per cent, or 78 of 165 
patients) of NCPU were Stage One, while only 6.6 per cent (11 of 165 patients) were Stage 
Four lesions. As opposed to incidence, the severity of PU lesions among those patients 
admitted with PU was 44 per cent (106 of 242 patients), which increases the risk of 
developing new NCPU among those patients included in the study. O'Dea (1995) finds that 
166 
the source of PU damage was in the hospital, but the study findings imply that this is not 
so. This may be explained either by the patients receiving protective measures to relieve 
pressure and tissue damage, or by the possibility that pressure and shearing forces are 
scrambled with the effect of patients' tissue tolerance, which may reduce the occurrence of 
severe ulcers. However, more clarification is needed to explore this area. 
The AHCPR (1992) classification system was used in this study. Calculating Stage One PU 
may limit comparability with other studies that indicate Stage Two and higher because 
there is a debate on the usefulness and accuracy of using Stage One (Bethel! 2003). Some 
researchers (Schoonhoven et al. 2006, Schoonhoven et al. 2002, and Kaltenthaler et al. 
2001) omit this stage completely, although this may lead to further complications (Bethell 
2002). Inclusion of Stage One is considered in the early diagnosis of PU development, and 
may result in the reduction of the number of patients needing prevention, which is 
consistent with Vanderwee et al. (2007); there is no international consensus on specific 
staging system as mentioned by Bethell (2002) and Harker (2000). Furthermore, Schultz et 
al. (1999) suggest that the studies report their rates of Stages One to Four inclusive and then 
report Stages Two to Four in order to resolve the problem of including Stage One. 
More than half (50.3 per cent) of NCPUs were developed on the sacral area, which is 
consistent with previous studies such as Schoonhoven et al. (2006), Schultz et al. (1999), 
Whittington et al. (2000), Gunningberg et al. (2001), Schue and Langemo (1998) and 
Defloor 1999). The most severe ulcers (Stage Four) appeared on the sacrum, heels, ankle 
joints and toes. The majority (53.8 per cent) of patients developed Stage One PUs and 
nearly half (48 per cent) were admitted with severe ulcers (Stage Four) on the sacrum 
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challenges the effectiveness of patients' turning programmes and suggests special care 
when applying preventive measures. 
The impact of patients' demographic characteristics on PU incidence 
This section discusses the impact of those recorded patient demographic characteristics 
which may mask the effects of RASs on PU development. This section explores the effects 
of gender, age, and diagnosis on PU development. 
The findings (Appendix S) show that 67.2 per cent (111 of 165) of the patients who 
developed NCPU were male. Nevertheless, 92.4 per cent of Group A patients were male 
and the majority (66.2 per cent) of Group C patients were female, which clearly was not 
associated with PU development because relatively similar PU incidence rates (24.4 per 
cent in Group A and 21.1 per cent in Group C) was found in both groups. The findings also 
show a similar distribution of male and female patients in pre-test and post-test stages; this 
suggests no association with PU development, as there was a significant difference in this 
development between the two stages. This finding substantiates similar ones in previous 
studies including Schultz et al. (1999) and Whittington et al. (2000), but contradicts Tannen 
et al. (2004) who find that more females than males suffer from PUs. Although gender was 
statistically significant (x2= 192.93, P<0.001, df= 2) within the study groups, it was not 
in relation to PU incidence. Moreover, gender was not found to be a predictor of PU 
development, a finding consistent with Anthony et al. (2003) This implies that gender may 
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not be a risk factor of PU and should be reviewed in current risk assessment scales such as 
the Waterlow scale, which may simplify the scale and improve its performance. 
Descriptively, the findings (Appendix S) showed that the sample population was mildly 
skewed toward older patients. Group B patients were younger and showed a similar PU 
incidence rate compared to group A and C patients. 60 per cent of those patients who 
developed PUs were 60 years and older. This finding was similar to Whittington et al. 
(2000) and is supported by Tannen et al's. (2004) conclusion that age had the highest 
impact on PU occurrence of any variable. A relation was found between PU development 
and patients' ages. Age was statistically significant in the study groups and PU incidence. 
Moreover, it was found to be a predictor (x2 = 8.920, P=0.003, OR = 1.132) of PU 
development when logistic regression analysis was performed. Age was also shown as a 
predictor of PU development in many studies (Anthony et al. 2003, Schultz et al. 1999, 
Halfens et al. 2000 and Gunningberg et al. 2001b). This finding, therefore, confirms that it 
is important to consider age as a relevant item in a risk assessment scale for hospitalised 
patients, a consideration which may improve the RASs predictive performance. 
Although 40 per cent (289 of 719 patients) of the sample and 50 per cent of patients 
developed NCPU had medical diagnosis, it was noted that diagnosis was statistically 
significant within both the study groups and PU incidence rates. The findings (Appendix S) 
showed relatively similar PU incidence rates among groups A and C in which medical 
disorders formed nearly 50 per cent of their patients. When diagnoses were entered in 
logistic regression analysis with a series of variables (the Braden scale, clinical judgement, 
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protective measures of PU and demographic variables), neuro-surgical diagnosis was found 
a predictor of PU development; this is consistent with Halboom et al. (1999). Although 
only 8 per cent of those patients who developed NCPUs were neuro-surgical, the data 
confirmed that such patients were at greater risk of PU development. Neuro-surgical 
patients spend long time under surgery, are immobile and are unable to feel pain or respond 
to any signs of tissue damage caused by prolonged pressure effects, which is consistent 
with Defloor's (1999) conceptual model of PUs. It seems that this subgroup of patients do 
not receive initial PU prevention in the immediate post-operative phase compared to other 
diagnostic groups who may have a lower risk, better levels of activity and mobility and who 
may receive better prevention such as ambulation post-operation and PU protective 
mattresses. The findings (Appendix S) indicate that the turning schedule for the neuro- 
surgical patients in Group B was either every 2 hours, every 3 to 4 hours or every 6 hours. 
This was erratic: 50 per cent of patients were turned every 6 hours. Since these patients 
have been showed to be at severe risk, a consistent turning schedule should have been 
performed, combined with the use of appropriate protective mattresses. 
However, analysing variations of incidence among such subgroups is beyond the scope of 
this study. Further research is required to explore risk factors among specific diagnostic 
groups. 
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The impact of protective measures on PU incidence 
The study was performed on inpatients at the RMH, where a range of protective mattresses 
are available for use. Protective mattresses were considered in patients at risk of PU 
development (Lindgren et al. 2002) and in accordance with the AHCPR (1992) guidelines. 
Special mattresses and beds or overlays were used to prevent PUs in those patients at high 
risk, as well as in PU treatment (Cullum et al. 1995). However, their use may potentially 
distort the effects on PU incidence among different patient groups and may decrease the 
predictive value of the RASs (Defloor and Grypdonck 2005); (Defloor et al. 2004). 
Apparently, PUs continue to develop despite the use of protective mattresses, which implies 
that the effectiveness of these mattresses is limited, in general, in the study groups. For 
example, although 52 per cent of Therakair mattresses (the most expensive type of 
protective mattress) were used in Group A where the Braden scale was introduced, the 
incidence rate was relatively similar between study groups. 
However, nurses in Phase Three (the post-test stage) used more protective mattresses, and 
here the incidence rate was significantly decreased. For example, 53 per cent (69 of 130) of 
Therakair mattresses were used in the post-test stage, while only 28 per cent (37 of 130) of 
these mattresses were used in the pre-test stage (Appendix S). Moreover, 51 per cent (282 
of 554) of those patients who did not develop NCPU used one of the protective mattresses 
and only 39.3 per cent (65 of 165 patients) of those patients who developed NCPU were 
placed on one of protective mattresses (Appendix S). Patients placed on standard hospital 
mattresses have a higher risk of developing NCPU, as shown by logistic regression 
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analysis, a statistic that is congruent with Cullum et al's (1995) findings, which suggest that 
the standard hospital mattress is less effective in PU prevention than some other protective 
mattresses. These findings suggest that using protective mattresses is an essential part of the 
prevention programme implemented at the RMH, which is consistent with the 
recommendations of international clinical guidelines such as AHCPR (1992) and NICE 
(2003). 
The present study does not demonstrate a protective function for the mattresses in PU 
prevention. The logistic regression analysis revealed no predictive effect for any protective 
mattresses on PU development; it was even different within the study groups and initially 
for PU incidence. Limited effects of protective mattresses among study groups may be 
explained by their appropriate utilisation. The nurses were not able to distinguish the use of 
different protective mattresses according to patient risk categories in order to provide the 
optimum effect. It is presumed that Therakair mattresses are used for patients at severe risk 
and the alternating one for the other risk categories. For example, introducing the Braden 
scale to Group A patients encouraged the nurses to use Therakair mattresses (52 per cent), 
while only 34 per cent (84 of 248) of those patients rated as high risk according to the 
Braden scale were from Group A (Appendix S). 
The link between scores and types of protective mattresses should be investigated further, 
as there are too many types of protective mattresses available in clinical practice. 
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Skin care is one of the major issues in PU prevention, as dry or moist skin has been shown 
to increase PU development. The intensity of shearing force is influenced by wet and dry 
skin, which fosters the occurrence of PU (Defloor 1999). 
Preliminary data analysis (Appendix S) showed that 52 per cent of those patients who 
developed PU used skin barrier creams. Also it showed that skin barrier creams were not 
significant within the study groups but they were significant for PU incidence. Hodgkinson 
et al. (2007) reviews the poor evidence regarding interventions (included topical skin care) 
that may improve the skin condition in older people. Logistic regression analysis revealed 
that skin barrier creams have a significant protective function in PU development. It implies 
that skin barrier creams can be used as an adjunct as part of an overall PU management 
programme. There is consistency with most PU prevention clinical guidelines, which 
include a reference guide on skin care. For example, AHCPR (1992) guidelines indicate the 
use of topical agents that act as barriers to moisture, and EPUAP (1998) guidelines include 
skin dryness and moisture as elements of skin assessment in order to maintain and improve 
tissue tolerance to pressure so as to prevent injury. 
Although the AHCPR (1992) PU guidelines were adopted for the RMH PU prevention 
programme and positioning devices were suggested to keep bony prominences from direct 
contact with one another, the data showed that turning was not significant among the study 
groups and in PU incidence. Furthermore, logistic regression analysis shows that turning 
patients is not a predictor of PU development. Such findings are strange when turning is 
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suggested by most international PU prevention clinical guidelines such as AHCPR, 
European Pressure Ulcer Advisory Panel (EPUAP), the National Institute for Clinical 
Excellence (NICE) and The Dutch consensus guideline (Defloor et al. 2004). It is 
inconsistent with Defloor et al. (2004) and Defloor and Grypdonck (2005) and Cullum et 
al. (1995), who find that turning does decrease the PU incidence when used in combination 
with pressure-reducing materials. These inconsistent findings may need more exploratory 
studies. However, it could be explained as follows: because the majority of developed 
NCPUs were of the Stage One category, the non-blanching erythema was not stable and 
was not caused by pressure and shearing forces in most cases. Another possibility is that 
the turning procedure itself may not have been applied properly, and therefore has no effect 
on PU incidence. 
Assessment of nutritional intake and nutritional support was suggested as a factor in 
maintaining skin integrity and preventing PU development (AHCPR 1992). This was 
supported in Defloor's (1999) conceptual scheme of PU development, which states that 
proteins and vitamin C may encounter reduced tissue tolerance and the risk of tissue 
damage. Although the role of vitamins and nutritional supplements are obvious in PU 
prevention and wound healing, the findings of this study show that they are not significant 
in reducing PU incidence and are not predictors in PU development. These findings do not 
agree with Stratton et al's (2005) systematic review, which shows that enteral nutritional 
support, particularly high protein, can significantly reduce the risk of developing PUs by 25 
per cent and may improve healing of PUs as well. It is also incongruent with current 
Cochrane review findings conducted by Langer et al. (2003). A possible explanation for 
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these contradictory findings is that perhaps nutrition and vitamin intake are observed in 
patients who may already be in good nutritional condition (Halfens et al, 2000). 
Consequently, these patients may have good tissue tolerance to the development of PUs. 
However, further study is needed to explore the effects of nutritional supplements on PU 
development among the RMH patients. 
5.5 Summary 
This chapter incorporates interpretation, explanation and discussion of the study findings. It 
explores the impact of utilising theoretical knowledge of risk and risk management to 
improve patient outcomes associated with PU risk management in health care. It also 
presents the methodological discussion and interprets the contribution of this work in PU 
risk management. It has discussed the main findings of the study, the usefulness of using 
PU prevention programmes in the RMH, the clinical effectiveness of using RASs on 
patients' outcomes and the similar effects of using RASs and nurses' CJs in improving 
patients' outcomes in terms of PU incidence. Additional findings of the study interpreted, 
discussed and incorporated to PU prevention and management. The study addresses the 
importance of utilising age, and reviewing gender variables in patient risk assessment. It 
also presents the usefulness of using skin barrier creams and protective mattresses in PU 
prevention. The discussion provides evidence of the risk factors associated with PU 
development. The PU risk is nine times as great among those patients who had neuro- 
surgical disorders compared with those who had different diagnoses. 
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The focus group discussion was analysed, interpreted and incorporated into the study's 
findings. It reveals agreement and support to the study findings in that the use of RASs 
facilitates and aids the nurses' CJs. The nurses believe that RASs may have a clinical effect 
on PU prevention through a holistic prevention programme. 
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Chapter Six: Limitations, Recommendations 
and Conclusions 
Introduction 
The present study explores the effects of using RASs (The Braden scale) on patient 
outcomes in terms of PU incidence reduction, and its findings can be applied to national 
and international nursing communities. Although it is the first study conducted in Saudi 
Arabia, it contributes to the national and global body of knowledge. It is one of few studies 
to examine the effects of RASs on patient outcomes and the first to examine the effects of 
using the Braden scale on patients' outcomes, all of which yield a new approach to 
evaluating RASs compared to conventional methods of using their predictive value. 
Additionally, it provides the local hospital with baseline data and recommendations for 
future developments in improving the quality of care provided to those patients at risk of 
PU development at the RMH and other health care facilities in Saudi Arabia. 
This chapter encompasses the usefulness of the study findings in terms of limitations, 
recommendations and conclusions which are given in order to enable practitioners, 
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managers and researchers to broaden their understandings about PU risk assessment, and to 
change their practice towards optimum PU prevention. 
Although the researcher used the best accessible design to manage this research, it is 
important to mention several limitations which were encountered throughout the course of 
the study. The limitations included methodological design, study sample and data collection 
process. 
This chapter also suggests recommendations for future research, implications for nursing 
practice and for policy change; all of which incorporate optimum PU prevention through 
the development of nurses' skills to identify those patients at risk of PU development. 
6.1 Study limitations 
Although this research shows considerable strengths as an initial study in the field of PU 
risk assessment, several limitations are evident: 
1) It uses a quasi-experimental design and lacks randomisation, which may imply 
concerns about the generalizability of the findings compared to experimentally 
designed studies because of weak casual inference and an increased threat to 
internal validity (Talbot 1995 and Polfit and Hungler 1999). In this study, the 
researcher examined the effects of RASs (the Braden scale) on patient outcomes in 
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terms of PU incidence reduction, which introduces a valid and new approach to 
evaluating the effectiveness of RASs. Additionally, the researcher integrated 
prospective control groups and pre-test post-test designs. This restricts the effects 
of external factors and strengthens the validity of the study's findings. Proper 
methodological procedures were applied and nevertheless the generalizability of the 
findings was considered with caution. The PU is a problem of multifactorial nature 
where it is difficult to report and collect reliable data (Anthony et al. 2006 and 
Gunningberg et al. 1999). However, although the study adds cumulative evidence to 
the effectiveness of RASs on the patients' outcomes, it suggests the desirability of 
more studies of mixed nature (qualitative and quantitative) to answer different 
questions about the clinical usefulness of risk assessment on patients' outcomes. 
2) A non-probability purposive sampling design was used to select the study 
sample. The probability sampling is a more respected approach than non-probability 
because greater confidence can be placed in the representativeness of the sample 
(Polft and Hungler 1999 and Talbot 1995). Although the researcher was not able to 
randomise the aggregate patients and nurses at the same ward level due to ethical 
considerations and the nature of PU problem, the wards were randomised for 
inclusion in different study groups. Even though a sound rationale behind using the 
sampling design and adjunctive procedures was clearly cited to give the findings 
more validity, the generalizability should be handled with caution. Furthermore, the 
study was from one referral military hospital in Saudi Arabia. This also limits the 
generalizability of the findings to similar settings. It should be noted that the 
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sample size was adequate according to statistical procedure by using the G power 
test (Faul and Erdfelder 2006) and the effect size was 0.3, between a medium and 
small effect. 
3) The inclusion criteria for those patients considered at risk was the Braden scale 
cut off point of 518. The use of such a cut off point indicated that there were more 
patients at risk, which was one of the main reasons for distorting the sensitivity of 
the Braden scale. The literature reviewed indicated different cut off points among 
different populations; the use of the <18 cut off was acknowledged by Brown 
(2004) and Pancorbo-Hidalgo et al. (2006). Although the inclusion criteria 
encompassed those patients admitted with extant PUs (Stages One to Four 
according to the AHCPR (1992), which added more objectivity and captured more 
intrinsic and extrinsic factors that might affect the results, they may also have led to 
bias because these patients may have received more preventative treatment. 
4) The study reveals a number of issues with regard to the data collection process. 
Firstly, the study used different data collection methods: the majority of data 
was collected through patients' observation, but self report and focus group 
discussion was also used. In this study, patient observation included 
inspecting the skin for the presence of NCPU according to the AHCPR 
(1992) PU classification system which includes Stage One PUs. Although 
several researchers indicated Stage Two and higher in their studies such as 
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Schoonhoven et al. (2006), there is no international consensus on specific 
staging system to be used (Bethell 2002 and Harker 2000). Difficulty in 
observing patients with darkly pigmented skin was reported in some 
instances. Self reporting was used to collect ward nurses' CJs among 
included patients; the ward nurses did not know the patients' Braden scores. 
The method by which the nurses' made their decisions was not described or 
observed. Furthermore, although the focus group discussions supported the 
study findings, they reflect the viewpoints of the participant nurses, who 
may have given idealised responses. 
Secondly, the patients were observed on a weekly basis. With such a long 
interval period between skin inspection, PU changes over a shorter period of 
time could have been missed. Furthermore, the eight week observation 
period was relatively long as the patient may develop several PUs during 
this period. 
Thirdly, the researcher was the TVNS for the RMH, which may have 
encouraged the ward nurses to use more PU prevention measures. 
5) The scale used in this study (The Braden scale) has not been previously tested 
and/or used in Saudi Arabia. The Braden scale was extensively studied and has been 
acknowledged as providing optimal validation. The face and content validity were 
maintained by experts. The reliability of the instrument was tested throughout the 
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pilot stage of the study, yielding a complete agreement of total Braden scores 
between ten nurses who assessed one patient with a very tiny variance among the 
scores of the Braden subscales. The Braden scale was chosen because of the reasons 
mentioned previously in chapter three (section 3.5). 
6) Another limitation is related to staff turnover and newly employed nurses, which 
is a well-recognised problem in such large clinical settings. This problem had a very 
limited effect on the study as the training and education system is a mandatory 
activity and policy at the RMH. 
7) The limited resources influenced the number of nurses who could contribute to 
the research and the numbers of patients that could have been observed. Patients in 
many parts of RMH were not studied. 
6.2 Recommendations 
The current study draws attention to PU risk assessment as a preventative strategy. At the 
same time the true scale of the PU problem is unknown, but it is certain that it has been 
vastly underestimated. Numerous studies on PU risk assessment scales have been 
conducted, all of which revealed variations in the study population, different data collection 
methods, a lack of national and international consensus on PU staging systems, risk 
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assessment scales used and inadequate documentation of prevalence and incidence as 
outcomes. All of this lead to a lack of comparability between data sets collected and cast 
doubt on the quality of the findings. The present study supports the comprehensive PU 
prevention programme implemented at the RMH and helped to achieve some of its long 
term objectives: 
1) The quality of nursing care improved among those patients at risk of PU 
development, as was evident through the reduced figures of PU incidence among 
hospitalized patients. 
2) It provided base line evidence which contributes to the development of the body 
of nursing knowledge in this area of specialization. This development was 
strengthened by the unique opportunity presented by the Braden scale's recent 
introduction into the RMH to research the clinical effectiveness of RASs. As a 
result, this study tried to provide a valid and reliable scale of data regarding PU risk 
assessment. It tried to overcome other studies' methodological flaws, and attempted 
to shed light on risk assessment, which plays a significant part in PU prevention. 
Although the study did not offer a solution to the PU problem, it contributes to future 
improvement and provides suggestions for future research. 
PU prevention remains an important area of patient care in acute and community health 
settings. Hence, risk assessment is essential to any PU prevention strategy. 
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The study suggests recommendations for practitioners working with patients. It also 
provides recommendations for policy makers who have a responsibility towards the 
improvement of PU prevention policies. Additional recommendations are made for further 
research in this field. 
6.2.1 Recommendations for nursing practice 
The study produces recommendations to improve nursing practice in relation to PU care 
and prevention, including PU risk assessment. These recommendations fall into two main 
themes: 
1) The implementation of RASs as a tool for assessing risk of PU development. 
There is national and global consensus on using RASs as key components in any 
PU prevention guideline such as AHCPR (1992) and EPUAP (1998). RASs are 
structured models of PU risk factors which present systematic and objective sets 
of information that are suggested to aid and facilitate nurses' CJs associated 
with PU risk assessment and management (Scott 2000, Edwards 1994, Brown 
2004 and Flanagan 1995). These scales offer an objective alternative in 
assessing the risk of PU development, as no other options are superior. They are 
dynamic to change and maintain a reasonable degree of validity through 
continuous investigation, refinement and critical review. The RASs should not 
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be used in isolation, as they are central in a risk-based system implemented in 
clinical practice. For example, RASs can be used as clinical audits to monitor 
patient's state of risk and to ensure that these patients receive appropriate PU 
prevention. 
Implications of using RASs into practice 
a) PU training and education programmes. The successful implementation of 
RASs cannot be achieved across the RMH unless there is sufficient 
preparation of nurses who are expected to use the tool. A systematic and 
organised PU training programme will provide consistency and broaden 
nurses' knowledge and understanding of PU risk factors which are essential 
for effective and appropriate application of RASs. Mandatory PU training 
including RASs and use of different educational strategies need to be 
implemented to enhance and improve nurses' utilisation of knowledge. 
b) Nurses' should be deemed to be competent for the effective implementation 
of RASs into practice. Hence a continuous ongoing PU training programme 
should be put in place to ensure that practice remains up to date and 
competency is checked 
c) Managers have to be involved in decisions associated with implementation 
of RASs. Managers can be instrumental in maintaining a cooperative 
environment, allocating time and resources necessary of using RASs. 
Furthermore, managers should take the responsibility for ensuring that staff 
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are motivated, as lack of motivation may result in an inappropriate 
implementation of RASs. Additionally, managers should monitor the 
application of RASs as it is also essential to sustain appropriate and effective 
use of RASs into practice. 
d) A Tissue Viability Team (TVT) should be set up to oversee the overall 
programme of PU prevention at clinical level. TVT and managers should be in 
agreement on the composition of the team. The TVT can improve the 
application of RASs through dynamic and continuous monitoring of using 
these tools in clinical practice. Furthermore, the TVT can provide further 
refinements of RASs through active examination of their effectiveness in 
clinical use. 
e) The setting up a two phase pathway for the management of patients: In 
phase one, an assessment will be carried out on all patients on admission by 
the nurses Those patients who are identified as `high risk' should proceed to 
phase two in which the patients will undergo a more comprehensive PU 
assessment by the TVNS for expert advice on prevention and management 
strategies.. This approach may facilitate the application of RASs and clinical 
decisions related to PU risk assessment, prevention and management through 
better understanding and perception of information related to risk and risk 
management. 
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2) Better use of available resources in PU prevention 
The nurses need to know what PU prevention resources are available that can 
be used in their clinical areas, when to use them, how to use them and in what 
basis these measures are evaluated. This demonstrates the following 
implications: 
a) a need to review and revise protocols and guidelines of using PU 
prevention measures in the RMH. This includes clear and flexible 
guidelines of what PU prevention measures are available and when and 
how to use them. These guidelines should clarify what prevention 
strategies are required for the different categories of risks. For example, a 
patient at severe risk and scored at (9-10) by using the Braden scale has to 
be placed on a low air loss mattress such as Therakair. These guidelines 
should be based on research evidence which enhances accuracy and 
effective use of prevention measures and minimises their misuse. 
b) Availability of protective measures. The nurses need to know what 
protective measures are available in RMH to reduce risk of PU 
development. Managers should ensure that adequate resources are 
available in clinical practice. Hence a financial plan is necessary to support 
the purchase of necessary equipments/ resources. These measures should 
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meet and satisfy the needs of patients at risk and evaluated in the light of 
new research evidence. 
c) Nurses' accountability and empowerment. Managers should encourage 
nurses and empower them to sustain professional accountability and 
support autonomous decision making in relation to PU prevention and 
management through decision analysis and evidence-based approaches. 
6.2.2 Recommendations for policy improvement 
A Risk management strategy (RMS) should be developed in order to improve policies in 
relation to PU prevention and management at the RMH. RMS refers to a systematic 
approach that integrates recognition of risk, risk assessment and activities to manage risk 
(Robillard 2001). RMS should be based on theoretical understanding of risk and risk 
management models as described earlier in Chapter Two. Clinical governance including 
RMS can be used as a broader framework in order to maintain and improve the quality of 
patient care within a health organisation. RMS aims to reduce not only PU risk but also 
other risks (risks to patients, practitioners, organisation) using organisational resources. The 
implications of applying RMS are: 
a) The appointment of risk manager responsible for implementation of 
RMS through: making sure that RMS process is applied effectively, 
ongoing consultation and communication with management board and 
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ensuring that RMS activities are integrated in decision making and 
clinical governance systems. The risk manager aims to incorporate the 
infrastructure of risk management activities, correlate RMS to be aligned 
with organisation's overall objectives, provide clear direction for senior 
management and get their financial support, and contribute in refining 
the existing risk management policies. Building staff capacities in risk 
assessment and management, establishing training plans and using risk 
assessment and management tools can be additional functions of risk 
manager. 
b) Risk culture environment. RMS cannot be applied in isolation. A 
cultural shift towards risk awareness is an essential element in order to 
implement RMS activities in RMH. A sustained commitment and 
proactive assessments of risk are required in order to manage risks 
created by rapid changes in health care. A cultural shift towards better 
awareness of risk through equity, transparency and openness is necessary 
in order to secure a higher quality of care for patients. 
c) Staff empowerment. Staff have to work together and with the risk 
managers to inspire a shared vision and objectives of a risk management 
strategy which creates a sense of organisational ownership. Furthermore, 
managers in RMH have to support staff by developing a reward system 
and encourage team work. The engagement of staff in these activities 
will encourage ownership and act as a powerful driver for change. 
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The implementation of a PU prevention programme in RMH can be part 
of RMS. Although the programme resulted in a reduction of the PU 
incidence rate, it needs to be in alignment with vision and objectives of 
RMS in order to maximise its potential effectiveness. For example, the 
PU prevention programme should have a broad scope of PU risk 
management including patients in the community and home health care 
together with those patients in RMH as an acute health care institution. 
Furthermore, the components of the programme have to be refined in the 
light of updated research evidence to inform effective prevention which 
implies, at the end, an effective outcome from using RMS. 
6.2.3 Recommendations for future research 
The study of PU risk assessment is a challenging and controversial area of research because 
of the multifactorial nature of PU problems and the difficulty of collecting valid and 
reliable data about PUs. Further research is needed to explore entire variables which 
interact to cause the problem. PU risk assessment is essential for prevention; this makes it 
necessary to conduct more studies in this field in order to explore its role in PU prevention 
and its impact on patients' outcomes through cumulative research evidence that will in turn 
lead to generalised findings and improvements in practice. However, more studies are 
needed on this topic that take into account the present study's limitations. 
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The following areas of research will add more to the evidence base, which in turn may 
result in the improvement of PU risk prevention and management practices and the 
reduction of patients' suffering: 
1) Developing RASs for better risk assessment of PUs 
Numerous RASs have been developed and evaluated, with no clear conclusion on 
their effectiveness and their protective effects in reducing PUs occurrence. These 
studies have used different designs, populations and outcome measures. 
Furthermore, the absence of national and global consensus on PU definition, 
classification, and threshold scores of RASs make it difficult to draw conclusive 
evidences in relation to effects of using RASs in health care. Although these studies 
have suggested a variety of refinements and modifications of existing RASs 
(Anthony et al. 2003, Halfens et al. 2000, Gunningberg et al. 2001b and Tannen et 
al. 2004), they demonstrate limited clinical effects on patient's outcomes 
(Gunningberg et al. 1999). Less is known about reasons for these limitations and 
scope of improvement (Papanikolaou et al. 2007) in dynamic and rapidly changing 
health care organisations. Thus, there is a need to develop robust RASs in order to 
facilitate and aid PU prevention and management. 
Risk assessment models (Chapter two, Section 2.8) should be used as a framework 
in the development of RASs as it will allow the problem to be contextualised. It is 
also important to understanding how risk factors, which are the fundamental units of 
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RASs, reflect the real state of the patient in relation to risk of PU development. It is 
crucial and timely for further research to be conducted in developing RAS which 
will enhance greater sensitivity and be more effective at reducing PU. 
The current research findings, valid research evidence, modern knowledge in PUs 
and known models of the PU development process such as Defloor's model (1999) 
can be used together to develop new RASs. All of these provide essentially needed 
risk factors associated with PU development which are the core structure of RASs. 
Several restraints may limit researching the development of RASs such as the 
absence of consensus on PU classification. A more comprehensive model for 
researching PU RASs would be to base them on real physiological changes that are 
fundamental in physiology of PU development process. This ensures better 
understanding of changes reflecting the real state of the patient in relation to PU 
development. For example, Vanderwee et al (2007) have selected such an approach 
to examine whether the use of non blanching erythema can be used as an indicator 
to start preventative care resulting in better outcomes in terms of PU occurrence 
rather than conventional use of RASs. It also supports the clinical value of using 
RASs beyond a paper exercise in assessing patients at risk of PU development. 
A suggested approach in developing RASs is to structure PU assessment in two 
phases, as described in (Section 6.2.1), which may facilitate the application of RASs 
in clinical practice. 
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A continuous, ongoing researching of RASs is suggested to provide evidence in 
relation to effective use of newly developed RASs which can be used to sustain 
improvement of the clinical value of using RASs in health care and to meet the 
needs of policy changes associated with risk and risk management. 
2) Improvement of nurses' CJs 
A limited number of studies have been conducted to study the role of nurses' 
knowledge and experiences (CJs) in relation to decisions made to prevent and 
manage PUs such as Gould et al. (2004). Future research is required to study this 
complex area of decision making in relation to PU prevention. For example, to 
explore what factors nurses use when making CJs in PU risk assessment and what is 
the role of nurses' experience in the CJ process. 
Several constraints may arise when researching CJ as practitioners will have to be 
more explicit and be able to articulate how they are making decisions. Additionally, 
there is no definite framework that explains the process of human judgment itself 
and/ or explains the role of knowledge and experience in clinical decision making. 
6.3 Conclusions 
After fifty years of using more than forty RASs in clinical settings, the clinical evidence on 
the effects of RASs on patients' outcomes is scanty. The current study contributes to the 
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body of nursing knowledge in PU prevention and management and adds additional 
evidence about the use of RASs. The study achieves its main objectives in examining the 
impact of using RASs (The Braden scale) on patient outcomes in terms of PU incidence. 
The outcomes of the study are important and have implications for practitioners, 
administrators and researchers. The study results in the following valuable conclusions: 
It confirms that there is no significant clinical impact for using RASs (The Braden scale) on 
patients' outcomes in terms of PU incidence reduction. The findings suggest the clinical 
effectiveness of the comprehensive PU prevention programme implemented in the RMH to 
reduce the PU incidence rate. The components of the prevention programme, including the 
use of RASs (The Braden scale), preventive measures and PU training and education 
programmes should be considered consistently and collectively. 
Although the study concludes that there is no significant difference between using RASs 
(The Braden scale) and nurses' CJ on the patients' outcomes in terms of PU incidence 
reduction, the study supports the use of RASs to aid and facilitate nurses' CJ in order to 
produce better PU prevention outcomes as currently recommended by EPUAP (1998) and 
AHCPR (1992). 
The PU training programme had limited effect in reducing PU. Therefore a continuing 
professional development programme should be implemented to ensure staff having the 
necessary up to date knowledge on the management of patients at risk of developing PUs. 
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To sum up, the present study provides an opportunity to examine the clinical effectiveness 
of RASs (The Braden scale). It supports the conceptual framework which was suggested in 
Chapter One and adds strength to the claim that clinical effects for using training, RASs, 
and CJ should be used equally to improve patients' outcomes in terms of PU incidence rate. 
It also emphasised some potential applications of RASs as discussed throughout the 
literature. The study suggests new venues for future research to decide the improvement of 
RASs and nurses' CJ until new clinically effective risk assessment system has been created. 
All of these can be employed as input in a broader context involving better understanding 
of risks and risk management in relation to decisions made to improve PU prevention and 
management. The study goes beyond the scope of PU risk assessment and management to 
suggest implications applicable to improve practice, research and management of other 
risks in health care. 
6.4 Summary 
This chapter discussed the study limitations that were encountered during the course of the 
study. The methodology, sampling and data collection process were critically analysed. 
This chapter also suggested recommendations for further research, implications for 
practitioners and policy changes for administrators. These recommendations are based on a 
broader understanding to the concepts of risk and risk management in health which 
incorporates more PU prevention in identifying those patients at risk of PU development, 
and in turn reduces patients' suffering and complications resulting from newly developed 
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PUs. The study concludes by recommending the use of risk management strategy in RMH 
to satisfy the clinical effectiveness of using RASs (The Braden scale) on patient outcomes 
in terms of PU incidence reduction and implementing the comprehensive PU prevention 
programme 
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Different forms used in RMH for wound assessment and 
wound management including PU assessment forms 
Form 1 
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rat ent's Name 
SAMPLE 
WOUND ASSESSMENT SHOULD BE 
CARRIED OUT WEEKLY 
Number PLEASE TAKE A WOUND SWAB 
FOR C&S AT FIRST VISIT. 
ASSESS Week t Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 














Odour Yes / No yl '1 N ^f 











Swab Taken Yes / No `i 1lJ f'J (j 
Healing Yes / No N tj 
Doctor Informed Yes / No y td rJ 
Needs Referral Yes / No JJ (J 
Nurses Signature 44. 1 (44 
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(Yellow / Green) 
Odour Yes / No 










. olour Blue 
Swab Taken Yes / No 
sealing Yes / No 
)octor Informed Yes / No 





MSD Wound ASSESSMENTS Chart 
Dirsctlons. PATIENTS NAME: 
I Complete the Wound Assessment Chart MIR No. 
2 Document the findings in the NURSES 'Progress Netes AGE / SEX: 
3 In tote en appropnate plan of care ROOM No 
ASSESSMENT DATE: 
" PATIENT INFORMATION: 
Primary Diagnosis. 
Past and Present Medical History: 
Medications: 
" ANATOMIC LOCATION OF WOUND 
Site: 
Dab of Onset: II 
Wound etiology: 
Ilj 
Q Surgical Q Arterial Q Venous 
Q Pressure ulcer pt 
Q Diabetic or Neurotrophic ulcer 0 Other 
APE OF WOUND 
'7 Acute: Post op <7 days Q Acute: post op' 7 days 
D Chronic: c1 month 
O Chronic: >1 month days i months 




SHAPE: Q Oval Q Round Q Irregular Q Other 
ITAOL' bbpa of prw ura ulcer ("PU) 
Q1Q II Q 111 Q IV Q Unable to stage; ulcer necrotic 
Wagner ulcer grade for neurotrophic ulcers ('NU) 
Q0Q1Q2Q3Q4Q5 
Classification of venous disease ('VD) 
Q0 Q1 Q2 Q3 Q4 Qs i, s 
Cla. lfleatlon of skin tears (BTI 
Q0Q1Q2Q3 
SIU3TRACT. TUNNELING, UNDERMINING, FISTULAS 
Q None Q Present: located 
at o'clock, cm depth 
Q UOATE 
Amount: Q None Q Scant Q Moderate Q Large 
Color: Q Serous Q Serosanguineous Q Sanguineous 
Consistency: Q Thick Q Purulent Q Milky 
6"8 
[I System, - Local Q Both Q None Q Odor present 
WURROUNDING SKIN 
[3 Intact Q Erythomalous Q Edematous 0 Induration 
Q Warm Q Cool Q Discolored C Dry , Other 
MACERATION 
r] Not present 
(] Present cm, location. 
isiatniý 
QT rrie the affected oreo 
O Edge attached Q Edge not attached Q Edges rolled 
O Surgical incision approximated Q Surgical incision open 
Q Sutured staples Intact O EpiW6alizatlon not present 
Q Epithellalization present: cm 
NECROTIC TISSUE Q Not Present O Present 
Type. 
Q Yellow slough Q Black O Soft Q Hard Q Stringy 
Percentage of wound (check closest percentage): 
Q 100% of wound Q 75% of wound Q 50% of wound 
Q 25% of wound O Other: _% 
TISSUE BED 
O Moist Q Dry Q Granulation tissue not present 
Q Granulation tissue present amount 7. 
Tenderness or pain 10 being no pain, 10 being intense pain t 
PAIN SCALE 11CORE-TCorcle appropnefe number) 
0123456789 10 
Pam present: 
Q On touch Q Anytime Q Only when performing wound care 
Q Other (specify) 
Pain management: Specify method 
Q Not effective Q Effective 
STATUS 
Wound status: Initial assessment date /I 
Q Improved: date Q Unchanged: date 
Q Healing: date Q Deteriorating: data __ 
Q Supportive therapy Q Compression Q Off-loading 









NURSING MIR No 
Age'Sex 
DECUBITUS ULCER REPORT 
Room No.: 
STAC 1: 
INFLrtMATION OR REDNESS OF 
THE J(IN. 
STAG 11 : 
SUPRFICIAL SKIN BREAK WITH 
RED=SS OF SURROUNDING AREA 
STAE III : 
SKIPaREAK WITH DEEP TISSUE 
INYNEMENT 
v : STAE t 
SKIN3REAK WITH DEEP TISSUE 



























Site Stage Size(cm) Drainage 
III 
Odour Treatment Progress Sign. 
ýý 
/ý I I 








DEPT. - WARD CODE DATE PATIENT 
NUMBER 
CONSULTANT NAME NUMBER 
FIT 
, TYPE If CONDITION OF WOUND (J) AS APPROPRIATE INSTRUCTION 
SURGICAL 
OPERATION 
CLEAN REMOVAL OF SuTUREstcups DATE OF REMOVAL 
/ 
TYPE OF SUTUR/CLIPS 
ABSCESS INFECTED 
TYPE OF 
TRAUMA NECROTIC DRESSING 








NEXT APPT. WITH REFERRING DOCTOR: 
DATE: // 
OTHER PROCEDURES: REFERRING DOCTOR NAME NUMBER 
SIGNATURE: 


























Nursing data base form in RMH including the Norton Scale 
for PU risk assessment 








IDENTITY BAND ISSUED () YES () NO 
TYPE OF ADMISSION: 
NEXT OF KIN NAME: 
TEL NO. 
MEDICATION BROUGHT TO HOSPITAL 
() NONE () YES () SENT HOME 
VALUABLES BROUGHT TO HOSPITAL 
NONE DECLARED () YES () DISCLAIMER 
() HOME ()L BOX () SECURITY 
MEDICAL HISTORY 
PrASnN tna anu: CCinwi 
DIAGNOSIS: 
DATE & TYPE OF OPERATION: 
PREVIOUS OPERATION: 
PATIENTS KNOWLEDGE OF CONDITION 
E. G. DIABETES. HYPERTENSION 
KNOWN ALLERGIES (INCLUDING DRUGS) 
ACTIVITIES OF DAILY LIVING 
NUTRITION (APPETITE & KNOWN DIETARY PROBLEMS) 
DIET 
ELIMINATION (KNOWN PROBLEMS) BLADDER: BOWEL: 
SLEEP (KNOWN PROBLEMS) 
MOBILITY (KNOWN PROBLEMS) 
EYESIGHT: () NO DIFFICULTY. EXPLAIN LIMITATION: 
() SPECTACLES () CONTACT LENS () PROSTHESIS 
HEARING: () NO DIFFICULTY. EXPLAIN LIMITATION: () HEARING AID 
SPEECH: () IMPEDIMENT () DYSPHASIA 
OBSERVATIONS: 
( ) COUGH ( ) ALERT 
( ) CYANOSIS ( ) CONFUSED 
( ) DVSPNOEA ( ) UNRESPONSIVE 
236 
EMOTIONAL STATE: () ANXIOUS () UNCOMMUNICATIVE 
( )EXCITED () APATHETIC 
CONDITION OF MOUTH: () CLEAN/MOIST () DRY/CRUSTED () CARIES () DENTURES 




PRESSURE SORES RISK INDICATOR 
POINTS- 4"- 3 2 1 SCORE 
Emaciated 
GENERAL CONDITION: Well nourished Underweight Obese Dehydrated 
Oedematous 
MENTAL STATE: Alert Apathetic Confused Stuporous 
MOBILITY: Ambulant Walks with help Chairfast Bedfast 
INCONTINENCE: Not Occasionally Urinary Double 








(KEY: 1.14 - HIGH RISK 15-16-MOD. RISK. 17-18-MILD RISK. 19-20-MNI: RISK) TOTAL-f_ 
PRESSURE (SORE(S) PRESENT ON ADMISSION: LOCATION: DIMENSIONS: 
ABNORMALITIES ORTRAUMA: 
CONTUSION (LOCATION) RASH (LOCATION) 
ECZEMA (LOCATION) SCAR (LOCATION) 
LACERATION (LOCATION) ULCER (LOCATION) 
BURN (LOCATION) 
SOCIAL HISTORY 
PRIMARY LANGUAGE: () READ ENGLISH SPOKEN: () NIL,. (, ) BROKEN () FLUENT 
RESIDES WITH: 
TYPE OF HOME: () STAIRS () GROUND LEVEL 
FAMILY HEALTH: eg () DIABETES () ALLERGIES 
ORIENTATION OF PATIENT: () TO ROOM () CALL BELL () BATHROOM 
( )DAY ROOM ( )WARD ROUTINE 
ADMITTED BY; Signature 






Mandatory Wound Care Management study day (Syllabus) 
RIYADH AL-KHARJ HOSPITAL 
Nursing Academic Affairs 
INTRODUCTION TO WOUND CARE 
MANAGEMENT 
PREPARED BY: MOAHAMMAD Y. N. SALEH 
RN BSc, MSN, Post graduate PhD. student 
Wound Care Coordinator/RKH/Saudi Arabia 
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COURSE DESCRIPION: 
This course intended to provide the nurses with knowledge and skills about 
guidelines for consistent and evident based wound management practice. In 
the fact that this course will be adherent to variant aspects of wound 
management starting to explain normal wound healing process, then 
explaining the factors affecting negatively and delay normal healing, also this 
course describing the different strategies of wound management stress on the 
Importance of wound assessment in deciding modern dressing would be cost 
effectively used and indicate the concepts of preparing wound environment, 
cleansing and irrigation and the intrusion of high technology to this field of 
practice. 
COURSE OBJECTIVES: 
Upon completion of this course the participants will be able to: 
1. Describe anatomy and physiology of the skin. 
2. Analyze the normal healing process. 
3. Define the factors delay normal healing process. 
4. Assess the wound according to wound assessment process. 
5. Describe complications adherent to wound healing process. 
6. Access appropriate modern wound dressings. 
7. Indicate appropriate use of wound cleansing solutions. 
8. Describe proper environment to allow effective wound healing . 9. Provide effective wound care according to general principles of wound 
management 
10. Manage effectively acute and chronic wounds according to wound care 
guidelines. 
TEACHING METHODS AND LEARNING STRATEGIES: 
1. Lecture discussion 
2. Group work 
3. Computer assisted instruction. 
LEARNING MATERIAL: 
1. White board 
2. Overhead projector 
3. Desktop presentation 
4. Laptop/computer assisted device 
5. Sample modern dressings 
6. Handout and pre learning material 
7. Postures and brochures 
240 
EVALUATION METHODS: 
1. Written exam (passing mark is 70% in post test). 
2. Course evaluation questionnaire. 
COURSE TIME TABLE : 
TOPIC TIME 
Introduction 9.00am - 9.1 Sam 
Anatomy and Physiology of the skin 9.15am - 9.30am 
Physiology of normal wound healing 9.30am -10.00am 
Factors affecting normal healing 
process 
10.00am - 10.1 5am 
Wound assessment process 10.15am -11.00am 
General principles of wound care 11.00am - 11.30amam 
BREAK 11.30am -11.50am 
Effective wound environment 11.50am -12.05 m 
Wound cleansing & Irrigation 12.05 pm -12.20 m 
Guidelines for acute& chronic wound 
management 
12.20pm - 12.45pm 
Evaluation & Feed back 12.45 pm - 13.00m 
241 
COURSE OUT LINE 
Title Paz e 
Review anatomy and physiology of the skin 2 
3 
Function of the skin 
4 
What is the wound 
5 
Wound healing process 
7 








The management of chronic wounds 
21 
The management of leg ulcers 
24 
The management of fun atin wounds 
25 
The management of Patients with acute wounds 
28 





Pressure Ulcer Prevention and Management Training 
Programme (Syllabus) 
RIYADH MILITARY HOSPITAL 
Nursing Academic Affairs 
PRESSURE ULCERS 
PREVENTION & MANAGEMENT 
PREPARED BY: MOAHAMMAD Y. N. SALEH RNBSc, MSN 




This course intended to provide the nurses with knowledge and skills about 
Pressure Ulcers utilizing consistent and evident based wound care 
management practice. This course will be adherent to variant aspects of 
Pressure Ulcers prevention and management through active definition of 
Pressure Ulcers , describing physiological and epidemiological perspectives 
of Pressure Ulcers , analyzing chronic wound healing in Pressure Ulcers and factors delayed it , enabling nurses to develop appropriate assessment 
process in which they will be able to develop prevention and management 
action plans utilizing wound care management principles and guidelines. 
COURSE OBJECTIVES: 
Upon completion of this course the participants will be able to: 
11. Describe anatomy and physiology of the skin. 
12. Define Pressure Ulcers. 
13. Describe Physiology of Pressure Ulcers development. 
14. Describe epidemiological perspective of Pressure Ulcers. 
15. Analyze chronic wound healing process in Pressure Ulcers. 
16. Define the factors delay healing in Pressure Ulcers. 
17. Assess Pressure Ulcers according to wound assessment process. 
18. Develop Pressure Ulcers prevention Plan utilizing risk assessment tools. 
19. Manage Pressure Ulcer wounds effectively according to wound care 
guidelines. 
TEACHING METHODS AND LEARNING STRATEGIES: 
4. Lecture discussion 
5. Group work 
6. Computer assisted instruction. 
LEARNING MATERIAL: 
8. White board 
9. Overhead projector 
10. Desktop presentation 
11. Laptop/computer assisted device 
12. Sample modern dressings 
13. Handout and pre learning material 
14. Postures and brochures 
EVALUATION METHODS: 
3. Written exam (passing mark is 70% in post test). 
4. Course evaluation questionnaire. 
244 
COURSE TIME TABLE : 
TOPIC TIME 
kiatomy and Physiology of the skin 0800-0900 
Epidemiological perspective of Pressure 
Ulcers 
0900-1000 
Coffee Break 1000-1030 
Chronic Wound Healing in Pressure Ulcers 1030-1130 
lunch 1130-1230 
Pressure Ulcers Assessment Process 1230-1330 
Pressure Ulcers Prevention Guidelines 1330-1430 
Coffee Break 1430-1445 
Pressure Ulcer Wounds Management 
Guidelines 
1445-1545 
Evaluation & Feed back 1545-1630 
245 
Cnl1RSP [)l1Tl INF 
Title Page 
Introduction 1 
Anatomy and Physiology of the skin 2 
Definition of Pressure Ulcers 4 
Physiology of Pressure Ulcers development 5 
Epidemiological perspective of Pressure Ulcers 7 
Chronic Wound Healing in Pressure Ulcers 11 
Factors Delay Healing in Pressure Ulcers 17 
Pressure Ulcers Assessment Process 25 
Pressure Ulcers Prevention Guidelines 42 






Beds Allocation in RMH 
BUILDING I11 BUILD NG ºO: 1 
Ward Beds F. cds 
IC. U 6ICU closed 24-ý-tbt'ý; hi_aryý 
IR 1 King's Suite_ 3A 29 Antenatal (Obstetric) 
2#1 3 Royal Suites 4A 'CC'PoMnatal (obstetn'cc) 
2N 17 Short Stay 43 2ti i-l. I. C. U. 
(all specialties) ý4C 27 N. C. I. I. P. 
9 (closed) 5A 32 Postnatal Obstetric 
3N 15 Oncology 59 26 Cynaeeotogy 
10 Short Stay GA 32 Nenhrology 
all specialties 68 26 Rehabilitation 
Slums unit 10 Bums 7A 5 Obstetric & Gynaecol 
(Plastic Surgery) S All Specialties 
4N 28 Surgery 7ß 7 Obstetrics & Gynaeco 
(all specialties) 
_ 
SN 2 Gastroenterology TOTAL[ 263 
3 Oncology 
6 Medical E3EDS NOT INCLUDED 
5 Neurology IN THE ABOVE 
12 Surgery r1u 70 Cots 
(all specialties) 3B 6 Delivery Suites 
6N 23 All Specialties 3 H. U. U. for Obstetrics 
7N 23 All Specialties 





Ind floor 14 Isolation 
TOTAL 14 
_E 
ZUILOING . CO 
Ward _ Gels 
1.1 10 Op hthalmo! ogy 
5 Neurology 
15 Ncurosumr-" 
1.2 14-General Surgery 
3 Vascular Surgery 
_ 
2 Plastic Surgery 
1 Dental 
4 V. I. P. 
1-3 13 E. N. T. 
y 5 General Surgery 
4 Single 
Y 1-4 14 General Surgery 
7 E. N. T. 
t Vascular Surgery 
8 Orthopaedics 
1-5 11G Haematology 
2-1 32 Orthopaedic 
1 Dental 
2 Nephrotogy 
2 V. I. P. 




2-4 23 hicaical 
7 Gastroenicrolo 
3.1 8 (Closed) 
8 High Dependency 
2 Isolation in I. C. U. 
8IC. U. 
3-2 22 Medical 
2 Dental 
2 V. I. P. 
5 Gastroenrerol3ay 
I Plastic S:, roery 
. ý_ u 3-3 W^ 'aediaincs 16 f 
+ 3_4ý-- 1 _ _ 30 (flus^3i ý_ 
4.1 15 Naedýatnc I. C. U. 
4 Paediatric Chronic 
3 Paediatric Oncology 
P a_dianc Isolation 
4-2 31 F'accýains 
I Burris 
5 Day Cases 
4-3 4 Single 
6 Chronic Diseases 
i Security 
v Liver Transplant 
15 Liver T(ansalant 
_ TOTAL. 416 
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APPENDIX G 
Waterlow and Norton Scales for PU Risk Assessment 
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The Study Instrument 
A) The Braden Scale for PU Risk Assessment 
BRADEN SCALE-For Predicting Pressure Sore Risk 
SEVERE RISK T .a 0'. ne 9 HIGH RISK -ota! s: ore 10- 17 MODERATE RISK ,... MILD RISK `", t, 
"" SCOREMESCRIPTION M M 2 1 1 " 
SENSORY 1 COMPLETELY LIMITED- 2 VERY LIMITED 3 SLIGHTLY LIMITED- 4. NO IMPAIRMENT 
I 1 PERCEPTION u kci, ". F Y. "1vß r. I rnioa ý! v . -: or " h. ý" r 'a F l. s_u. .' er. vp' : r, a' A"S . Irlflun ele qu- ce .. i". ' "I"M press d nisnid leve of moaning or restlessness, comfort or need to be woulo 1 ni" en , t, I 
d, sco-, fen consnausnessa M turned, O'voiceooo nr sedat'o-r has a Sensory impalrrfMI on dýscomlr, ri 
a wEsEn limes the AllM to has some Sensory 
Lmde1 alollty In feel pan feel pain or discomfort , mpamrwnt which limits 
w' m051 of hpds su°ac0 we, of crodj 3h'6N to feel pain if dww- 
comlcn 1n 1 o" 2 
er're'ný: ws 
MOISTURE 1. CONSTANTLY MOIST- 2. OFTEN MOKT-Sk^. 0 3. RCCAEE0NAU. Y MOIST- 4. RARELY MOIST-'-- 
Degree 10 . vn, Cn 
Si "Sa mgs1 on" but not always m0-5' SMir 6 OCCas oa! 1511311 111, r ncn " 
Skm is 0-powd tL to rahnn 
Linen mus to. drangen a' m'NSt 'Ito l] w- i PC -'acp nu t 
to neu st, ýre 
ýa' p ess rs lea5' once a whirl I nen Cnanpe app- oL rr 1-t 
11 P 'rj nme 11 7l once a 1a'ß 
"c moDM o' 
Ire.. 
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B) PU Wound Assessment and Wound Management 
Checklist 
1) Pressure Ulcer Wound Assessment 
General characteristics of the patients 
1. Hospital File Number ....................... 2. Ward ............... Room Number.......... 3. Date of admission ........................... 4. Gender: A. Male B. Female 
5. Age: 
A. 5 20 Years B. 21-30 Years C. 31-40 Years D. 41-50 
Years 
E. 51-60 Years F. 61-70 Years G. 71-80 Years H. 80+ 
Years 
6. Diagnosis: 
A. Medical B. Surgical C. Oncology D. Renal 
E. Neuro-surgery F. Rehabilitation G. Vascular 
H. Others/ specify......... 
7. Norton scoring: 
A. 5-14 B. 15-16 C. 17-18 D. 19-20 
E. Not recorded 
Assessment 
tages PU stages guide according to AHCPR 
(1992) 
'Ound location 
t'd size Length x Width /cm. 
Ad Present /Specify in cm....... 
xMining Not present 
Ad Not visible 
'Dais Non adherent yellow slough 
Loosely adherent yellow slough 
Adherent soft black eschar 






colored Beefy Bright red 




ýd Pinky whitish 
elializtion Pale & dull 
Macerated, fragile and dry 
lo 
No E ithelializtion 
ft Ad Scar Completely healed wound with scar 
Scab formation 
H ertro hic scar formation 
No scar 








end Swab culture result....... 
on Fever 
Cellulites/inflammation at the wound 
site 
Wound induration and reddened 
edges 
Other manifestations of wound 
infection 
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2) PU wound management 
M- 
a ement Item Management category Date 





f. Medicated dressings 
g. VAC 
h. Others (specify) 






e. Others (specify) 
ective 1. Protective mattresses 
sures a. Standard bed 
mattress 
b. Alternating system 
c. Therakair 
d. Genadyne 
e. Atmosair system 
f. Gel overlay 
g. Clinitron bed 
h. Water mattress 
i. Others (specify) 
2. Patient turning 
o Eve 2 hours 
o Every 3-4 hours 
o Every 6 hours 
3. Skin barrier creams 
4. Vitamins and special 
nutritional formulas 
254 
3) Other observations: 
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C) C. Nurses' Clinical Judgement Rating Scale 
Nurses' Clinical judgment of patients at risk of Pressure Ulcer 
Development 
Dear colleague, 
This rating is part of a PhD research study. It is intended to investigate the effects of 
using Risk Assessment Scales of Pressure Ulcer on patient outcomes in terms of 
pressure ulcer incidence rate among hospitalised patients at RMH-Saudi Arabia. 
You are kindly pleased to rate your assigned patient carefully according to your 
experience with patients at risk of pressure ulcer development. Your rating shall 
include one of the categories below. Once you completed the rating, please hand it 
to wound care coordinator or one of the wound care practitioners. 
Completion of this rating is voluntary and given information will be kept confidential 
for research purposes. Your name is not requested and your participation will not 
affect your current professional status. 
If you have any further queries, please feel free to contact wound care coordinator 
on Bleep 0140 or Tel. extension 1599. 
Many Thanks for your unlimited cooperation 
Mohammad YN Saleh 
Wound Care Coordinator/RMH 
PhD Candidate 
" According to your experience with patients at risk of pressure ulcer 
development, please rate your assigned patient at one of the risk 
categories mentioned below (Please tick as appropriate) 
No risk Minimal risk Moderate risk High risk Severe risk 
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APPENDIX J 
Braden Scale for PU Risk Assessment 
BRADEN SCALE-For Predicting Pressure Sore Risk 
SEV ERE RISK Tu"; 1 St ilrO -4 HIGH RISK T, , ', i acorn' '0 17 
MODER ATE RISK 14 MILD RISK Tntaý '. r o, e 10 -1H 
SENSORY 1. COMPLETELY LIMITED- 2. VERY LIMITED- 3. SLIGHTLY LIMITED- 4. NO IMPAIRMENT- 
PFRCEPTION _.... .;...., - ... .. - ... r:., ... r pýýndc t 
l. I.. Ir, ti[ý" ß. r1 ' .. 3 
nsean. ngtoIty to l atr ... =p1 b1 atr ors r l. o' , lr I 
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over most of cold, su'tarr over it pod; All to feel pair or ni< 
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estremmes 
- --- - MOI{TURE 1. CONSTANTLY MOIST- 2. OFTEN MOIST-Sbn 1s 3. OCCASIONAUY MOIST- 4. AMELY MOST-Skin '. 
Degree to which 
Skin is kept mors, almost often out not a'. Ha, a 'oo 51 Skin K ntcasronalt, usually dry linen only 
slunt K eaposod c0nstanllv my perspuatmn Linen muss tw '. 10400 at moist reiumng an il requires changing at 
to rnOgtuee unnn etDampness is least nn ra sn't linen change approximately routine intervals 
detected e, er, time once a day 
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'urnno 
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activity n0'enite^I Cannot bea" dar but for VPr, cM'1 at least twice a day and 
olU ýl v. '' a I',! '. 'I usl distances win P, , Shoat inside room at least nnc- 
. l'S C". "' ' i'I AI' IF a, S15tanCe 
Spe', 0i cunt 2 hours dUlioa ý 
ýr ... n maIwdy or oat' c'=R r v, ak, no hours 
'M, D' ; Mali 
MOBILITY 1. COMPUTELY IMMOBILE- 2. VERY UMFFED-H1aOes 3. SLIGHTLY UNITED- 4. NO LIMRATIONS- 
AI Irty to Change 
Does ) .. x, ýýOnal cllpm change, Maces frepuer' I toil 5 major and 1 "CdývI' 
and control body ctanq s 
ý 
n trod, 0' eruemit1 sbaht' es In ties bon 
portion vitrem 
t( ,. ".. p0sdln0 bunt unable to 
ý 
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Total parenrera. Til 'a III - and ur '0(0+115 Irss than optimum TPN' regimen which l 
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reposngn ng with maxi positron in chair or bed 
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APPENDIX K 
Letter from Authors of The Braden Scale for PU Risk 
Assessment 
Plus 
Home of the Braden Scale 
Date: November 23.2004 
To: Mohammed Salch. Wound Care Cixordinator 
From: Barbara Braden. PhD. RN. FAAN & Nancy Bergstrom, PhD. RN. FAAN 
RE: Permission to use the Braden Scale* 
As holders of the official copyright for the Braden Scale for Predicting Pressure Sore Risk, and 
the interventions, we hereby grant permission for the use of the scale in the Riyadh Military 
I lospital in Riyadh-Saudi Arabia and in your research as a risk assessment tool of pressure ulcers 
to assist in clinical decision making. 
Olt is understood that the name of the instrument and the indication that the copyright belongs to 
Braden and Bergstrom remain on any copies and that you do not make any changes to the 
wording or the scoring of this tool. 
ý__<.. _, 
ýý___ rý 







































Research Training Course for Research Team 
RKH 
Research Team Training 
Terminology 
Research: 
The systematic, logical and empirical inquiry into the possible relationship among 
particular phenomena to produce verifiable knowledge. 
Nursini Research: 
1. Provides the basis for expanding body of scientific knowledge. 
2. Emphasizes clinical issues, problems and outcomes. 
Qualitative Research: 
The investigation of phenomena typically in an in-depth and holistic fashion, through 
the collection of rich narrative materials using a flexible research design. 
Quantitative Research: 
The investigation of phenomena that lend themselves to precise measurement and 
quantification, often involving a rigorous and controlled design. 
Variables: 
A defined concept e. g. Length of stay 
Could be (independent) : variables that has the presumed effect on the dependent 
variable ( cause). 
Or (dependent ): = the effect. 
Example: the effect of cigarette smoking on incidence of lung cancer 
Incidence: 
The number of new cases occurring within a predetermined time span 
Prevalence: 
The number of cases at a given point of time. 
Continuum of Quantitative Research Desi n 
MO N- EXPERIMENTAL ------- 
UAZI- EXPERIMENTAL ---- 
EXPERIMENTA 
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1. Non- experimental studies : 
Used in studies in which the researcher wishes to : 
a. construct a picture of a phenomena 
b. explore events people or situations as they naturally occur. 
2. Experimental studies : (true experimental studies) 
a. manipulation: provision of some experimental treatment in one or 
varying degrees to some of the subjects in the study 
b. randomization :a selection process which each element of the 
population has an equal and independent chance of being included 
in the sample. 
c. Control 
3. Quazi- experimental : 
A study design in which random assignment is not used but the 
independent variables are manipulated and certain 
mechanisms of control are used . 
SURVEYSTUDIES 
Definition: 
Is a type of non - experimental studies which aims to collect detailed descriptions 
of existing variables and use the data to justify and assess current conditions and 
practices or to make more plans for improving health care practices. 
Classification: 
1. Descriptive : 
To describe certain phenomena characteristics of particular subjects 
, frequency of occurrence 2. Exploratory: 
To explore issue perceptions regarding clinical practices. 
3. Comparative : 
To determine differences between variables. 
IN SUR VEY, investigators attempt only to relate one variable to another, or 
assess differences between variables, but they DO NOT attempt to 
determine causation. 
Survey studies advantages : 
1. Great deal of information can be obtained from a large population in a 
fairly economical manner. 
2. Survey research information can be surprisingly accurate 
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3. A relatively small number of subjects can provide an accurate picture of 
the population. 
Disadvantages : 
1. Obtained data tends to be superficial. 
2. The breadth rather than the depth of the information is emphasized 
3. The survey investigator must know sampling technique questionnaire construction 
interviewing and data analysis to produce reliable and valid study. 
4. Large -scale survey can be time consuming and costly. 
HINT: 
RESEARCH CONSUMERS SHOULD RECOGNIZE THAT A WELL- 
CONSTRUCTED SURVEY CAN PROVIDE A WEALTH OF DATA ABOUT 
PARTICULAR PHENOMENA OF INTEREST, EVEN THOUGH CAUSATION 
IS NOT BEING EXAMINED. 
Samplinj Desiin: 
1. Probability sampling: 
Simple random, stratified random, cluster, systematic 
2. Non - probability : 
Convenient, quota, purposive 
Purposive sampling desiin: 
A non probability sampling strategy in which the researcher selects subjects who 
are 
considered to be typical of the population. 
" Disadvantages : 
low generalisability and bias 
Tool Construction: 
A SELF - REPORT INSTRUMENT (STRUCTURED SELF - 
ADMINISTERED QUESTIONNAIRE) INCLUDE : 
Open &Closed ended questions 
" Advantajies : 
- cost effective in comparison to interview 
- anonymity 
" Disadvantages: 





response set bias 
CAN BE EASLY OVERCOME BYEFFECTIVE RESEARCH 
COMMUNICATION 
SESSIONS. 
TRY TO A VOID BIAS. - 
- judgmental errors 
- conscious bias 
- extreme bias 
References 
1. Wood G. and Haber J. Nursing Research: methods, critical appraisal, and 
utilisation. 2002.5`h. edition. Mosby 




Ethical Approval from RMH Research and Ethics 
Committee 
- jI L. 1 . Li - 
MINISTRY OF DEFENCE AND AVIATION LUaII sjl. ýj 
MEDICAL SERVICES DEPARTMENT 
RIYADH AL KHARJ HOSPITAL PROGRAMME 
RIYADH ARMED FORCES HOSPITAL 
P. O. Box 7897 
Riyadh 11159 
Kingdom of Saudi Arabia 
Tel 4777714 
Telex 401645 RKHPA Si 
tVVVV"t J, ý1. 
R. K. H 
RESEARCH & ETHICAL COMMITTEE 
09 November 2004 
Mr Mohammad Yousuf Nassar Salch 
Coordinator 
Nursing Wound Caro Service 
Re Tlx;. Innaa uL i15lL s _, 9., 
dsscyNmcnt- pcrformwii; t? -v)L wound management 
practices 
anioi>kýts_r iv care units q4ticrits 
Dear Mr Salch 
As acting chairman of the Research K Ethical Committee. I am pleased to inform you that I 
approved this research proposal with the some proviso (sea attached) 
Your research protocol has nosy been documented under 
Project No 242 
Sens of 2004 
Kindh quote the project number indicated herein in all transactions and communications You arc 
advised to submit a report in relation to this research scheme to update the committee of its 
progress 
I trust our research scheme proses fnutfiul and beneficial to the RKI I Program 
Yours smccrcls 
4 EMGRIT S SOR DAVID A PRICE IiVANS, MD DSc PhD FRCP 
Acting Chairman Rcscarch and Ethical ('omm«tec 
First Fluor, Building 136 
Cc Mr Da% Id Purvis. A/Dircctur cd Nursing 
hic 
AD 108 2 Sb k No 779148, U. f. D. Pr -g Vm. 
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APPENDIX 0 
Ethical Approval from Faculty of Health and Life 
Sciences Research Ethics Committee in De Montfort 
University 
Mr Mohammad Saleh 
Wound CareCoordinator 
Nursing Wound Care Service 
Riydah Military Hospital 
17 Feburary 2005 
Dear Mr Saleh 
Re: The Impact of Nurses Wound Assessment Performance OnWound Management 
Practices. 
I am pleased to inform you, that following consideration by the Faculty of Health and 
Life Sciences Research Ethics Committee, both the above project have been granted 
ethical approval. 
Yours incerely, 
Professor Paul Whiting 
Chair of the Faculty of Health and Life Sciences Research Et ics Committee 
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APPENDIX P 
Letter from Head Nurse of Medical Surgical Ward for 






RIYADH AL KHARJ HOSPITAL PROGRAMME 
INTERNAL MEMORANDUM 
Date 16" December 2006 
To Mr. Mohd YN Salleh, Wound Care Coordinator 
From Moon Phane. Head Nurse 4N. 5N. CDU. 
RE: RESEARCH STUDY 
- 
JI 
Further to the verbal discussion about piloting your research instrument on the Braden Scale for 
Pressure Ulcers Risk Assessment and its role in the prevention and treatment, one patient from 
4N Surgery will be identified for this study. This matter has been discussed with the staff and 
they are interested to assist you in the application of the tool. Please liaise with the Charge Nurse 




B-1404, Ext. 1443 
266 
APPENDIX Q Tables of Summary Study Findings 
Table 1 Frequencies and percentages of the main general 
charactpricfirc of fha nnfit nfc invnlvPd in the study 
Characteristics Frequency Percentage 
Group A 225 31.3 
B 228 31.7 
C 266 37.0 
Type Pretest 265 36.9 
Posttest 256 35.6 
Excluded 198 27.5 
Gender Male 464 64.5 
Female 255 35.5 
Age group Less than 30 years 119 17.0 
31-40 36 5.0 
41-60 139 19.0 
61-70 149 20.7 
71-80 163 22.7 
80+ 59 8.2 
Diagnosis Medical 289 40.2 
Surgical 155 21.6 
Oncology 72 10.0 
Renal 38 5.3 
Neuro-surgical 29 4.0 
Rehabilitation 52 7.2 
Vascular 2 0.3 
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Table 2 Frequencies and percentages of the main general 
characteristics of the patients involved in the study by groups 
Characteristics Frequency Percentage 
GA GB GC GA GB GC 
Type Pretest 79 91 95 29.8 34.3 35.8 
Posttest 74 76 106 28.9 29.7 41.4 
Excluded 72 61 65 36.4 30.8 32.0 
Gender Male 208 166 90 92.4 72.8 33.8 
Female 17 62 176 7.6 27.2 66.2 
Age group Less than 20 17 16 4 7.6 7 1.5 
21-30 16 59 7 7.1 25.9 2.6 
31-40 6 19 11 2.7 8.3 4.1 
41-50 9 26 36 4 11.4 13.5 
51-60 20 19 29 8.4 8.3 10.9 
61-70 44 42 63 19.6 18.4 23.7 
71-80 64 26 73 28.4 11.4 27.4 
80+ 22 9 28 9.8 3.9 10.5 
Diagnosis Medical 103 41 145 45.8 18 54.5 
Surgical 67 67 21 29.8 29.4 7.9 
Oncology 7 14 51 3.1 6.1 19.2 
Renal 2 33 3 0.9 14.5 1.1 
Neuro-surgical 6 14 9 2.7 6.1 3.4 
Rehabilitation 3 49 0 1.3 21.5 0.0 
Vascular 0 0 2 0 0 0.8 
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Table 3 Frequencies and percentages of selected patients' 
r_harartprictics by the natients' tvoe 
Characteristics Frequencies Percentages 
Pretest Posttest Excluded Pretest Posttest excluded 
ender Male 177 165 122 38.1 35.5 26.2 
Female 88 91 76 34.5 35.6 29.8 
Age Less than 30 42 52 25 35.2 43.6 21.0 
coup 30-50 39 45 23 36.4 42 21.4 
51-60 28 24 16 41 35.2 23.5 
60+ 128 122 121 34.5 32.8 32.6 
gnosis Medical 113 98 78 34.1 33.9 26.9 
Surgical 58 62 35 37.4 40 22.5 
Oncology 30 19 23 41.6 26.3 31.9 
Renal 12 7 19 31.5 18.4 50.0 
Neuro- 
surgical 
16 10 3 55.1 34.9 10.3 
Rehabilitation 19 15 18 36.5 28.8 34.6 
Vascular 1 0 1 50 0 50.0 
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Table 4 Frequencies and percentages of selected attributes in relation 
to PU incidence (NCPIJI 




Group A 55 24.4 
B 54 23.4 
C 56 21.1 
Type Pretest 83 31.0 
Posttest 49 19.0 
Excluded 33 17.0 
PU Location Sacral 83 50.3 
Trochanter 20 12.1 
Heels 21 12.7 
Ischium 8 4.8 
Buttocks 13 7.9 
Occipital 1 0.6 
Ankle joint 4 2.4 
Toes 8 4.8 
Ears 5 3 
Metatarsum 1 0.6 
Knees 1 0.6 
PU stage Stage one 78 47.2 
Stage two 60 36.3 
Stage three 16 9.6 
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Stage four 11 6.6 
Age group Less than 30 18 10.9 
30-50 years 17 10.3 
51-60 years 25 15.1 
61-70 27 16.3 
71-80 57 34.5 
80+ 13 7.8 
Gender Male 111 67.2 
Female 54 32.7 
Diagnosis Medical 82 49.6 
Surgical 32 19.3 
Neuro-surgical 13 6.0 
7 4.2 
Oncology 10 6.0 
Renal 5 3.0 
Braden scores Sever risk 10 6.0 
High risk 73 44.2 
Moderate risk 41 24.8 
Mild risk 41 24.8 
CJ scores Severe risk 4 2.4 
High risk 50 30.3 
Moderate risk 61 36.9 
Minimal risk 37 22.4 
At no risk 2 1.2 
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Table 6 Frequencies and percentages of using certain attributes related 
to protective measures 












Therakair 130 18.0 
Genadyne 26 3.6 
Atmosair 49 6.8 
Gel overlays 8 1.1 
skin barrier creams 302 42.0 
Vitamins & nutritional 
supplements 
275 38.2 
Patients' Every 2 hours 125 17.3 
turning Every 3-4 hours 541 75.2 
schedule Every 6 hours 30 0.4 
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Table 7 Frequencies and percentages of using certain attributes 
related to protective measures by group and type 
``. rrtes; GA GB GC Pretest Posttest Excluded 
Ltive Standard 29.7(119) 33.2(133) 37.0(148) 38.7(155) 25.5(102) 35.7(143) 
bsses mattresses 
Alternating 16.9(18) 34.0(36) 49.0(52 51.8(55) 33.9(36) 14.0(15) 
system 
Therakair 52.3(68) 24.6(32) 23.0(30) 28.4(37) 53.0(69) 18.4(24) 
Genadyne 57.0(15) 3.8(1) 38.4(10) 26.9(7) 57.6(15) 15.3(4) 
Atmosair 4.0(2) 44.9(22) 51.0(25) 10.2(5) 67.3(33) 22.4(11) 
Gel 37.5(3) 50.0(4) 12.5(1) 75.0(6) 12.5(1) 12.5(1) 
overlay 
barrier creams 31.0(94) 33.0(100) 35.8(108) 44.3(134) 36.4(110) 19.2(58) 
ins & nutritional 24.3(67) 36.7(101) 39.0(107) 42.5(117) 33.0(91) 24.3(67) 
4me nts 
cts' Every 32.8(41) 33.6(42) 33.6(42) 48.0(60) 13.6(17) 38.0(48) 
'1g 2hours 
'Jule Every 3- 31(167) 31(169) 37.8(205) 33.4(181) 42.8(232) 23.6(128) 
4 hours 
Every 6 20(6) 50(15) 30.0(9) 50.0(15) 6.6(2) 43.3(13) 
hours 
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Table 8 Frequencies and percentages of certain attributes related to 
protective measures by NCPU 
Attribute Frequency Percentage Frequency Percentage 
of use of use with of use of use 
with NCPU without without 
NCPU NCPU NCPU 
(n=165) (n=554) 
Protective Standard 100 60.6 300 54.1 
mattresses mattresses 
Alternating 28 16.9 78 14.0 
system 
Therakair 29 17.5 101 18.2 
Genadyne 6 3.6 20 3.6 
Atmosair 0 0.0 49 8.8 
Gel 2 1.2 6 1.0 
overlay 
Patient Every 2 28 17.0 97 17.5 
turning hours 
schedule Every 3-4 128 77.5 413 74.5 
hours 
Every 6 5 3.0 25 4.5 
hours 
Skin barrier creams 86 52.1 216 39.0 
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Descriptive statistical analysis 
1. General characteristics of the patients involved in the study 
In total, 719 patients were included in the study. All conformed to the inclusion criteria. 
During the study, data was collected from newly admitted and/or inpatients from nine 
medical and surgical wards, including 237 beds and 264 nursing staff. The nine medical 
and surgical wards were divided into three groups: Group A (GA), which included 
patients from the Male Medical, Isolation and Male Orthopaedic and Spinal Surgery 
wards; Group B (GB), which included patients from the Rehabilitation, Renal and 
Neuro-Surgery wards; and Group C (GC), which included patients from the Female 
Medical, Oncology and VIP Medical-Surgical wards. 
Of the sample, 72.4 per cent (n=521) of the patients completed the eight week 
observation period and 27.6 per cent (n=198) did not complete this period because of 
discharge, transfer or death. Of the patients who did complete the period, 265 were 
observed in the pre-test and 256 in the post-test stages. The findings indicate that 31.3 
per cent (n=225) of the patients were from Group A, 31.7 per cent (n=228) from Group 
B and 37 per cent (n=266) from Group C. 
The distribution of patients by the group and type (pre-test or post-test) as shown in 
Figure 4.1 indicated that the patients included from groups A, B and C (n=265) before 
intervention (pre-test) accounted for 29.9 per cent (79 of 265 patients), 34.3 per cent (91 
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of 265) and 35.8 per cent (95 of 265) respectively while those patients included after 
intervention (post-test) (n=256) accounted for 28.9 per cent (74 of 256), 29.7 per cent 
(76 of 256 patients) and 41.4 per cent (106 of 256 patients) of those groups respectively. 
Of the sample, 198 patients did not complete the eight week observation period. They 
accounted for 36.4 per cent (72 of 198 patients), 30.8 per cent (61 of 198 patients) and 
32.8 per cent (65 of 198 patients) from the groups A, B and C respectively. 

















The patients' age as shown in a histogram in Figure (2) revealed that nearly half, 51.6 
per cent (n=371) of the patients were aged 60 years and over. Of the sample, 17 per cent 
(n=1 19) were less than 30 years old, 5 per cent (n=36) were 30 to 40 years old, 19 per 
cent (n=139) were 40 to 60 years old, 21 per cent (n=149) were 60 to 70 years old, 23 
per cent (n=163) were 70 to 80 years old, and 8 per cent (n=59) were over 80. 
279 
19 s/ `Osf o`Oa 
Furthermore, the distribution of age indicated a negative skewness (-0.6) towards older 
patients. 
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The distribution of patients' age by group described in Figure (3) and presented by box 
plot showed that the patients' ages ranged from 18 to over 80. The findings indicated 
that GB patients were younger. The number of patients between 20 and 30 accounted 
for 25.9 per cent (59 of 228 patients) in GB and 7.1 per cent (16 of 225 patients) in GA 
and 2.6 per cent (7 of 266 patients) in GC. The findings showed that 57.8 per cent (130 
of 225) patients aged 60 years over belonged to (iA and a relatively similar percentage 
of 61.6 (164 of 266 patients) to GC, while 33.7 per cent (77 of 228 patients) belonged 
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to GB. The number of patients in GA and GC aged between 70 and 80 was nearly 
threefold the number in GB, being 28.4 per cent (64 of 225 patients) in GA, 27.4 per 
cent (73 of 266 patients) in GC and 11.4 per cent (26 of 228 patients) in GB. 
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The distribution of age by type of patient showed a relatively minimal variation among 
different age groups. Among those patients less than 30 years old, 35.3 per cent (42 of 
119 patients) were pre-test compared to 43.7 per cent (52 of 119 patients) post-test and 
21 per cent (25 of 119 patients) excluded. The results indicate that, of those patients in 
the middle-aged group (30 to 50 years old), 36.5 per cent (39 of 107 patients) were pre- 
test compared to 42 per cent (45 of 107 patients) post-test and only 21.5 per cent (23 of 
107 patients) excluded. There was minimal variation among those patients who were 50 
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to 60 years old, 41 per cent (28 of 68 patients) being pre-test compared to 35.2 per cent 
(24 of 68) post-test and 23.5 per cent (16 of 68) excluded. The variation almost 
disappeared in the age group over 60, of whom 34.5 per cent (128 of 371) were pre-test 
compared to 32.8 per cent (122 of 371) in post-test and 32.6 per cent (121 of 371) 
excluded. Sec Figure 4. 









265 256 198 
The findings showed that 64.5 per cent (n=464) of the patients were male and 35.5 per 
cent (n=255) were female. The distribution of gender varied among groups A, B and C. 
Although male patients accounted for 92.4 per cent (208 of 225 patients) in GA, they 
were 33.8 per cent (90 of 266 patients) in GC and 72.8 per cent (166 of 228 patients) in 
GB. Only 7.6 per cent (17 of 225) were female in GA while they accounted for 66.2 per 
cent (176 of 266) in GC and 27.2 per cent (62 of 228) in GB, as shown in Figure 5. The 
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findings showed minimal variation among the distribution of age by type of patient. Of 
the sample, 38.1 per cent (177 of 464 patients) were male in pre-test compared to 35.5 
per cent (165 of 464 patients) in post-test and 26.2 per cent (122 of 464 patients) in 
excluded, while 34.5 per cent (88 of 255 patients) were female in pre-test compared to 
35.7 per cent (91 of 255) in post-test and 29.8 per cent (76 of 255 patients) in excluded. 
See Figure 6. 
Figure 5 Distribution of patients' gender by group 
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Of the sample, the majority of patients (40.2 per cent (n=289)) had medical diagnosis 
while patients with surgical diagnosis accounted for 21.6 per cent (n=155), oncology 10 
per cent (n=72), renal 5.3 per cent (n=38), rehabilitation 7.2 per cent (n=52), neuro- 
surgery 4 per cent (n=29); only 0.3 per cent (n=2) were vascular patients. See Figure 7. 
The findings indicate that nearly half the patients in GA, 45.8 per cent (103 of 225) and 
54.5 per cent (145 of 266) in GC had medical disorders, while only 18 per cent (41 of 
228) were reported in GB. 
The findings show that patients with surgical diagnosis in GA were 29.8 per cent (67 of 
225 patients), with a similar total in GB (29.4 per cent (67 of 228 patients)), while only 
7.9 per cent (21 of 66 patients) had surgery in GC. The findings showed that GB 
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retained more patients for rehabilitation (21.5 per cent (49 of 228)) compared to GA 
with only 1.3 per cent (3 of 225); GC retained no patients. Oncology patients accounted 
for 19.2 per cent (51 of 266) of patients in GC, 6.1 per cent (14 of 228) in GB and 3.1 
per cent (7 of 225) in GA. Patients with renal diagnosis accounted for 14.5 per cent (33 
of 228) in GB, 1.1 per cent (3 of 266) in GC and only 0.9 per cent (2 of 225) in GA; 
patients with neuro-surgical diagnosis accounted for 6.1 per cent (14 of 228) in GB, 3.4 
per cent (9 of 266) in GC and 2.6 per cent (6 of 225) in GA. Patients with vascular 
diagnosis appeared only in GC for 0.8 per cent (2 of 266 patients). See Figure 8. 
The findings show variations among some patients' diagnoses in relation to the type of 
the patient, examples including oncology, neuro-surgical and rehabilitation. Of those 
patients with medical diagnosis, 39.1 per cent (113 of 289 patients) were pre-test 
compared to 33.9 per cent (98 of 289) post-test and 27 per cent (78 of 289) excluded. Of 
those patients with surgical diagnosis, 37.4 per cent (58 of 155) were pre-test, 40 per 
cent (62 of 155) post-test and 22.6 per cent (35 of 155) were excluded. Among 
oncology patients, 41.8 per cent (30 of 72) were pre-test while only 26.3 per cent (19 of 
72) were post-test and 31.9 per cent (23 of 72) were excluded. Among renal patients, 
31.5 per cent (12 of 38) were pre-test while only 18.5 per cent (7 of 38) were post-test 
and 50 per cent (19 of 38 patients) were excluded patients. Of neuro-surgical patients, 
more than half (55 per cent (16 of 29)) were pre-test compared to 34.8 per cent (10 of 
29) post-test and 10.2 per cent (3 of 29) excluded. Rehabilitation patients accounted for 
36.5 per cent (19 of 52) of pre-test compared to 28.8 per cent (15 of 52) of post-test and 
34.7 per cent (18 of 52) excluded. Of those patients with vascular diagnosis, 50 per cent 
(1 of 2) were from each of the pre-test and excluded categories. See Figure 9. 
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Figure 7 Distribution of patients by Diagnosis 
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In order to sum up the findings of this section, tables were constructed as shown in 
Appendix Q, tables 12 and 3. A total of 719 patients were included in the study from 
nine medical and surgical wards according to the inclusion criteria. 31.3 per cent 
(n=225) of patients from GA; 31.7 per cent (n=228) from GB and 37 per cent (n=266) 
from GC. 
Almost two thirds (72.4 per cent (n=521)) of the patients completed the eight week 
observational period. 36.8 per cent (n=265) of them were from the pre-test, 35.6 per 
cent (n=256) from the post-test and 27.5 per cent (n=198) from the excluded categories. 
Nearly half of the patients studied (51.6 per cent (n=371)) were 60 years old and over, 
and the majority (64.5 per cent (n=464)) were male. 
Among the patient groups, 25.9 per cent of GB patients were young (20 to30 years old), 
while approximately 28 per cent of GA and GC patients were older (70 to 80 years old). 
GA contained 92.4 per cent (n=208) male patients while GC had 66.2 per cent (n=176) 
female ones. The majority of patients (40.2 per cent (n=289), mostly from GA and GC) 
were diagnosed with medical disorders. 21.5 per cent (n=49) of GB patients were 
retained for rehabilitation while GA and GB had the same number of surgical patients 
(n=67). 
There were minimal variations in patient types among those patients less than 60 years 
old; these had almost disappeared among those above this age. It was reported that 34.5 
per cent (128 of 371) of pre-test patients were 60 years old and over while 32.8 per cent 
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(122 of 371) were in the post-test and 32.6 per cent (121 of 371 patients) in the 
excluded categories. 
A relatively similar gender frequency was reported among the patient type, with very 
minimal variation among male patients. Furthermore, it was noted that more variations 
were reported for patient types among oncology, renal, neuro-surgical and rehabilitation 
patients than among other diagnoses. 
2. Pressure ulcer incidence and prevalence among the patients 
The PU incidence rate (referred to as Nosocomial PU (NCPU)) is defined in chapter 
three (section 3.11) 
Of the sample, 22.9 per cent (n=165) of the patients developed Stage One to Four PUs. 
In GA, 24.4 per cent (55 of 225 patients) were reported with NCPU, in GB 23.4 per cent 
(54 of 228 patients) were reported with NCPU and in GC 21.1 per cent (56 of 266 
patients) (Figure 10). 
The findings also revealed that 31 per cent (83 of 265) of the NCPU developed in pre- 
test while only 19 per cent (49 of 256) developed in post-test and 17 per cent (33 of 198 
patients) developed in excluded patients (Figure 11). 
Of those patients with NCPU, 47.2 per cent (78 of 165 patients) were Stage One, 36.4 
per cent (60 of 165 patients) were Stage Two, 9.7 per cent (16 of 165 patients) were 
Stage Three and 6.7 per cent (11 of 165 patients) were Stage Four (Figure 12). More 
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than half (50.3 per cent, or 83 of 165 patients) developed NCPU on the sacral area, 12.7 
per cent (21 of 165 patients) on the heels, 12.1 per cent (20 of 165 patients) on the 
trochanter, 7.9 per cent (13 of 165 patients) on the buttocks, 4.8 per cent (8 of 165 
patients) on the toes, 4.8 per cent (8 of 165 patients) on the ischial area, 3 per cent (5 of 
165 patients) on the ears, 2.4 per cent (4 of 165 patients) on the ankle joints, and 0.6 per 
cent (1 of 165 patients) developed one PU on their occipital area, knee and metatarsum 
(Figure 13). 
The distribution of NCPU stages by location showed that 53.8 per cent (42 of 78 
patients) developed Stage One NCPU on the sacral area, 14.1 per cent (11 of 78 
patients) on the trochanter and 11.5 per cent (9 of 78 patients) on the heels. The results 
showed that 53.3 per cent (32 of 60 patients) had Stage Two NCPU on the sacral area 
and 11.7 per cent (7 of 60 patients) on each of the knees and the heels. 37.5 per cent (6 
of 16 patients) of Stage Three NCPU developed PUs on the sacral area, 18.8 (3 of 16 
patients) on the heels and 12.5 per cent (2 of 16 patients) on each of the heels and the 
trochanter areas. It was also reported that the most common site for Stage Four NCPU 
are the heels, the sacrum, the ankle joint and the toes, all of which reported relatively 
similar values and accounted for 27.3 per cent (3 of 11 patients) in all of the above four 
sites (Figure 14). 
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Furthermore, the findings indicate that higher incidence rates were noted for older 
patient age groups. It showed that approximately 60 per cent (97 of 165 patients) of 
patients who developed NCPU were over 60 and 35 per cent (57 of 165) were 70 to 80 
years old (Figure 15). Additionally, the findings indicated that 67.2 per cent (I il of 165 
patients) of those who developed NCPU were males. 
The results show that half of those patients who developed NCPU were diagnosed with 
medical disorders, 19.3 per cent with surgical diagnosis, 8 per cent with neuro-surgical 
diagnosis, 6 per cent with oncology diagnosis and 4.2 per cent for rehabilitation, while 
no patients from those with vascular diagnosis developed NCPU (Figure 16). 
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The findings suggest that a higher percentage of patients developed PU and were 
identified as being at risk using the Braden scoring. 44.2 per cent of those patients who 
developed NCPU (n=165) had been scored at high risk, mild and moderate risk patients 
accounted for 24.8 per cent and only 6 per cent of the patients had scored at severe risk 
(Figure 17). The findings also showed that, of those patients who developed NCPU 
(n=165), 36.9 per cent were judged by the nurses as at moderate risk, 30.3 per cent at 
high risk, 22.4 per cent at minimal risk, and 1.2 per cent at severe or no risk (Figure 
18). 
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The prevalence rate is the total number of patients admitted with PU or had a PU during 
the eight week observation period divided by the total number of patients at risk 
according to the Braden score <18 multiplied by one hundred. 
The findings showed that the prevalence rate among the sample was 33.7 per cent 
(n=242). Of those admitted with PU (n=242), 37.7 per cent (n=84) were from GA, 26.4 
per cent (n=64) from GB and 38.8 per cent (n=94) from GC (Figure 19). 40 per cent 
(n=97) of those admitted with PU were reported in pre-test while 33.4 per cent (n=81) 
in post-test and 26.4 per cent (n=64) in the excluded patients' group (Figure 20). 
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The prevalence findings indicate that 43.8 per cent (106 of 242 patients) of patients 
were admitted with Stage Four PUs, 27.6 per cent (67 of 242 patients) with Stage Two, 
16.1 per cent (39 of 242 patients) with Stage Three and only 12.3 per cent (30 of 242 
patients) with Stage One (Figure 21). 
The findings showed that nearly half (47.9 per cent (n=1 16)) of PUs were reported in 
the sacral area while 19.8 per cent (n=48) were reported on the trochanter, 15.7 per cent 
(n=38) on the heels. 7.4 per cent (n=18) on the ischium, 2.8 per cent (n=7) on buttocks 
and the occipital areas, 1.2 per cent (n=3) on the ankle and the toes and only 0.4 per cent 
(n= I) on the ears and the metatarsum areas (Figure 22) 














-Admitted without PU 
-Admitted with PU 
297 
0 019 co 











w ithout PU 
_Admitted 
w ith PU 
298 
ý ýý 


























cs ti T Fd, ýa ý, a 4, °'o SS's s Fý ýf 0,0 
To sum up this section's findings, tables were constructed as shown in Appendix Q, 
tables 4 and 5.22.9 per cent (165 of 719 patients) of patients developed NCPU. The 
NCPU among the groups showed relatively similar distributions ranging from 21 per 
cent in GC to 24 per cent in GA, while it was variable among patient types, ranging 
from 19 per cent in post-test to 31 per cent in pre-test patients. 
47 per cent (78 of 165 patients) of patients developed Stage One PUs compared to only 
6.6 per cent (1 1 of 165 patients) who developed Stage Four. Half of the NCPU 
developed on the sacrum. 
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Of those patients who developed Stage One and Stage Two PUs, more than half 
developed on the sacrum, while of those patients who developed Stage Four, NCPU 
were equally distributed on the sacrum, heels, ankle joint and toes. 
The findings indicate that 67 per cent (111 of 165 patients) of those patients who 
developed NCPU were male and were medically diagnosed. They also show that 60 per 
cent (97 of 165 patients) of those patients who developed NCPU were over 60 years old 
and 35 per cent (57 of 165 patients) were 70 to 80 years old. Moreover, the results point 
out that 44 per cent of those developed NCPU scored at high risk according to the 
Braden scale while only 30 per cent were scored at high risk by using CJ. 
The results show that the prevalence rate was 33.7 per cent (242 of 719 patients). It was 
reported that 38 per cent were admitted with PUs in GA compared to 39 per cent in GC 
and 26 per cent in GB. It was noted that the distribution of PU prevalence among patient 
types was variable. It showed that 40 per cent of those admitted with PUs were pre-test 
patients while 33.4 per cent were post-test and 26.4 per cent were excluded. Nearly half 
(48 per cent) of prevalent PUs were developed in the sacrum, 44 per cent of which were 
Stage Four PUs. 
3. Pressure ulcer prevention strategies (protective measures) 
3.1 The use of protective mattresses 
The findings indicate that more than half 55.6% (400 of 719 patients) of the sample 
were placed on standard hospital mattresses while other protective mattresses were used 
as follows: The alternating pressure reducing system was used only in 14.5% (n=106) of 
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the patients, low air loss and pulsating system (referred to as Therakair) in 18.1% 
(n=130), low air loss system (referred to as Genadyne) in 3.6% (n=26), self adjusting 
technology system (referred to as Atmosair) in 6.8% (n=49) and Gel overlays were used 
in 1.1 % (n=8) of the patients (Figure 23). 
The findings show a slight difference among those patients who used the standard 
mattresses in relation to the type of the patients. 38.7 per cent (155 of 400) of the 
standard mattresses used in pre-test phase, 35.8 per cent (143 of 400) in excluded 
patients and 25.5 per cent (102 of 400) in post-test patients. The findings show that 
more than half of an alternative system 51.9 per cent (55 of 106) were used in pre-test, 
33.9 per cent (36 of 106) in post-test and 14 per cent (15 of 106) in excluded patients. It 
was reported that 53 per cent (69 of 130) of Therakair system used in post-test patients 
compared to only 28.4 per cent (37 of 130) in the pre-test and 18.4 per cent (24 of 130) 
in the excluded patients. Among Genadyne system, a majority of 57.6 per cent (15 of 
26) were used in post-test patients compared to 26.9 per cent (7 of 26) in pre-test and 
15.3 per cent (4 of 26) in the excluded patients. The use of the Atmosair system was 
reported in 67.3 per cent (33 of 49) in post-test patients compared to only 22.4 per cent 
(11 of 49) in excluded patients and 10.2 per cent (5 of 49) in pre-test. Among the use of 
Gel overlays, it was noted that the majority (75 per cent, or 6 of 8) used in pre-test 
patients compared to only 12.5 per cent (1 of 8) in each in the post-test and the excluded 
patient groups (Figure 24). 
The findings show that 37 per cent (148 of 400) of those standard mattresses were used 
from GC patients compared to 29.8 per cent (119 of 400) from GA and 33.2 per cent 
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(133 of 400) from GB. Of the alternating system, 49 per cent (52 of 106) were used 
from GC compared to 34 per cent (36 of 106) from GB and only 17 per cent (18 of 106) 
from GA. The results also showed that 52.2 per cent (68 of 130) of the Therakair system 
were used from GA compared to 23.9 per cent (30 of 130) in both GB and GC. An 
increase in use of the Genadyne system was noted in GA, which accounted for 57.7 per 
cent (15 of 26) compared to 38.4 per cent (10 of 26) in GC and only 3.9 per cent (1 Of 
26) in GB. The use of the Atmosair system accounted for 51 per cent (25 of 49) in GC, 
45 per cent (22 of 49) in GB and only 4 per cent (3 of 49) in GA. The use of Gel 
overlays accounted for 50 per cent (4 of 8) in GB, 37.5 per cent (3 of 8 patients) in GA 
and 12.5 per cent (1 of 8) in GC (Figure 25). 
The findings also indicate that of those patients who developed NCPU (165 of 719 
patients) only 39.3 per cent (65 of 165 patients) were placed on a protective mattress, 
while 50.9 per cent (282 of 554 patients) of those who did not develop NCPU used one 
(Figure 26). 
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3.2 The use of skin barrier creams 
Of the sample, 42 per cent (n=302) were treated with skin barrier creams as a protective 
measure of PU. 31.1 per cent (94 of 302 patients) of those were in GA compared to 33.1 
per cent (100 of 302 patients) in GB and 35.8 per cent (108 of 302 patients) in GC 
(Figure 27). 
The findings show that 44.3 per cent (134 of 302 patients) of those patients who treated 
with skin barrier creams were from pre-test, 36.4 per cent (110 of 302 patients) from 
post-test and only 19.2 per cent (58 of 302 patients) from the excluded patients (Figure 
28) 
Of those patients who developed NCPU (165 of 719 patients), 52.1 per cent (86 of 165 
patients) were treated with skin barrier creams. Of those patients who did not develop 
PUs (554 of 719 patients), 39 per cent (216 of 554 patients) were treated with skin 
barrier creams (Figure 29). 
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3.3 The use of vitamins and nutritional supplements 
Of the sample, 38.2 per cent (275 of 719) of the patients used vitamins and nutritional 
supplements as a protective measure of PU development. Of those patients who used 
vitamins, 24.3 per cent (67 of 275 patients) were from GA compared to 36.7 per cent 
(101 of 275 patients) from GB and 39 per cent (107 of 275 patients) from GC (Figure 
30). 
The findings show some variability among those patients who used vitamins in relation 
to the type of the patients: 42.5 per cent (117 of 275 patients) of those who used 
vitamins were from the pre-test patients compared to 33 per cent (91 of 275 patients) 
from post-test patients and only 24.3 per cent (67 of 275 patients) from excluded 
patients (Figure 31). 
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Furthermore, of those patients who developed NCPU (165 of 719 patients), 42.4 per 
cent (70 of 165 patients) used vitamins, and of those patients who did not develop 
NCPU (554 of 719 patients), 63 per cent (349 of 554 patients) did not use vitamins 
(Figure 32). 








































3.4 Distribution of the patients' positioning (patients' turning schedules) 
The findings indicate that the majority of the patients (75.2 per cent (n=541)) were 
turned every three to four hours compared to 17.3 per cent (n= 125) every two hours and 
only 4.1 per cent (n=30) every six hours. 
Equal frequencies of patients from the different groups (GA, GB and GC) 
(approximately 33.5 per cent (42 of 125 patients)) were turned in the two-hour schedule; 
37.8 per cent (205 of 541 patients) of whom turned every three to four hours from GC 
and 31 per cent (168 of 541 patients) in GA and GB. Among those patients turned every 
six hours, 50 per cent (15 of 30 patients) were from GB compared to 30 per cent (9 of 
30 patients) in GC and 20 per cent (6 of 30 patients) in GA (Figure 33). 
The results also show variability in the type of patients in relation to the turning 
schedule. It was noted that about 50 per cent (60 of 125 patients) of those patients who 
turned every two hours were from pre-test patients compared to only 13.6 per cent (17 
of 125 patients) from post-test patients, while 42.8 per cent (232 of 541 patients) of 
those patients who turned every three to four hours were from post-test patients 
compared to 33.4 per cent (181 of 541 patients) from pre-test patients. Approximately 
50 per cent (15 of 30 patients) of those patients who turned every six hours were from 
pre-test patients compared to only 6.6 per cent (2 of 30 patients) from post-test patients 
(Figure 34). 
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Among those patients who developed NCPU, 77.5 per cent (128 of 165 patients) were 
turned every three to four hours. A relatively similar figure (74.5 per cent, or 413 of 
554) was reported for those who did not develop NCPU (Figure 35). 













































Tables were constructed as shown in Appendix Q, table 6,7, and 8 to sum up this 
section. In summary the utilisation of protective mattresses was not optimum among 
those patients who developed NCPU. Of the sample, 55.6 per cent of the patients were 
placed on standard mattresses. A slightly similar distribution of standard mattresses was 
noticed among the groups A, B, and C. Around 50 per cent of the Atmosair system use 
by GC patients while more than half of the Therakair and Genadyne systems were used 
in GA and nearly half Gel overlays were used in GB. 
The results show more utilisation of protective mattresses among post-test patients. 53 
per cent of Therakair, 58 per cent of Genadyne and 67 per cent of Atmosair mattresses 
were utilised by post-test patients while 39 per cent of the standard mattresses, 52 per 
cent of the alternative systems and 75 per cent of Gel overlays were utilised for pre-test 
patients. It is important to point out that, of those patients who developed NCPU, only 
39 per cent were placed on one of the protective mattresses; 50.9 per cent of those who 
did not develop NCPU were nursed on one of the protective mattresses. 
The use of skin barrier creams indicated that 42 per cent of the sample used creams and 
were similarly distributed among the groups A, B and C. The pre-test patients showed 
more use of creams. Since the objective of applying creams was to protect against and 
decrease the incidence of NCPU development, the findings that 52.1 per cent of those 
patients who developed NCPU used skin barrier creams and 61 per cent of those 
patients who did not develop NCPU did not use them casts some doubt on their positive 
effect. 
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In relation to the use of vitamins and nutritional supplements as protective measures, the 
findings show that 38.2 per cent of the patients were supplied with vitamins. Some 
variability was noticed among the groups in relation to vitamins supply, ranging from 
24.3 per cent in GA patients to 37 per cent in GB and 39 per cent in GC. 43 per cent of 
those supplied with vitamins were from pre-test patients compared to 33 per cent from 
post-test. Based on these findings, it is doubtful that a conclusive effect of vitamins on 
reducing NCPU development can be inferred. The results reveal that 42.4 per cent of 
those patients who developed NCPU were supplied with vitamins and 63 per cent of 
those were did not develop NCPU were not. 
75 per cent of patients were turned every three to four hours; their distribution among 
the groups was relatively similar. 43 per cent of those who turned every three to four 
hours from post-test patients and half of those who turned every two hours were from 
pre-test patients. The effect of patients' turning schedules on NCPU development is still 
uncertain. The findings showed that almost 78 per cent of those patients who developed 
NCPU were turned every three to four hours and about 75 per cent of those who did not 
develop them were turned on the same schedule. 
4. Braden and CJ scoring 
4.1 The Braden scores 
The findings show that the Braden scores among the sample patients were as follows: 
37 per cent (n=266) were at mild risk, 34.4 per cent (n=248) at high risk, 24 per cent 
(n=172) at moderate risk and only 3 per cent (n=22) at severe risk (Figure 36). 
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Of those patients who were scored at severe risk, 59 per cent (13 of 22 patients) were 
from GA compared to 18 per cent (4 of 22 patients) from GB and 23 per cent (5 of 22) 
from GC, while of those at high risk, 43.5 per cent (108 of 248 patients) were from GC 
compared to 34 per cent (84 of 248 patients) from GA and 22.5 per cent (56 of 248 
patients) from GB. Of those patients at moderate risk, 42 per cent (73 of 172 patients) 
were from GC compared to 30 per cent (51 of 172 patients) from GA and 28 per cent 
(48 of 172 patients) from GB. Of those at mild risk, 44.3 per cent (118 of 266 patients) 
were from GB compared to 26 per cent (68 of 266 patients) from GA and 30 per cent 
(80 of 266 patients) from GC (Figure 37). 
The distribution of the Braden scores by type of patient indicated remarkable 
differences between pre-test and post-test patients. It was noted that 68 per cent (15 of 
22 patients) of patients were scored at severe risk; 42 per cent (104 of 248 patients) of 
those at high risk were pre-test; this compared to no patients at all in post-test stage at 
severe risk and 36.6 per cent (91of 248 patients) at high risk. On the other hand, 42 per 
cent (72 of 172 patients) of those at moderate risk and 35 per cent (93 of 266 patients) at 
mild risk were post-test compared to 32 per cent (55 of 172 patients) at moderate risk 
and 31.5 per cent (84 of 266 patients) at mild risk in pre-test (Figure 38). 
The results show that, of those patients scored as severe risk, 45.5 per cent (10 of 22 
patients) were placed on alternative systems and 36.4 per cent (8 of 22 patients) on 
standard mattresses, only 9 per cent (2 of 22 patients) on Therakair and Genadyne 
systems, and no patients on Atmosair and Gel overlays. Among those patients at high 
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risk, 44.3 per cent (110 of 248 patients) were nursed on standard mattresses while 17 
per cent (42 Of 248 patients) used alternative systems, 28.6 per cent (71 of 248 patients) 
used Therakair, 7.3 per cent (18 of 248 patients) used Genadyne and only 0.8 per cent (2 
of 248 patients) used Gel overlays. It was noted that nearly half (48.8 per cent, or 84 of 
172) of patients scored at moderate risk were placed on standard mattresses while 17.4 
per cent (30 of 172 patients) used alternative systems, 24 per cent (41 of 172 patients) 
used Therakair, 7.5 per cent (13 of 172 patients) used Atmosair and 1.1 per cent (2 of 
172 patients) used Genadyne and Gel overlays. Unsurprisingly, among those patients at 
mild risk, the majority (70.7 per cent, or 188 of 266 patients) used standard mattresses 
while 8.6 per cent (23 of 266 patients) used alternative systems, 6 per cent (16 of 266 
patients) used Therakair, 11.6 per cent (31 of 266 patients) Atmosair and only 1.5 per 
cent (4 of 266 patients) Genadyne and Gel overlays (Figure 39). These findings suggest 
that the use of protective mattresses does not solve the problem, and is in fact 
inappropriate in relation to the Braden scores especially in high and severe risk 
categories. 
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4.2 The clinical Judgment (CJ) scores 
The findings show that the nurses' CJ scores were distributed as follows: 0.8 per cent 
(n=6) at severe risk, 22.9 per cent (n=165) at high risk, 32.3 per cent (n=232) at 
moderate risk, 30.7 per cent (n=221) at minimal risk, 0.6 per cent (n=4) at no risk and 
12.7 per cent (n=91) not recorded (Figure 40). 
The results show minimal variability among CJ scores in relation to the patient group. 
Of those scored at minimal risk, 41.2 per cent (91 of 221 patients) were from GB 
compared to 31.2 per cent (69 of 221) from GC and 27.6 per cent (61 of 221 patients) 
from GA. Of those patients scored at moderate risk, 41.4 per cent (96 of 232 patients) 
were from GC compared to 34 per cent (79 of 232 patients) from GA and only 24.6 per 
cent (57 of 232 patients) from GB. Of those patients scored at high risk, 44.2 per cent 
(73 of 165 patients) were from GC compared to 35.2 per cent (58 of 165 patients) from 
GA and 20.6 per cent (34 of 165 patients) from GB. Among those patients scored at 
severe risk, 50 per cent (3 of 6 patients) were reported from both GA and GC (Figure 
41). 
The findings indicate that nurses' CJ scoring changed little between patient types. The 
results show that 75 per cent (3 of 4 patients) of no risk patients were pre-test compared 
to no post-test patients and 25 per cent (1 of 4 patients) excluded ones. Of those patients 
scored at minimal risk, the scoring was similar: 33.5 per cent (74 of 221 patients) were 
pre-test, 35.3 per cent (78 of 221 patients) were post-test and 31.2 per cent (69 of 221 
patients) were excluded. Some variability was evident in relation to those scored at 
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moderate risk (36.6 per cent (85 of 232 patients) in pre-test compared to 43.1 per cent 
(100 of 232 patients) in post-test and 20.3 per cent (47 of 232 patients) in the excluded 
patient group). Of those patients scored at high risk, 38.2 per cent (63 of 165 patients) 
were in pre-test compared to 40 per cent (66 of 165 patients) in post-test and 21.8 per 
cent (36 of 165 patients) excluded. It was noted that those patients scored at severe risk 
in pre-test were twice (66.6 per cent (four of six patients)) the number of the patients in 
the post-test (Figure 42). 
The findings describe the nurses' CJ in relation to the protective mattresses. It was 
noted that all patients scored at no risk were provided a standard mattress. Of those 
scored at minimal risk, 64.3 per cent (142 of 221 patients) used standard mattress 
compared to 14 per cent (31 of 221 patients) using alternative systems, 11.3 per cent (25 
of 221 patients) using Atmosair, 9 per cent (20 of 221 patients) Therakair, 0.9 per cent 
(2 of 221 patients) Genadyne and only 0.45 per cent (1 of 221 patients) using Gel 
overlays. Of those patients scored at moderate risk, 45.2 per cent (105 of 232 patients) 
used the standard mattress while 15.1 per cent (35 of 232 patients) used alternative 
systems, 25 per cent (58 of 232 patients) Therakair, 5.6 per cent (13 of 232 patients) 
Genadyne, 8.2 per cent (19 of 232 patients) Atmosair and only 0.9 per cent (2 of 232 
patients) used Gel overlays. 
The results show an appropriate utilisation of protective mattresses among patients 
scored at high risk. It was reported that, 42.4 per cent (70 of 165 patients) of those 
patients scored at high risk used standard mattresses compared to 20.6 per cent (34 of 
165 patients) using alternative, 27.2 per cent (45 of 165 patients) Therakair, 5.6 per cent 
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(9 of 165 patients) Genadyne, 1.8 per cent (3 of 165 patients) Atmosair and only 2.4 per 
cent (4 of 165 patients) using Gel overlays. Among those patients scored at severe risk, 
50 per cent (3 of 6 patients) were nursed with alternative systems compared to 33.4 per 
cent (two of six patients) with Therakair, 16.6 per cent (1 of 6 patients) with standard 
mattresses; other protective mattresses were not used (Figure 43). 
The findings also describe the nurses' CJ scores in relation to the Braden scores. They 
show that both coincided at 68.7 per cent (152 of 221 patients) of patients scored at 
minimal risk. Furthermore, both scoring systems were correlated (Table 1) especially 
among those patients who scored moderate risk, 37 per cent (87 of 232 patients) of 
whom, for example, who were scored on this level by CJ were scored at high risk by the 
Braden scale. Of those patients who scored at high risk by CJ, 67.8 per cent (112 of 
165) were also rated as such by the Braden scale. Among those patients who scored at 
severe risk by CJ, only 16.6 per cent (1 of 6 patients) scored the same by using the 
Braden (Figure 44). 
TQhIP 1 ('nrrPintinn hPtwPen RpvPrcPd Rraden Scares and CJ scores 
Reversed 
Braden 
scores CJ scores 
Spearman's Reversed Correlation Coefficient 
rho Braden 1.000, . 
589(**) 
Scores 
Sig. (2-tailed) . 
000 
N 719 628 
CJ scores Correlation Coefficient . 
589(**) 1.000 
Sig. (2-tailed) . 
000 
N 628 628 
** Correlation is signiticant at the 0.01 level (2-tailed). 
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A table was constructed (Appendix Q, table 9), and the results show that the Braden 
scoring varied throughout the sample. 37 per cent of patients were scored at mild risk, 
34 per cent at high risk, 24 per cent at moderate risk and only 3 per cent at severe risk. 
Most of the patients evaluated as severe risk were from GA while 44 per cent of high 
risk patients and 42 per cent of moderately risk patients were from GC. Additionally, 44 
per cent of patients scored at mild risk were from GB. The findings also show that most 
patients scored at severe and high risk were reported at the pre-test stage while those 
patients scored at moderate and mild risk were from post-test. When selecting protective 
mattresses, it was noted that only 10 of 22 patients who were scored at severe risk on 
the Braden scale were placed on alternative systems, most of other risk groups being 
placed on standard mattresses. 
When using the CJ scoring, the sample showed 32 per cent of patients scored at 
moderate risk while 31 per cent were at minimal risk, 23 per cent at high risk and only 
0.8 per cent at severe risk. The distribution of CJ scores was variable among groups. 41 
per cent of moderately risk and 44 per cent of high risk patients were from GC while 41 
per cent of minimal risk were from GB. Patients scored as severe risk were distributed 
equally between GA and GC. The patients in the pre-test and post-test stages had 
relatively similar CJ scores in the minimal, moderate and high risk categories. Only 
three of six patients scored at severe risk were placed on alternative systems. Moreover, 
the findings show that the Braden scale and CJ scores coincided at 68 per cent among 
minimal and high risk patient groups. 
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